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 Summary
Sexually transmitted infections (STIs) are a major health problem in many parts of the 
developing world. STIs cause substantial morbidity and mortality, which disproportionately 
affect women. Because many of the complications are pregnancy-related (1, 2), adequate 
diagnosis and effective treatment of STIs in pregnancy is critical. Additionally, there is 
substantial evidence that the presence of other STIs increases both HIV infectiousness and 
susceptibility (3, 4), and a long-term STI-control program is emphasized as one of the 
cornerstones of HIV prevention (5). Striving for optimal strategies and high performance in 
the STI program is essential; in countries where health care budgets are limited, the 
potential for improvement is often larger and can have a substantial effect on the overall 
burden of disease. 
In countries without laboratory support, the diagnosis and treatment of STIs are 
based on the syndromic approach, in which simple flowcharts (usually called algorithms) 
are used to classify presenting symptoms and clinical signs into defined syndromes (6). 
Asymptomatic patients are not diagnosed with this strategy – thereby risking the 
development of complications and transmission of the infection. Low specificity results in 
high levels of overtreatment, which increases drug costs and the risk of drug resistance. 
Patients who are diagnosed and treated with an STI they don’t have, unnecessarily 
experience anxiety, stigma, and side effects of drugs. The strategy relies heavily on the 
quality of care provided, and it is a recognized problem that health care providers 
frequently fail to follow the guidelines (7-10). Also, STI clients who actually are 
adequately assessed must overcome a series of hurdles before they can be considered cured: 
obtain prescribed drugs, comply with treatment, and ensure that their partners are treated to 
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 avoid reinfection (11). There has long been a consensus that for chlamydia and gonorrhoea, 
simple, affordable and preferably on-site tests are needed to improve the management (12). 
Major progress has recently been made, and several tests are now on the market.  
This study has two components. In a cross-sectional study, 703 antenatal care 
(ANC) attendees were interviewed and examined, and specimens were collected to identify 
the prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, 
bacterial vaginosis, Candida species and syphilis. We evaluated the syndromic approach 
for the detection of vaginal and cervical infections in pregnancy, and determined if risk 
scores could improve the diagnostic accuracy. Subsequently, we used data from the 
epidemiological study to conduct an economic evaluation of the STI management. A 
decision analytic model was developed to compare the costs and health consequences of 
using point-of-care (POC) tests versus syndromic management to diagnose chlamydia 
among antenatal care attendees in sub-Saharan Africa, using Botswana as a case. In this 
analysis we also compared erythromycin with azithromycin treatment and universal with 
age-based chlamydia management. We chose to focus on chlamydia, which is more 
common than gonorrhoea in this population, but the model can be adapted to the economic 
evaluation of the management of other STIs such as gonorrhoea and trichomoniasis.  
 The aim of the first paper in this thesis is to draw attention to the effectiveness (or 
the lacking effectiveness) of the extensive prescription of antibiotics to STI patients in 
Botswana and to discuss possibilities for improving the cure rates. We found that many of 
the women had a history of STI symptoms in their current pregnancies and had been 
prescribed STI treatment. There was no significant difference in the prevalence of 
chlamydia among the women who had and the women who had not been prescribed 
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 erythromycin four times daily for ten days. Contrarily, none of the women who had been 
prescribed a single dose of ceftriaxone had gonorrhoea. The different effectiveness between 
the two drugs may reflect low compliance with the complex erythromycin regimen. We 
conclude that interventions to increase compliance could improve cure rates, and the use of 
a simpler drug regimen should be considered when low compliance is likely. This is 
discussed in the economic evaluation. 
In paper two and three, we evaluate the syndromic approach, and discuss that 
diagnosis and treatment of cervical and vaginal infections among pregnant women in sub-
Saharan Africa presents major challenges. Chlamydia and gonorrhoea were found in one 
out of ten of the pregnant women in the cross-sectional study, whereas one of two had 
trichomoniasis or bacterial vaginosis. Although in extensive use, the syndromic 
management is not suited to detect these conditions among pregnant women. The high 
prevalences among women who had gone through routine antenatal care, as well as the 
evaluation of the syndromic approach for study purposes, indicate that management 
guidelines for trichomoniasis and bacterial vaginosis in antenatal care should be revised. 
For chlamydia and gonorrhoea, the conclusion is even clearer: Without diagnostic tests, 
there are no adequate management strategies for cervical infections in pregnant women in 
Botswana, a situation which also is likely to apply to other countries in sub-Saharan Africa. 
The results of the economic evaluation of chlamydia management are presented in 
the last paper. Azithromycin was less costly and more effective than was erythromycin. The 
specific POC tests resulted in more cases cured than the syndromic approach, substantially 
reduced the overtreatment with antibiotics and improved partner management. The 
incremental costs of POC tests appeared acceptable, especially when testing was restricted 
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 to younger women. Our findings indicate that changes in the management of chlamydia 
among pregnant women in sub-Saharan Africa have the potential to improve people’s 
health, reduce unnecessary costs and improve the cost effectiveness of the current strategy. 
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 Background
Global inequity in health care  
The geographical distribution of financial resources for health is uneven. The 30 member 
countries of the OECD make up less than 20% of the world’s population, and spend 90% of 
the world’s resources on health (13). Poorer regions, such as Africa and South-East Asia, 
account for more than 50% of the global burden of disease, but spend about 2% of the 
global resources. In sub-Saharan Africa, the health challenges seem unmanageable in their 
number and degree of seriousness. The region has the highest child and adult mortality in 
the world, with the HIV/AIDS epidemic representing the highest burden of disease (14).  
 
The Millennium Development Goals
In September 2000, 189 countries committed to accelerate development in poor countries 
by endorsing an interrelated set of development goals; the Millennium Declaration (15). 
Improving health received considerable prominence. Three of the eight goals focused on 
reducing key causes of mortality in poor countries: maternal and perinatal conditions, 
diseases affecting children and infants, and major communicable diseases including 
HIV/AIDS (16). When evaluating the status five years after the declaration, progress was 
disappointing, particularly in sub-Saharan Africa, where life expectancy has actually fallen 
in many countries (17). Wars, political instability and corruption have all contributed in 
different settings, but a common factor has been the lack of resources. Total health 
expenditures per capita from all sources did not reach  $20 in 29 of the poorest countries in 
2002, and an additional $13-25 per person a year is required immediately (16).  
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  With regards to the lack of monetary resources, the need to increase the funding for 
health care is one of two major policy issues (16-18). Accurate costing is necessary, as well 
as active planning of practical actions that need to be undertaken, including raising the 
necessary funds (19). Making best use of available resources is equally important. If 
countries are to have any chance of achieving their goals, they need to re-evaluate the 
existing strategies to determine whether more could be achieved with the resources already 
available (16). It is likely that improvements in health could be achieved immediately by 
replacing less effective strategies with more effective ones. Further, the health worker crisis 
must be addressed. According to the World Health Report 2006, there are 57 countries with 
critical shortages equivalent to a global deficit of 2.4 million doctors, nurses and midwives 
(20). Again, the crisis is proportionally largest in sub-Saharan Africa. Inadequate skill 
mixes and distributional imbalances participate to the problem, and “the exodus of skilled 
professionals in the midst of so much unmet needs places Africa at the epicentre of the 
global health workforce crisis”. 
    
Priority setting in developing countries 
In this first decade of the 21st century, immense advances in human well-being coexist with 
extreme deprivation (20). In all economies, budgets are insufficient to meet all health care 
needs - and demands (21). For decision makers in resource poor settings, making best use 
of the resources is a vital, yet extremely difficult task with serious consequences for 
people’s health and public health. A basic criterion in priority setting in health is the 
societal wish to maximize general population health given the available resources (22). 
Many societies also want to distribute resources to reduce health inequalities, by giving 
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 high priority to interventions that target poor, children, or severely or chronically ill people. 
Next, the society may have specific preferences such as providing acute care in life 
threatening situations.  
Although societies may have explicit objectives and strategies for the health system, 
priority setting of health interventions is often ad-hoc, and resources are not used to an 
optimal extent (22). An underlying problem is that multiple criteria play a role and 
decisions are complex (23). Policy makers face not only budgetary, but also practical 
constraints, such as the availability of health personnel – a considerable challenge in 
developing countries (24). Interests groups exercise their influence on policy makers to 
prioritize interventions according to their preferences, and policy makers may act in order 
to maximize political support. Policy makers in developing countries may also follow 
funding preferences of international organizations or donor communities (22). 
 
The role of economic evaluations 
The systematic approach of economic evaluations has the potential to contribute to an 
informed debate and a more rational and transparent priority setting(22). The breakthrough 
for the use of economic evaluations in developing countries came with the 1993 World 
Development Report, Investing in Health (1, 18). The actual use and impact of cost-
effectiveness analyses face numerous challenges, especially in developing countries. A 
number of technical and implementation problems have been experienced, such as the 
heterogeneity of methods and outcome measures, complicating the synthesis and 
interpretation of cost-effectiveness results (24).  
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 Since 1998, the CHOICE project in the World Health Organization (WHO) has 
worked with assembling regional databases on the costs, impact on population health and 
cost-effectiveness of key health interventions (http://www.who.int/choice/en/). Their 
‘generalized cost-effectiveness analysis’ uses a common set of tools and methods to allow 
comparability of strategies and interventions within maternal, neonatal and child health, 
HIV/AIDS, tuberculosis and malaria (25). The desired usefulness of this information for 
health policy and planning is in assessing if current intervention strategies represent an 
efficient use of the available resources, and which of the potential additional interventions 
that are not yet implemented, or not implemented fully, should be given priority on the 
grounds of cost-effectiveness (24). However, knowledge gaps are numerous and wide for 
health interventions and economical evidence still lacks for important disease groups, 
particularly for historically marginalized services and currently under-served populations 
(24). For the disease groups that happen to be covered, evidence is missing or inadequate 
for many of the relevant alternatives (18).  
 
STI management in sub-Saharan Africa  
The evaluation of the syndromic approach for the detection of vaginal and cervical 
infections in pregnancy is based on our epidemiological study from Botswana, whereas the 
economic analysis on costs and benefits of chlamydia management strategies is partly 
based on these data. It is our explicit wish that our results will be useful for other countries 
in sub-Saharan Africa. The antenatal care framework and the STI management are similar 
in these countries as well as in other developing countries (Box 1). In the WHO’s 
epidemiological grouping of countries, Botswana is within the Afr-E region; sub-Saharan 
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 African countries with very high adult and high child mortality rate. Botswana is 
simultaneously, along with Gabon, South Africa and three islands, classified as an “upper 
middle income” country, whereas the remaining countries in sub-Saharan Africa are 
classified as “lower middle income” or “low income” countries (26). Due to their relative 
wealth and a well functioning primary health care, Botswana may have the possibility to 
explore new health interventions and act as an example to more resource constrained 
settings.  
 
Box 1 HIV/AIDS, STIs and antenatal care in sub-Saharan Africa  
Sub-Saharan Africa: Since the end of the last Ice Age, the north and 
sub-Saharan regions of Africa have been separated by the extremely 
harsh climate of the sparsely populated Sahara. Today, sub-Saharan 
Africa (in red) is a term used to describe those countries of the 
African continent that are not considered part of the political North 
Africa (27). There are 42 countries in sub-Saharan Africa, located in 
Central, East, West and Southern Africa, and six islands. Generally, sub-Saharan Africa is the 
poorest region in the world, and home to 34 of the world's 49 least developed countries. The 
region will continue to need the highest per capita levels of technical and financial support of 
any region, along with sustained political commitment by all stakeholders, if it is to make major 
progress towards meeting the Millennium Development Goals by 2015 (28). 
            HIV/AIDS: Sub-Saharan Africa is the region in the world most seriously affected by 
HIV/AIDS, with AIDS remaining the leading cause of death. Examinations by UNAIDS and 
WHO of global and regional trends suggests the pandemic has formed two broad patterns: 
generalized epidemics sustained in the general populations of many sub-Saharan African 
countries, especially in the southern part of the continent; and epidemics in the rest of the world 
that are primarily concentrated among populations most at risk, such as men who have sex with 
men, injecting drug users, sex workers and their sexual partners.
            STIs: The world’s highest rates of new STI cases per 1 000 population occur in sub-
Saharan Africa (29). The high prevalence and incidence of STIs can be explained by a variety of 
social, cultural, and economic factors, patterns of sexual activity, and lack of access to 
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 appropriate treatment. As in other developing countries, the diagnosis and treatment of STIs in 
sub-Saharan Africa is mainly based on the syndromic approach guidelines. 
            ANC: In sub-Saharan Africa, fully 68% if women report at least one antenatal visit (30). 
The ANC coverage in Botswana, Cape Verde and Zambia is extremely high, above 95%, and ten 
additional countries are all above 90%. Of the women who receive antenatal care, 36% attend   
2-3 times, 54% attend four or more times. A key objective of maternal health care programs has 
been to ensure that women present for antenatal care early in pregnancy in order to allow enough 
time for essential diagnosis and treatment regimens such as treatment of STIs and management 
of anaemia. Unfortunately, women in the region are most likely to wait until the second 
trimester, and a substantial proportion present only in the third trimester. 
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 Introduction
Sexually transmitted infections in sub-Saharan Africa 
Sexually transmitted infections (STIs) are highly prevalent in the developing world. WHO 
estimated that 340 million new cases of gonorrhoea, chlamydia, trichomoniasis and syphilis 
occurred throughout the world in 1999 in men and women aged 15-49 years (29). Sub-
Saharan Africa has the highest worldwide prevalences of these infections, which are major 
causes of morbidity, particularly in women (31). STIs can cause acute symptoms, but a 
large number of infections are asymptomatic. Both symptomatic and asymptomatic 
infections can lead to the development of serious complications such as pelvic 
inflammatory disease, ectopic pregnancy and infertility.  For pregnant women and their 
offspring, there is a risk of additional complications: intrauterine growth retardation, pre-
term birth, perinatal morbidity and mortality, and postpartum upper genital tract infections 
(32). 
The advent and increase of HIV infection has further highlighted the importance of 
STIs as a major problem. Epidemiological and biological studies have shown that other 
STIs and non-communicable reproductive tract infections (RTIs) can enhance HIV 
transmission (Box 2). Consequently, UNAIDS and WHO have recommended that high 
priority be given to the development of STI control program s, as one of the most important 
interventions for curbing the spread of HIV/AIDS (33, 34). To explore cost-effective 
alternatives or additions to existing STI strategies is therefore of high relevance to health 
policy at both national and international levels.  
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 Box 2 The relationship between STIs/RTIs and HIV-transmission 
There is compelling biological and epidemiological evidence that both 
ulcerative and non-ulcerative STIs/RTIs are co-factors for HIV-
transmission (35). Numerous studies have examined the biological 
plausibility of the association. Among HIV positive individuals, other 
STIs/RTIs increase HIV infectiousness by increasing HIV shedding in 
the genital tract, probably by recruiting HIV-infected inflammatory 
cells as part of the normal host response (36). Treatment 
  of these infections reduces the HIV-concentrations in genital fluids to 
  levels that are not significantly different from those among controls  
  without the STI. In pregnancy, genital HIV shedding has an additional dimension, the potential 
for increased transmission from mother to child during delivery. Among HIV-negative 
individuals, STIs/RTIs appear to increase susceptibility to HIV by recruiting HIV target cells to 
the genital tract. Ulcerative STIs also increase the infectivity with HIV and susceptibility to HIV 
through disrupted mucosa and bleeding (36).  
          Cohort studies of HIV seroconversion have estimated the increase in the risk of HIV 
infection associated with specific STIs/RTIs or STI syndromes, and community level 
intervention studies have measured the effect that STI treatment can have on HIV incidence. 
However, estimating the proportion of HIV-infections attributable to STIs/RTIs, and further, 
preventable by treating STIs/RTIs, is methodologically challenging, and studies differ in their 
findings (37). The community based randomized trial in Mwanza, Tanzania found a 38% 
reduction in HIV incidence in communities where syndromic STI management was 
strengthened, and concluded that this intervention is highly cost-effective (an estimated cost of 
$10 per DALY saved) (38). A community based randomized trial in Rakai, Uganda, showed that 
mass treatment of STIs reduced the STI prevalence, but found no difference in HIV incidence 
between the study arms (39). Lack of agreement between studies may be explained by 
unobserved differences such as varying degrees of exposure bias and confounding (37). The 
importance of STIs/RTIs on new cases of HIV in a population will also be dependent of the 
phase of the HIV epidemic, the sexual networks, the RTI/STI under study and the STI 
management strategy (36, 40).  
 HIV particles budding  
from a human cell
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 Management of STIs in developing countries 
Most of the serious health problems caused by STIs and RTIs are preventable. 
Communities with good access to effective preventive community interventions and 
improved treatment services have lower rates of STIs/RTIs and their complications than 
communities where services are poor, disrupted or not used by people at risk. Reducing the 
burden of STIs requires a broad spectrum of activities, ranging from education and labour 
policies to good clinical management (Box 3).  
 
Box 3 Components in STI/RTI control at the community level (41) 
 Economic and social policies that reduce family separation may reduce risk and 
vulnerability. 
 Education and employment opportunities for girls reduce the economic pull of sex work, 
empower women and reduce STI risk. 
 Raise awareness of STI/RTI symptoms and complications, as well as how they can be 
prevented – especially among populations who may be at high risk.  
 Promote safer sexual practices – including consistent condom use, fewer partners, and 
delaying sexual onset. 
 Ensure easy access to condoms. 
 Preventive and treatment interventions targeting vulnerable groups such as sex workers. 
 Reducing barriers such as cost, distance, limited clinic hours and long waiting times 
means better access to care. 
 Promotion of improved health care services will convince more people to use services. 
 Screening and case finding of asymptomatic or less obvious infections when possible 
 Manage symptomatic STI/RTIs effectively. 
 Counsel patients on staying uninfected after treatment. Encourage them to comply with 
treatment, assist with partner notification and treatment, and reinforce prevention. 
 
  
Diagnosis and treatment of STIs in the developing world is usually limited to the 
syndromic approach. As early as in the 1970s, public health physicians, especially those 
working in Africa, became interested in testing simple clinical tools for controlling and 
treating STIs (42). This resulted in the design and promotion of “syndromic management” 
guidelines by the World Health Organization in the beginning of the 1990s (6). The 
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 syndromic approach is developed for the management of symptomatic STI patients, in 
countries where accurate laboratory diagnosis is out of reach. With the use of simple 
flowcharts, usually called algorithms, presenting symptoms and clinical signs are classified 
into defined STI syndromes such as genital ulcer and vaginal or urethral discharge 
syndrome. The patients are treated with standardized drug regimens including at least two 
antibiotics - to cover the possible causes of their syndrome. The advantages of syndromic 
management include prompt and standardized management and treatment at the first visit, 
as well as cost and resource savings by not having to use laboratory tests.  
This thesis has its primary focus on the management of the five cervical and vaginal 
infections within the vaginal discharge syndrome (VDS) (Table 1). This is the most 
commonly used syndromic management algorithm, but its inappropriateness has been 
acknowledged for decades (43). First, the five conditions can all be cured, but their 
detection and treatment is complicated by their frequently asymptomatic nature. The entry 
point to the VDS algorithm is symptoms of abnormal vaginal discharge; and many people 
with an STI/RTI are not identified because they are asymptomatic or have mild symptoms. 
The low sensitivity is a major disadvantage of the syndromic approach, reducing the 
possibility of preventing reproductive complications and sequelae and of interrupting 
onward transmission (32, 42, 44, 45).  
Second, abnormal vaginal discharge is common and has thus low specificity for the 
conditions in the vaginal discharge algorithm. This results in high levels of overtreatment, 
which increases drug costs and the risk of drug resistance, while patients unnecessarily 
experience side effects of drugs and changes in endogenous flora. Studies have consistently 
shown that for the cervical infections, treating patients with symptoms and signs of 
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 abnormal vaginal discharge is not, or only modestly, better than random treatment (43, 46-
48). The high level of over-diagnosis also undermines partner notification. In most low-
income countries, partner notification is patient based; patients are told to inform their 
partners and refer them for treatment. In the syndromic approach, all presenting partners are 
empirically treated. However, as most patients diagnosed with vaginal discharge syndrome 
do not have an STI, their partners should neither be notified nor treated (49). It is also 
problematic that both the complexity of multiple drug regimens and the diagnostic 
uncertainty may reduce patient compliance (50). 
Table 1 The infections and conditions within the vaginal discharge syndrome 
Cervical infections 
Chlamydia
    
Gonorrhoea
A sexually transmissible infection caused by obligate intracellular 
bacteria which may cause cervicitis in women and urethritis in men. 
A sexually transmissible infection caused by bacteria which may cause 
cervicitis in women and urethritis in men.
Vaginal infections/conditions 
Trichomoniasis 
 
 
Bacterial vaginosis 
     
 
 
 
Vulvovaginal 
candidiasis
A sexually transmissible infection with a single-celled protozoan parasite 
which may cause increased discharge, vulvovaginal soreness and itching 
and dyspareunia in women and urethritis in men. 
An endogenous syndrome marked by an increased vaginal pH, milky 
creamy discharge, and amine or fishy odour. Microbiologically, bacterial 
vaginosis is characterized by a shift in the vaginal flora from the dominant 
flora of Lactobacillus spp. to a mixed flora that includes Gardnerella 
vaginalis, Bacteroides spp., Mobiluncus spp., and Mycoplasma hominis.  
An endogenous fungal infection of any of the Candida species (of which 
Candida albicans is most common) which may result in increased 
discharge, vulvovaginal soreness and itching and dyspareunia in women. 
The yeast may be transmitted to male partners and cause balanitis.
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 The syndromic approach relies heavily on the quality of care provided. It is a 
recognized problem in the routine care that STI patients quite often are assessed improperly 
and that the opportunity for counseling and health promotion is underutilized. In a national 
evaluation of the quality of the STI management in Botswana, only 17% of the patients 
were assessed and managed according to the guidelines (51). Another study showed that 
female STI patients in Botswana were managed in an average of 5.4 minutes (7). The lack 
of access to specific diagnostic tests and the uncertainties of the syndromic diagnoses may 
discourage health workers from following the guidelines, and partly explain inadequate 
history-taking, lacking or insufficient examination, insufficient or unnecessary 
prescriptions, and a lack of commitment to counseling on treatment compliance, safer 
sexual practices and partner notification (3).  
 
Figure 1 Challenges with the management of STI patients (The Piot-Fransen model) 
Individuals with STIs in the population
Symptomatic infections
Seek health care 
Compliant with drug regimen
Partner notified and treated
Cured patient
Healthy populationSTIs
STI identified and correct treatment prescribed
 
There are a number of challenges to providing effective STI/RTI services (Figure 
1). Evidence from Rakai, Uganda has shown that relying on treatment of only those with 
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 symptoms implies that less than 8% of the infected population receives effective treatment 
(52). Cure rates are even lower, as insufficient compliance and re-infection from untreated 
partners are effective obstacles to cure after the encounter with the health facility. Similar 
estimates from Mwanza, Tanzania are also pessimistic, indicating that cure rates among 
symptomatic patients visiting health centres are less than 10% (11). 
Alternative approaches to STIs in developing countries, in particular to solve the 
challenges with the vaginal discharge syndrome, have been thoroughly discussed (32, 45, 
53). However, strategies such as risk assessment and clinical screening do also have low 
sensitivity and specificity; whereas mass treatment is linked to development of antibiotic 
resistance and high drug wastage (54, 55). The development of simple POC tests for C 
trachomatis and N gonorrhoeae has been a high priority since the 1990s (54, 56, 57). The 
continued use of the syndromic approach in the management of cervicitis has been viewed 
as a temporary solution for health care providers awaiting the availability of such tests (57). 
Diagnostic tests for STIs 
The use of laboratory services has long been a natural and established routine in the 
management of STIs in high income countries. In sub-Saharan Africa, access to reliable 
diagnostic testing in general is severely limited (58), and advanced STI tests have been 
beyond reach for most laboratories. Simple, affordable diagnostic tests for STIs are needed 
in the developing world: to precisely diagnose symptomatic patients, reduce the over-
treatment, and to screen for asymptomatic infections in selected populations. Point-of-care 
tests are particularly valuable. As they allow immediate diagnosis and treatment, lower 
sensitivity than advanced, laboratory-based tests can be accepted. A POC test with a 
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 sensitivity of 65% can lead to a greater proportion of infected patients treated compared to 
a nucleic acid amplification test with sensitivity of 90% when the return rate for test results 
and treatment is low (59).  
Major progress in the development of POC tests has recently been made. A range of 
tests are now on the market for several STIs, including all microbes targeted with the 
vaginal discharge algorithm (Table 2) (42, 60). The Sexually Transmitted Diseases 
Diagnostics Initiative (SDI) at the WHO was founded in 1999 - in response to the widely 
perceived need to improve care for patients with STIs in resource-poor settings through 
improved diagnostics. Evaluation and field-testing of existing POC tests for chlamydia, 
gonorrhoea and syphilis are important priorities for SDI (60, 61).  
 
Table 2 Simple diagnostic tests for the microbes targeted with the VDS algorithma  
Infection Test Sensitivity Specificity Ref.
Chlamydia Immunoassay 25-85%  90% (60, 62-66) 
Gonorrhoea Immunoassay 
Microscopy 
25-85% 
 84-95% 
 50% 
 90% 
 95% 
 95% 
(60, 62, 66, 67) 
(62) 
(62) 
Trichomoniasis Microscopy  
Latex agglutination test 
45-70% 
>95% 
92-100% 
> 90% 
(60, 68-70) 
(71) 
Bacterial vaginosis  Nugent’s criteria b 
Amsel’s criteria b 
?/100% 
50-90%  
?/100%  
80-95%  
(60, 72) 
(60) 
Vulvovaginal 
candidiasis 
Microscopy  30-85%  95%c (69, 73, 74) 
 
aThe sensitivity and specificity of the tests are only for guidance, as it will depend on the prevalence of the 
condition in the population, the reference standard used etc.  
bBacterial vaginosis is a clinical syndrome, and the sensitivity and specificity of Nugent’s criteria is uncertain 
in the absence of a reference standard. The performance of Amsel’s criteria is compared with Nugent’s 
criteria. 
cColonization with candida species is common, and the detection of candida by microscopy (or culture) is 
highly specific, but does not necessarily confirm infection. 
 
 
POC tests for the diagnosis of chlamydia and gonorrhoea currently include 
microscopy of cervical or urethral smears for gonorrhoea and immunoassays for both 
 23
 infections (62). The immunoassay detects antigen using high-affinity antibodies fixed onto 
nitrocellulose strips, does not require additional equipment and can give a visual result 
within 30 minutes. So far, evaluations of POC tests for chlamydia and gonorrhoea have 
shown variable sensitivities (25-85%), but high specificity (>90%) (62, 66). A recent study 
found that a commercially available chlamydia test which is widely used in China had a 
sensitivity of 50% and a specificity of 98-99% (63). A study of a rapid test to diagnose 
gonorrhoea in high risk Brazilian women found a sensitivity of 60% and a specificity of 
90% (67). More tests are in development, and most likely, more sensitive tests will be 
available within a few years. Encouraging data on an improved rapid test for ocular 
chlamydial infection have recently been published (75). The evaluated test had a sensitivity 
of 84% and a specificity of 99% using a polymerase chain reaction (PCR) test as the 
reference standard. 
 
Point-of-care tests for chlamydia in the antenatal care in Botswana 
One of the aims of this thesis was to conduct an economic evaluation of using POC tests for 
chlamydia in the antenatal care in sub-Saharan Africa, using Botswana (Box 4) as a case. 
We chose to focus on pregnant women because of the additional advantage of preventing 
adverse obstetric outcomes and neonatal infections. We focused on chlamydia because it 
was the most common cervical infection in this population and because of the described 
severe weaknesses of the existing diagnostic strategy. Although POC tests for chlamydia 
can prove to be cost saving in a broader perspective, health authorities in resource poor 
settings may be discouraged by the direct cost of purchasing and using such tests. In 
Botswana, the prevalences of HIV and other STIs are very high. In 2005, 33% of the 
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 antenatal care attendees were HIV infected (76). STIs are a major public health problem: 
during the last decade, there have been registered between 100 000 and 200 000 STI-related 
outpatient consultations each year (77, 78). To explore POC tests as an alternative or 
addition to the current STI management is consistent with the health policy in Botswana 
(79, 80), and the economic possibility to introduce this intervention should be present.  
Currently, pregnant women in Botswana complaining of vaginal discharge or lower 
abdominal pain are managed with the vaginal discharge algorithm according to national 
syndromic approach guidelines (Figure 2) (81). Based on a risk assessment and the signs 
found on clinical examination, the women receive treatment for chlamydia and gonorrhoea 
and/or trichomoniasis and bacterial vaginosis and/or candidiasis. In addition, all antenatal 
care attendees are clinically screened for STIs/RTIs. The antenatal care guidelines 
recommend a routine speculum examination at the first antenatal visit, to “exclude genital 
infections, abnormalities and pelvic tumors” (82).  
There is a logistic advantage of introducing an extra service to a relatively well-
functioning antenatal care program. The attendees meet at the clinic routinely; a good 
framework for diagnosis, treatment and follow-up. Screening for syphilis and HIV is 
incorporated into the antenatal routine, and at the first visit, blood is drawn for Hb, blood 
group, rhesus-factor, syphilis and HIV tests (82). Specimens for a POC test can be taken at 
the genital examination at the first visit, the test can be analysed on-site and treatment 
provided if necessary. Thus, POC testing for chlamydia will not lead to any change in the 
number or overall content of the routine antenatal care visits. 
In the process of implementing the prevention of mother-to-child-transmission 
(PMTCT) program, and subsequently the antiretroviral treatment program, the laboratory 
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 capacity in Botswana has been extensively upgraded to manage routine and clinical HIV 
testing, monitor the epidemic and perform research. In addition, all health posts and clinics 
have a lay counselor who performs point-of-care tests for HIV. This experience shows that 
utilizing clinicians or lay counselors to perform simple rapid tests in the primary health care 
is feasible.   
Box 4 The health system and health situation in Botswana (79)  
Botswana is located in southern Africa, 
landlocked between South Africa, Namibia, 
Zambia and Zimbabwe. The country is flat, at 
about 1 000 metres above the sea, with an 
arid or semi-arid climate. More than two-
thirds of the land area consists of the Kalahari 
Desert. In North-West, the Okavango River 
drains inland to form the Okavango Delta, 
while the majority of the population lives in 
the eastern region. After 80 years as a British Protectorate, it attained self government in 1965 
and became the independent Republic of Botswana. The Botswana Constitution established a 
non-racial multiparty democracy, which maintains freedom of speech and affords all citizens 
equal rights. From being one of the poorest countries in Africa, it experienced a remarkable 
economic transformation due to the emergence of the minerals sector shortly after the 
independence. 
Botswana has one of the best health care systems in Africa, based on a primary health 
care ideology with access for all citizens to essential health care, and an equitable distribution of 
resources and utilization of health services. Almost 90% of the residents live within 15 km of a 
clinic or health post, while mobile stops cover small communities. The government health 
services are affordable, with either small user fees or free services. Drugs are provided free of 
charge. Experienced nurses lead the clinics, and nurses are responsible for the outpatient 
consultations and the antenatal care. ‘Family welfare educators’ work in the villages and play an 
important role in the primary health care, representing a tradition of successfully utilizing 
personnel with little training or education as health workers. 
ZambiaAngola 
Zimbabwe
Botswana 
Namibia
South Africa
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 As many other developing countries, Botswana is undergoing a health transition, where 
changes in lifestyle and economy has resulted in a decline in communicable diseases and an 
increase in cardiovascular diseases and diabetes. However, the transition is incomplete: the 
fertility as well as the occurrence of infectious diseases are still high, and AIDS has emerged as a 
major cause of morbidity and mortality. Improvements in core health indicators (Table 3) have 
stagnated or been reversed: infant and child mortality rates have dramatically increased, and the 
life expectancy has fallen from nearly 65 years in 1985-1990 to 40 years in 2000-2005 (83). The 
morbidity related to HIV comprises an enormous challenge for the health care system, which 
itself is struggling with the loss of manpower. 
The recently retired president Mogae described the HIV/AIDS epidemic as a national 
emergency, and the response to the crisis has been more comprehensive than anywhere else in the 
region (84). The Prevention of Mother to Child Transmission program (PMTCT) started in 1999, 
and Botswana has now lowered the rate of mother-to-child transmission of HIV from 40 to less 
than four percent. Since 2002, an antiretroviral treatment program has been expanded with the 
intention to reach all infected people with symptoms or a CD4-count less than 200. Shortage of 
skilled personnel was one of the largest challenges to treatment scale-up, partly solved by in-
service training of health professionals and the use of lay workers. Today the program is seen as a 
successful model for other African countries. 
 
Table 3 Core demographic, economic and health indicators in Botswana (85, 86) 
Country statistics Estimate Year
Demographic indicators 
  Total population 
  Annual population growth rate (%) 
 
1 858 000 
1.9 
 
2006 
1990-2006 
Economic indicators 
  Per capita GNI in US$ 
  % of government budget spent on health care 
 
5 900 
5 
 
2006 
1995-2005 
Health indicators 
  Total fertility rate  
  Maternal mortality rate  
  Life expectancy at birth 
  Infant mortality rate  
  Under 5 mortality rate 
 
3 
380 per 100 000 live births 
49 
90 per 1 000 live births 
124 per 1 000 
 
2006 
2005 
2006 
2006 
2006 
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 Figure 2 The vaginal discharge algorithm in Botswana, 2005 
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 Economic evaluations in health care 
Economic evaluation is the comparative analysis of alternative courses of action in terms of 
both their costs and consequences (87). It encompasses identifying, measuring, valuing and 
comparing the costs and the health consequences of the alternatives being considered, 
which means that the difference in costs is compared with the difference in health outcomes 
(87). The process is a systematic approach to decision making under uncertainty, designed 
to help decision makers think clearly about the many elements of complex decisions (88).  
The use of economics in health care is concerned with increasing efficiency of 
current and new health interventions. Technical efficiency exists when no greater output can 
be achieved with a given set of resource inputs. Allocative efficiency is used in a broader 
perspective, and exists when the available resources are allocated to maximize the 
objectives of the health care system. If an intervention can achieve the same or better 
results more cheaply relative to the existing care, or if greater effectiveness is achieved to 
the same costs, it will be judged better (more technically efficient) (89). Commonly, new 
interventions imply greater health benefits, but also greater costs compared to the current 
management. Implementation of such strategies raises allocative efficiency questions, as 
the benefits of improved care (unless the health care budget is increased) is likely to be at 
the expense of another group of patients (89). This is a basic principle in economic 
evaluation, opportunity cost (88, 89). In health care it means that devoting resources to one 
health intervention also implies a cost in the sense that opportunities for improving health 
or saving lives elsewhere are forgone.  
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 There are three types of full economic evaluations: cost effectiveness analysis 
(CEA), cost utility analysis (CUA) and cost benefit analysis (CBA) (87). In short, the 
methods are distinguished according to how the health outcomes are valued. In CEA, health 
benefits are measured in natural units such as life years gained, hip fractures avoided, or as 
in our study, cases of chlamydia cured. This is useful when striving for the optimal use of 
resources to maximize a specific health outcome. In CUA, the measure of benefit is quality 
adjusted life years (QALY) or disability adjusted life years (DALY), making it possible to 
compare interventions with widely different health outcomes. The CUA is a variant of the 
CEA, and in published medical literature, economic analyses with DALYs or QALYs as 
the health outcome are often labelled “cost-effectiveness analysis”. In CBA, the benefit is 
measured in monetary terms, which enables comparing projects across sectors. Partly due 
to the problem of valuing and expressing health benefits in monetary terms, CBA is rarely 
used for economic evaluations in health care. 
The costs included in an economic evaluation are dependent on the perspective of 
the analysis. In the societal perspective, all costs and health consequences should be 
captured, irrespective of who pays or who benefits: health sector costs; costs on other 
sectors; all relevant costs to the patient and family; and productivity losses. A health care 
provider perspective includes only the costs that are borne by the health care services.  
 
Cost-effectiveness analysis 
The economic study presented in this thesis is a cost-effectiveness analysis. The aim of 
such an analysis is to estimate the difference in cost (C) and the difference in effects (E) 
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 between interventions. The result can be summarized as the incremental cost-effectiveness 
ratio (ICER): 
12
12
EE
CCICER


  
 
The concept of a cost-effectiveness analysis can be illustrated graphically on the 
cost-effectiveness plane (Figure 3) (87, 90). The x-axis divides the plane according to 
incremental costs, and the y-axis divides the plane according to incremental effects.  
Figure 3 The cost-effectiveness plane 
                                  COST 
 
III 
Alternatives less effective 
and more costly 
 
 
        IA           IB 
Alternatives more effective
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       IIIA             IIIB 
Alternative less effective 
and less costly 
                              EFFECT 
 
II 
Alternative more effective 
and less costly 
 
Alternative strategies can be represented by a point in this plane, defined by the 
effectiveness and cost of the alternative relative to those of a reference standard. This 
reference, placed in the origin, represents either the current standard or a “do-nothing”-
strategy. Strategies in quadrant II are equally costly and more effective, or less costly and 
equally or more effective than the reference, and will by definition be categorized as cost-
effective relative to this reference. Interventions in quadrant IV are not cost-effective. 
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 In order to decide if strategies in quadrant I and III are worthwhile, their cost per effect 
gained must be compared to a specified monetary threshold; the maximum amount that the 
decision makers are willing to pay for a given health effect (yellow dashed line). A strategy 
is by convention defined as cost-effective if its incremental cost-effectiveness ratio is less 
than the maximum acceptable cost-effectiveness ratio (IB or IIIB) (90). 
In practice, most interventions fall into quadrant I (Figure 4). For each strategy, the 
average cost-effectiveness ratio (CER) is given by the slope of the line from the origin. 
Strategy A and strategy B have average CERs lower than the willingness to pay, and 
viewed separately, they would both be considered cost-effective. For meaningful 
comparison between two strategies, however, we have to examine the ICER, visualised by 
the slope of a line between one strategy and the next more effective treatment. In this case, 
the additional cost per additional outcome gained by moving from A to B is higher than the 
maximum CER. This is important to consider before it is decided whether the price is 
worth paying (87). 
Figure 4 Average and incremental cost-ef fectiveness atios  
COST
 
 
When three or more strategies are compared, they can be arranged according to 
ncreasing costs (Figure 5). Of the alternatives A-E, strategy B is strongly dominated by 
alternative C, because the latter is less costly and more effective (Figure 5). Alternative D is 
B
A
EFFECT
MAXIMUM CER
ICERCER 
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 32 
 extendedly dominated by alternative E; it has higher ICER than the next, more effective 
alternative. If the objective was to be taken based on cost-effectiveness principles, strongly 
and extendedly dominated strategies should be rejected. The remaining strategies A, C and 
E are ordered according to their ICER. To maximize the effect within a given budget, the 
strategy with the lowest ICER is adopted first (strategy A). Then independent strategies are 
successively added, or mutually exclusive strategies replaced, until the budget is exhausted. 
An alternative approach is to define the maximum acceptable CER, adopt all strategies with 
ICERs below this ceiling, and see what size of the budget this implies (87). 
Figure 5 Dominance and incremental cost-effectiveness ratios 
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Knowledge and knowledge gaps in economic evaluations of chlamydia
Being the most common bacterial STI in Europe and the United States, numerous cost-
effectiveness analyses of screening for chlamydia with laboratory based diagnostic tests 
have been published, most commonly among female out-patients (91-93). The most recent 
systematic review of the economic evaluations of screening for C trachomatis identified 
713 papers and included 57 formal economic evaluations and two cost studies - none from 
developing countries (91). Many of the studies use ‘infection treated’ or ‘infection cured’ as 
the outcome measure, whereas some use complications averted, such as pelvic 
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 inflammatory disease and infertility (91, 92). In general, it is found that the cost-
effectiveness ratio decrease with increasing disease prevalence (93). The cost-effectiveness 
is also highly dependent of the risk of complications in untreated patients, but the 
magnitude of this risk is yet to be determined (94). 
I have identified two economic evaluations of chlamydia screening programs 
specifically for pregnant women. Both papers present static cost-effective decision models 
and use ‘major outcomes averted’ as outcome. A study conducted in the Netherlands 
concludes that screening with advanced laboratory methods for asymptomatic C 
trachomatis infection in pregnant Dutch women would render net savings at a minimum 
prevalence rate of 3% or more (92). Nettleman and Bell in England evaluated culture and 
direct antigen testing of pregnant women, assuming different prevalences of infection. The 
probabilities of major outcomes averted were derived from published literature. They 
conclude that screening all pregnant women would not be cost-effective, but characterized 
the additional costs as ‘modest’ when direct antigen tests were used (95).  
It has been said that cost-effectiveness analyses do not travel well (25). There are 
several reasons why the results of these evaluations are not transferable to resource poor 
settings. The diagnostic tests used in industrialized countries are out of reach, and the 
differences in health and disease patterns, health care systems as well as economic systems 
are obvious. Economic evaluations of STI management in developing countries exist, 
although the so-called research gap1 is found also in this field. Common to these 
evaluations is that they mainly focus on STI syndromes, not specific STIs/RTIs. Broadly, 
they can be divided into two categories. The first includes studies examining the cost of 
                                                 
1 The 10/90 gap states that less than 10% of the global health research targets diseases affecting the poorest 90% of the 
world population. 
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 treating curable STIs/RTIs, using ‘treatment provided’ or ‘infection treated’ as the outcome 
measure. The service delivery modes which are evaluated include management of 
symptomatic STI clients; case finding among family planning clients or antenatal care 
attendees; and services aiming to reach specific high risk groups. A recent review reports 
that heterogeneity of methods and outcome measures used in the analyses, and the fact that 
methods are often not clearly documented, complicate the synthesis and interpretation of 
the results (96). Nevertheless, the authors conclude that clinics serving symptomatic 
patients were consistently less costly than outreach services, that syndromic management 
had lower cost than other management strategies and that unit costs decreased with scale. 
Analyses in the second category use ‘number of HIV-infections averted’ as outcome 
in the economic analyses, reflecting that STI management in developing countries is seen 
as one of many strategies to combat the spread of HIV/AIDS (97). With this outcome 
measure, the costs per DALYs or QALYs gained can be estimated, enabling comparison 
between STI management and other health interventions. The CHOICE group in WHO has 
published a series of papers examining the cost effectiveness of different strategies to 
achieve the millennium development goals. They found that reducing HIV transmission 
could most efficiently be achieved through mass media campaigns, interventions for sex 
workers and syndromic management of STIs (provided in primary health care facilities and 
available to the general population) (97). Other STI management strategies were not 
evaluated. 
When the work with this thesis was initiated, there were no economic evaluations of 
the use of simple POC tests for chlamydia. Since then, one group of researchers has 
modelled the cost-effectiveness of using a combined POC test for chlamydia and 
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 gonorrhoea, versus syndromic management, among sex workers in Benin. With the use of 
HIV infections averted as the outcome measure, the test strategy was considered cost 
effective and reduced inappropriate treatment (66). To our knowledge, there are still no 
economic evaluations of chlamydia management in pregnancy in resource poor settings. In 
conclusion, there is an obvious lack of cost-effectiveness studies from developing countries 
comparing the costs and health consequences of current or alternative chlamydia 
management strategies, including the use of POC test, in pregnant women. 
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 Objectives
 
My vision throughout this work has been to contribute to reduced levels of STIs and their 
complications in developing countries, thereby preventing HIV transmission, and 
ultimately improving the health status of the population. It is visionary, indeed, but with the 
origin in the established knowledge that the current STI management in developing 
countries had substantial potential for improvement. The resources allocated to the health 
services in developing countries are scarce. My hypothesis was that investing in the use of 
specific diagnostic tests for STIs would pay off because of reduced expenses to manage the 
complications of undetected and untreated infections. Concretely, the main objective of this 
thesis was to 
Compare the costs and health consequences of testing with specific diagnostic tests 
versus using the existing syndromic management of STIs among antenatal care 
attendees in sub-Saharan Africa.  
As has been argued for, we chose to focus on diagnostic and treatment alternatives to the 
vaginal discharge algorithm among pregnant women. We evaluated the syndromic 
management of all microbes within this syndrome, whereas the economic evaluation 
focused on chlamydia. The specific objectives were as follows:  
 
1. To estimate the prevalence of chlamydia, gonorrhoea, trichomoniasis, bacterial 
vaginosis and vulvovaginal candidiasis in a sample of pregnant women in 
Gaborone, Botswana. [Included in paper 1-3] 
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 2. To assess treatment success among the attendees who had been diagnosed with 
syndromic approach and prescribed treatment for cervical infections during the 
routine antenatal care earlier in pregnancy. [Paper 2] 
3. To evaluate the syndromic approach for the detection of chlamydia, gonorrhoea, 
trichomoniasis and bacterial vaginosis in pregnancy, using laboratory tests as the 
reference standard. [Paper 2 and 3] 
4. To determine whether risk scores could improve the diagnostic accuracy of cervical 
infections. [Paper 3] 
5. To compare costs and health consequences of the syndromic management with 
using point-of-care (POC) tests to diagnose chlamydia among antenatal care 
attendees in sub-Saharan Africa, including an evaluation of azithromycin versus 
erythromycin treatment and universal versus age-based management. [Paper 4] 
6. To suggest cost-effective modifications, additions or alternatives to the current 
syndromic management of STIs in sub-Saharan Africa. [Paper 4] 
Finally, I hope that we manage to distribute our findings to national health ministries, donor 
countries and other parties involved the STI management, having the great task of ensuring 
the most cost-effective use of resources and improve the functioning and performance of 
the health sector.  
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 Methods
The epidemiological study 
Sample and sample size 
A proportionate sample of attendees was recruited from each of 13 locations, based on the 
percentage of all antenatal care attendees who attended that facility the previous year. 
There were 6 300 women attending antenatal care in Gaborone yearly in 2000 and in 2001 
– approximately 525 per month. With a study sample of 703, we included 27% of the 
antenatal care attendees in Gaborone in the data collection period in our study.  
Participating in this study were 703 antenatal care attendees in Gaborone, Botswana, none 
were included twice. There are substantial differences between the richer and poorer areas 
of Gaborone, and we aimed at getting a sample representative of the population of ANC 
attendees in the city. Seventeen facilities provided antenatal care at this point of time. We 
included women from the 13 main facilities providing antenatal care: 12 primary health 
clinics and one outpatient department. For practical reasons, five facilities with less than 
700 antenatal care consultations the previous year (range 15-690) were not included in the 
study. These clinics were Sebele (outside Gaborone), two university clinics, the prison 
clinic and the police clinic, the two latter catering for employees and their families.  
Facilities were visited one-by-one by a medical doctor (the author) from the 5th of 
October 2000 to the 1st of March 2001. Each day at the clinic, the women were 
consecutively invited to be included in the study from the morning. The number of patients 
per day was limited by either the total number of women that day, or by the number of 
specimens that the laboratory could handle (usually 12, it varied because of varies in staff 
and other activities at the lab). In the majority of clinics, all attendees were included in the 
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 study. In the busiest clinics, only a sample of the attendees was included; the selection of 
attendees in these clinics was incidental. These clinics have many consulting rooms and 
several midwives conducting antenatal care simultaneously. The study doctor would work 
in a separate consulting room, conducting the ordinary pregnancy control and collecting 
data for the study. In a clinical setting like this, systematic randomization of the patients is 
virtually impossible to accomplish. It was incidental which women who were seen by a 
clinic midwife and subsequently sent home, and which were seen by the study doctor. We 
no reason to believe, however, that any systematic bias was involved in the selection of 
this attendee sample or that our sample is less representative than it would have been had 
our attendees been randomly chosen.  
The only exclusion criterion was the use of antibiotics during the previous two 
weeks.  
 
Interview and clinical examination 
A structured interview (Appendix 1), supplied with information from the patient-held 
antenatal record (Appendix 2) were used to obtain data on sociodemographic and 
behavioral factors and current RTI symptoms. When a patient is diagnosed with an STI 
syndrome during pregnancy, the syndrome and the prescribed drugs are documented in the 
antenatal record. Prescribed treatment for any STI during the current pregnancy was 
recorded along with the syndrome diagnosis. 
All patients underwent a genital examination; appropriate specimens were collected; 
and abnormal signs from external and internal genitalia were recorded in detail. Amount, 
consistency, color and odor of vaginal discharge were described. Signs of a sexually 
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 transmitted infection were classified into defined syndromes following the national 
guidelines and were treated accordingly. 
  
Laboratory analyses 
Urine was checked on site with a dipstick; all other specimens were transported at ambient 
temperature the same day for processing at the National Health Laboratory (NHL) in 
Gaborone. A desired outcome of this study pronounced by the NHL in addition to the 
specific study objectives was to develop human and technical laboratory competence on 
STI/RTI analysis in Botswana. Two laboratory technicians were trained in STI analysis 
prior to the study (in Center for Disease Control and Prevention in Atlanta, USA, and in 
South African Institute for Medical Research). The remaining staff was trained when the 
study was ongoing. A ligase chain reaction (LCR) machine was bought for study purposes 
and subsequently donated to the laboratory. 
A cervical smear was gram-stained to count polymorphonuclear leukocytes per high 
power field. For the identification of trichomoniasis and bacterial vaginosis, one high 
vaginal swab was placed in Stuart transport media; another was used for a vaginal smear. 
Wet-mounts made from the swabs in transport media were examined for motile 
trichomonads by light microscopy. The swabs were then agitated into bottles of Diamond’s 
modified medium, the bottles were incubated in Oxoid gaspack jars, and wet-mounts were 
examined for trichomonads once daily for up to five days.  
The vaginal smears were Gram-stained and scored for bacterial vaginosis by an 
experienced laboratory technician according to Nugent’s criteria (72). On a 0-10-point 
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 scale, a score of <4 is considered normal, 4-6 intermediate, and 7 and above is classified as 
bacterial vaginosis (Table 4).  
 
Table 4 Nugent’s criteria: Scoring system (0 to 10) for Gram-stained vaginal smearsa 
Score b Lactobacillus 
morphotypes 
Gardnerella and 
Bacteroides spp. 
morphotypes 
Curved gram-
variable rods 
0 
1 
2 
3 
4 
4+ 
3+ 
2+ 
1+ 
0 
0 
1+ 
2+ 
3+ 
4+ 
0 
1+ or 2+ 
3+ or 4+ 
 
aMorphotypes are scored as the average number seen per oil immersion field. Total score 
= lactobacilli + G. vaginalis and Bacteroides spp. + curved rods. 
b 0, No morphotypes present; 1, <1 morphotype present; 2, 1 to 4 morphotypes present; 3, 5 to 30 
morphotypes present; 4, 30 or more morphotypes present. 
 
Culture of Candida species was initiated by direct inoculation of Saboraud plates at 
the clinic, incubated at 35 °C (5% CO2), and examined after 24 and 48 hours. Smears of 
colonies from positive cultures were Gram-stained and examined for budding yeast cells 
and pseudohyphae. The wet-mounts and Gram-stained smears were also examined for 
candida. Presence of candida was defined as positive growth and/or microscopy.  
Cervical swabs were obtained from all women for LCR amplification technology 
for the direct, qualitative detection of specific target nucleic acid sequences of C 
trachomatis and N gonorrhoeae. The swabs were placed in LCx® transport media and 
stored at –20o C prior to batch processing.  The LCx® Assays (Abbott Laboratories, IL) 
were performed according to the manufacturer’s instructions. A case of C trachomatis or N 
gonorrhoeae infection was defined as an individual with a positive LCR analysis. Culture 
of N. gonorrhoeae was also performed. Last, venous blood samples were collected, and the 
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 maternal sera were tested with the RPR test and the specific Treponema pallidum 
haemagglutination assay (TPHA). 
Selected specimens were sent to Norway for analyses at the Norwegian Insistute for 
Public Health, including examining antibiotic susceptibility patterns of N gonorrheae 
isolates and typing of the Candida isolates. These results and the data on syphilis (98) are 
not included in this thesis. 
 
Statistical analyses 
Data were analysed using the statistical package SPSS. Univariate logistic regression 
analyses were used to assess the association between genital symptoms and signs, and the 
laboratory-verified diagnoses of trichomoniasis and bacterial vaginosis (paper 2) and of 
cervical infections (paper 3). Socio-demographic risk factors and genital symptoms and 
signs that, in univariate analysis, were associated at a 0.2 level (P-value of odds ratios 
[OR]), were included in multivariate logistic regression analyses. Validity of the vaginal 
discharge algorithm, of clinical screening and of risk scores for cervicitis were assessed by 
measuring sensitivity, specificity, positive and negative likelihood ratios (LR+ and LR-), 
and positive and negative predictive values, using the laboratory diagnosis as the reference 
standard. 
 Three levels of risk scores were computed and retrospectively applied, and each of 
them were assessed for their usefulness as a diagnostic tool to manage cervical infections in 
pregnancy (Table 1, paper 3). Receiver Operating Characteristic (ROC) curves were used to 
compare the different risk scores (Figure 6). The ROC curve was first used during the 
World War II for the analysis of radar signals. In medicine, ROC analysis has been 
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 extensively used in the evaluation of diagnostic tests, as a graphical plot illustrating the 
trade-off between high sensitivity and high specificity. The test result can be in a 
continuous output in which the disease must be determined by a cut-off value, for instance 
to determine whether a person has hypertension based on blood pressure measure, or it can 
be in a discrete value, for instance a positive or negative pregnancy test. The best possible 
diagnostic test would yield a point in the upper left corner of the ROC space, representing 
100% sensitivity and specificity. A completely random guess would give a point along a 
diagonal line.  
 
Figure 6 Receiver operating characteristic (ROC) curve (from Wikipedia)  
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 Ethical considerations 
The study was approved without questions by the relevant ethical committees: The 
Norwegian Committee for Medical Research Ethics, the Health Research Development 
Committee in Botswana and the Hospital Research and Ethical Committee at Princess 
Marina Hospital. The Ministry of Health granted permission to transport specimens to 
Norway for quality control.  
 Information about the study was distributed to the antenatal care clients in English 
and Setswana. All clients did also receive personal information and got the possibility to 
ask questions to the clinics’ midwives, in particular to those who did not speak English or 
could not read. Women who did not participate in the study received ordinary care, whereas 
among the consenting women, the short interview and the gynaecological examination were 
conducted as a part of the visit. Testing for STIs is not routinely provided, and most women 
expressed that they appreciated the advantages of the additional examination and tests.  
The patients were informed that they could return for their laboratory results after 
one week; otherwise they would receive the results at the next ANC visit. All participants 
received a number which all information was linked to anonymously. In the laboratory 
records, the results were coupled to both names and number, to ensure feedback to the 
patients. All laboratory findings were sent to the clinics for distribution, and in case of 
positive results, the specific diagnosis and correct treatment was written explicitly on the 
form. Anecdotic, in all clinics where I stayed more than a week, I frequently participated in 
providing attendees with results – and treatment. 
 HIV-status would have been an interesting and important variable in the 
epidemiological study. At the time when the field work was planned and permissions to be 
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 applied for, HIV-testing for research purposes was a controversial and loaded issue in 
Botswana, and could therefore not be included. In the routine antenatal care program, all 
attendees were invited to participate in the PMTCT program on a voluntary basis, but the 
uptake was far from optimal. 
 
Table 5 Core issues in the economic evaluation 
 
Research question 
 
 
 
 
 
 
Type of economic analysis 
 
Comparators  
 
 
 
Perspective  
 
Patient group  
 
Evidence of effectiveness 
 
 
Utilization of health care 
 
Unit costs 
 
Measure of effectiveness 
 
Time horizon  
 
 
Discounting 
 
Sensitivity analyses 
In the management of chlamydia infection among antenatal care attendees, 
what are the costs and health benefits of  
a) Syndromic management versus point-of-care tests? 
b) Erythromycin versus azithromycin treatment 
c) Universal management versus age-based selective management 
strategies? 
 
Cost-effectiveness analysis performed within a static decision tree model 
 
Syndromic approach versus point-of-care tests. For each of these main 
strategies, we also compared universal and selective management strategies, 
and treatment with erythromycin or azithromycin. 
 
 Health care provider 
 
New antenatal care attendees 
 
Indirect evidence from a study on chlamydia among antenatal care attendees 
in Botswana, and other published literature 
 
Expert judgment 
 
Costs of prescribing and providing treatment; cost of point-of-care test 
 
Successfully treated and cured infection 
 
The model captures events from a possible diagnosis of chlamydia at the first 
visit to the partner is treated (1 month) 
 
Not applicable due to the limited time perspective 
 
One-way and probabilistic sensitivity analyses 
The economic evaluation 
The core issues of the economic evaluation are listed in Table 5. The model is described in 
detail in a technical report (http://www.hero.uio.no/publicat/2007/HERO2007_10.pdf) (99). 
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The decision analytic model 
We used TreeAge Pro software to develop a decision analytic model comparing chlamydia 
management strategies in a hypothetical cohort of antenatal care attendees (Figure 1). The 
structure of the decision tree is shown as one main tree and three partner sub-trees (Figure 
1, paper 4). The decision tree is a branching structure in which decision nodes (squares) 
symbolise choices facing the decision maker. Chance nodes (circles) symbolize events 
where the possible outcomes are outside the decision maker’s control. The node’s branches 
represent the alternatives or outcomes associated with that event, and a terminal node 
(triangle) denotes the endpoint of a scenario. Information to feed the model was based on 
the epidemiological study of antenatal care attendees in Gaborone, literature reviews and 
expert opinions.  
The literature reviews consisted of extensive searches in MEDLINE, EMBASE, 
The Cochrane Library, text books, reports and other relevant sources, including local 
literature searches in Botswana. The reviews do not formally qualify for categorization as 
systematic as it was not feasible to do a full and systematic review for all the parameters in 
the model with such detail. The expert panel consisted of six medical doctors with wide 
clinical, administrative and research experience from the field. Issues discussed in the 
expert panel were also discussed with nurses in the primary health care in Botswana and 
with other resource persons in the country. The model parameters and their probabilities are 
shown in Table 1, paper 4 and described in detail in Appendix 3. The searches and the 
search results are described in the technical report (99).  
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 Health outcomes associated with treating chlamydia 
To fully capture the costs and health benefits of the different chlamydia management 
strategies, all prevented complications in chlamydia infected women, their partners and 
their offspring, and the resulting cost savings to the health system, should have been 
included in the model. Reviews of literature on complications of chlamydia in developing 
and developed countries revealed that published data are limited and inconclusive. These 
reviews are described in detail in the technical report (99). After substantial efforts to 
interview experts (medical doctors and nurses, health statisticians, health economists and 
officers in the health ministry) and collect health statistics, national health accounts and 
health budgets, we concluded that there is a lack of research, statistics and empirical 
experience on consequences and long term complications of C trachomatis infection in 
Botswana and similar settings. The health outcome estimated for each strategy is therefore 
limited to the number of cured infections among the attendees and their partners. We also 
estimated re-infections and the number of patients unnecessarily treated with the different 
strategies.  
Resource consequences and cost measures 
Our analysis adopted a health care provider’s perspective. The costs were presented in 2006 
US$ (Table 2, paper 4). For the syndromic management we modelled treatment costs 
(Ctreatment), which include the direct drug costs (Cazithromycin or Cerytrhromycin) and the cost of a 
pharmacy technician at the clinic outlet dispensing and informing about the drugs (t in 
hours x Cstaff2). The modelled costs of partner treatment (Ctreatment) also include the direct 
drug costs (Cazithromycin or Cdoxycyclin) and the dispensing process. For the use of POC tests we 
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 also included the test costs (Ctest per test) and the cost of the extra time needed to undertake 
each test (t in hours x Cstaff1). In the base case analysis, we used salary costs from 
Botswana and drug costs from Botswana and the International Drug Price Indicator Guide. 
Upper and lower ranges for the costs were estimated and evaluated in the sensitivity 
analyses to ensure relevance to countries with different personnel costs. 
STI management in pregnancy takes place within the framework of the antenatal 
care and the STI management programs. We modelled the direct costs of chlamydia 
management, assuming that following costs are covered in the antenatal program. 1. Capital 
costs: building costs, equipment and land and other capital-intensive items. 2. Overhead 
costs: resources that service different programs, as expenses related to the building (e.g. 
power, rates), and costs associated with administration, transport, maintenance, cleaning 
etc. We did not estimate intangible costs such as work time and leisure time forgone for 
care-givers and patients. The attendees routinely come to the clinic, and the individuals’ 
costs (travel costs and expenditure on goods and services) will not be affected by the STI 
management strategy. We also assumed that the STI management program, routinely 
training health workers, could cover the additional training needs. 
 
Deterministic and probabilistic sensitivity analyses 
To test the robustness of the model results, we undertook a range of sensitivity analyses. 
We first explored the consequences of parameter uncertainties in deterministic one-way 
sensitivity analyses, where one parameter at a time was varied up and down within the pre-
specified uncertainty bounds (Table 1 and 2, paper 4) while maintaining the others at their 
base-case values. In these analyses, screening all new antenatal care attendees with a 50-
85% sensitive POC test was compared to syndromic management in the same population 
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 using azithromycin as treatment. We also performed probabilistic sensitivity analyses using 
Monte Carlo simulation in which the model was run 10 000 times, allowing the effects of 
joint uncertainty across all the parameters of the model to be considered. Universal testing, 
first with a 50% sensitive and then with a 75% sensitive POC test, was compared to 
syndromic management, using azithromycin as the drug of choice. We adopted -
distributions for the probabilities to constrain the values between 0 and 1, and -
distributions for the costs because of their skewness. The probabilities in the two strategies 
were linked to account for interdependencies. 
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 Results and summary of the papers 
General results from the epidemiological study 
We did not register any women refusing to participate. All women were asked about 
antibiotic use, and 25 were excluded; all of them because they were currently taking 
STI/RTI treatment. Additionally, 9 women were excluded after interview, examination and 
specimen collection because information on antibiotic use (all for STIs/RTIs) was 
discovered later.  
Background characteristics of the study population and genital symptoms and signs 
are presented in Table 1, paper 2. Of the 703 women, 67 (10%) had laboratory-confirmed 
cervical infection: 51 (8%) were infected with C trachomatis and 21 (3%) with N 
gonorrhoeae. T vaginalis was identified in 131 (19%) women and bacterial vaginosis in 
268 (38%) women. Candida species were identified by microscopy and/or culture in 416 
(59%) of the women. In a total of 561 (80%) of the antenatal care attendees, one or more of 
these five infections and conditions were identified. 
We did not perform specific laboratory tests on microbes causing other syndromes. 
Few women reported other symptoms than vaginal discharge. Clinical signs of genital 
warts and genital ulcers were found in 4 % and 1 %, respectively. Five women had been 
diagnosed with genital warts and genital ulcers earlier in the current pregnancy, compared 
to 161 women who had been diagnosed with vaginal discharge. 
 
Chlamydia management strategies in the cost-effectiveness plane 
In the following, selected results from the cost-effectiveness analysis are illustrated 
graphically. Figure 7 presents the evaluation of the syndromic approach and of POC-testing 
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 strategies with a currently available 50% sensitive test. Figure 8 presents the results with a 
75% sensitive test. The costs and cases of chlamydia cured with the different strategies are 
plotted relative to a “do-nothing”-strategy. Noteworthy, additional benefits of the POC-
tests, such as reduced overtreatment and improved partner management are not included 
here. The uncertainty of the results is presented in paper 4.   
 
Figure 7 Chlamydia management strategies in the cost-effectiveness plane 
               (POC-testing with a 50% sensitive test) 
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All strategies with erythromycin treatment, regardless of the test sensitivity, were 
strongly dominated by the same management using azithromycin, exemplified by changing 
treatment regimen within the current management (moving from strategy B to strategy D).  
With a 50% sensitive POC-test, POC-testing among teenagers (strategy C), was extendedly 
dominated, albeit weakly. Strategy A, syndromic approach among teenagers, would imply 
the lowest cost per cured case and the lowest total cost. Neither the maximum accepted cost 
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 for a cured case of chlamydia is defined, nor is the budget for chlamydia management in 
sub-Saharan Africa. The black dashed line represents the estimated current budget, and 
strategy B represents the estimated current cost per case cured. The ICERs of strategy A, C 
and D were all lower than the CER of the current management. Implementing any of these 
strategies would imply reduced budget costs. If the objective was to maximize effectiveness 
within the existing budget, POC-testing could be partly implemented. 
 
Figure 8 Chlamydia management strategies in the cost-effectiveness plane 
               (POC-testing with a 75% sensitive test) 
C
D
A
B
E
0
20 000
40 000
60 000
80 000
100 000
120 000
0 500 1000 1500 2000 2500 3000 3500 4000
Total effectiveness (cases cured)
To
ta
l c
os
ts
 (U
SD
)
10 (Ref*A)
241 (AB)
 (CD)
18 (AC)
43 (CE)
10
66
15
21
31
A Syndromic approach with azithromycin treatment among teenagers
B Syndromic approach with erythromycin treatment among all attendees
C Point-of-care test (75% sensitive) with azithromycin treatment among teenagers
D Syndromic approach with azithromycin treatment among all attendees
E Point-of-care test (75% sensitive) with azithromycin treatment among all attendees
ICERCERStrategy
*ICER relative to the reference ”do-nothing”
 
 
The effectiveness and the cost per case cured with the POC-testing strategies 
improve with increasing test sensitivity. With a 75% sensitive POC-test, syndromic 
approach among all attendees was strongly dominated both with erythromycin and with 
azithromycin treatment. Strategy A, syndromic approach among teenagers, was still the 
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 most cost-effective of the strategies. The ICERs of strategies A, C, D and E were all lower 
than the CER of the current management.  
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 Paper 1: Chlamydia and gonorrhoea in pregnancy: effectiveness of diagnosis 
and treatment in Botswana 
Optimal performance of all levels of the STI program is essential; improvement can have a 
substantial effect on the overall burden of disease. After adequate clinical assessment, 
patients with an STI must obtain prescribed drugs, comply with treatment, and ensure that 
their partners are treated to avoid reinfection.  
In Botswana, more than 100 000 STI clients are prescribed multiple drug regimens 
yearly and STI drugs constitute a substantial share of the total drug use in the country 
(100). Despite the large number of prescriptions, treatment success among STI patients in 
the primary health care remains unknown. The aim of this paper was to draw attention to 
the consequences of prescribing antibiotics to STI patients in Botswana and to discuss 
possibilities for improving the cure rates. In our study among ANC clients, we evaluated if 
there was a lower prevalence of C trachomatis and N gonorrhoeae among ANC clients who 
had drugs against these bacteria prescribed to them in their current pregnancy, compared to 
ANC clients who did not have these drugs prescribed. 
There was no significant difference in the prevalence of chlamydia among the 
women who had and the women who had not been prescribed erythromycin four times 
daily for ten days (7% vs. 8%). Contrarily, none of the women who had been prescribed a 
single dose of ceftriaxone had gonorrhoea; whereas 4% of the women who had not had this 
drug prescribed did have gonorrhoea. Thus, the prescribing of erythromycin seemed to 
have had a limited effect on chlamydia in this population, whereas the prescribing of 
ceftriaxone lead to the curing of gonorrhoea. Ceftriaxone is provided as a single-dose 
injection at the point of care, and the differential effectiveness between the two drugs may 
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 reflect low compliance with the complex erythromycin regimen. We conclude that 
interventions to increase compliance could improve cure rates, and that the use of a 
simpler drug regimen should be considered when low compliance is likely. 
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 Paper 2: Trichomoniasis and bacterial vaginosis in pregnancy: inadequately 
managed with the syndromic approach 
Trichomoniasis (TV) and bacterial vaginosis (BV) may contribute substantially to the risk 
of preterm delivery, low birth weight and increased HIV transmission in sub-Saharan 
Africa (29, 45, 101-103). Although there are few studies from developing countries on 
effective strategies to prevent the adverse outcomes associated with TV and BV in 
pregnancy, it appears to be critical to diagnose and treat these conditions, especially in 
high-prevalence settings. The aim of this paper was to present results on the prevalence of 
TV and BV among antenatal care attendees in Botswana, examine the use of the vaginal 
discharge algorithm earlier in the current pregnancy, and evaluate the syndromic approach 
and clinical case finding in the diagnosis of these two conditions in pregnancy. 
TV and/or BV was present in as many as 359 (51%) of the antenatal care attendees, 
and three of four were asymptomatic. Symptoms of vaginal discharge was only weakly 
associated with TV (OR 1.6; 95%CI 1.0 to 2.5), only in the univariate analysis, and not 
associated with BV. The vaginal discharge algorithm detected only one of five cases of TV 
and BV. Also, women diagnosed by the algorithm were not significantly more likely to 
have TV and BV than women not diagnosed as diseased (LR+ 1.35, 95%CI, 0.97 to 1.89). 
Signs of non-candida-like vaginal discharge identified half of the cases and gave an LR+ of 
3.00 (95%CI, 2.31 to 3.92) in the diagnosis of the two conditions combined.  
TV prevalence was 15% for the new attendees, compared to 20% among the repeat 
attendees who had already been provided with standard care (p=0.22). BV prevalence was 
41% for new and 37% for repeat attendees (p=0.44). Prevalence of TV and BV was similar 
among women with and without a history of vaginal discharge, to a large extent explained 
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 by the finding that treatment guidelines were not followed appropriately. Consistent with 
the guidelines, metronidazole had not been prescribed to any of the 13 women diagnosed 
with vaginal discharge in first trimester. In the 143 cases an attendee was diagnosed in the 
second or third trimester, metronidazole had been prescribed to only 17 women (12%). 
None of these had a T vaginalis infection, compared to 132 (19%) of the remaining 686 
women. The difference in prevalence between the two groups is reduced, although not 
significant (Fisher’s Exact Test = 0.054 [2-sided]). Similarly, 3 (18%) of the 17 women had 
bacterial vaginosis, compared to 265 (39%) of the women who had not been prescribed 
metronidazole (Fisher’s Exact Test = 0.127 [2-sided]). 
There is a high prevalence of TV and BV among pregnant Batswana women, and no 
indication that the current STI management reduces the prevalence of these conditions. The 
vaginal discharge algorithm had low accuracy in diagnosing TV and BV. Although more 
effective, clinical case finding did also result in undetected cases and overtreatment. 
Apparently, diagnosis and treatment strategies for TV and BV among pregnant women in 
this setting require reconsideration. Simple tests could contribute to improving diagnosis 
and reducing the disease burden of these conditions in sub-Saharan Africa. 
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 Paper 3: Chlamydia and gonorrhoea in pregnant Batswana women: Time to 
discard the syndromic approach  
Chlamydia and gonorrhoea are major causes of morbidity among women in developing 
countries (31). Both infections have been associated with pregnancy-related complications, 
and case detection and treatment in pregnancy is essential (32). In countries without 
laboratory support, the diagnosis and treatment is based on the syndromic approach, but 
for cervical infections, this strategy is neither sensitive nor specific (6). As case finding 
with specific diagnostic tests have been out of reach, risk scores based on 
sociodemographic risk factors, symptoms or signs of infection, urine sticks and 
microscopy have been explored as screening tools to identify asymptomatic infections 
among pregnant women (2, 48, 54, 56).  
 In this study we measured the prevalence of chlamydia and gonorrhoea among 
antenatal care attendees in Botswana. We evaluated the syndromic approach for the 
detection of cervical infections in pregnancy, and determined if risk scores could improve 
the diagnostic accuracy. 
 Of the 703 women, 51 (8%) were infected with C trachomatis, and 21 (3%) with N 
gonorrhoeae. Age was the strongest predictor of cervical infection. The prevalence of 
infection was highest among teenagers (22%, 95% confidence interval (CI): 13 to 32), 
whereas two-thirds of the infections were within the largest age group: women 20-29 years. 
No symptoms predicted cervical infection, and subsequently, the VDS algorithm did not 
identify infected women (LR+ 1.1, 95% CI: 0.6 to 1.9). The current practice of clinical 
screening for signs of vaginal discharge (excluding candida-like discharge) also had low 
discriminative ability (LR+ 1.5, 95 % CI 1.1-1.9).  
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  The sociodemographic, clinical, and microscopy-based risk scores performed 
similar in the management of N gonorrhoeae and C trachomatis infection; all suffered from 
the choice between low sensitivity and low specificity. With a cut-off taken at an 
acceptable sensitivity of minimum 0.7, six pregnant women would be prescribed multiple 
antibiotic regimens unnecessarily per true case treated. With a cut-off at a sensitivity of 0.4, 
the majority of the cervical infections would remain untreated, and four pregnant women 
would still be unnecessary treated with multiple antibiotics per infected women.  
 Most of the antenatal care attendees in Botswana with cervical infection go 
undetected through normal antenatal care services. Our results show that the vaginal 
discharge algorithm is no better than random treatment in this population. A substantial 
improvement of the management of cervical infections in antenatal care in developing 
countries seems impossible without specific diagnostic tests. We argue that Botswana could 
well serve as an exploratory site for the use of rapid tests for chlamydia and gonorrhoea. 
Without such tests, health authorities in sub-Saharan Africa should consider reallocating 
their resources to other STI measures rather than diagnosing and treating cervical infections 
inadequately in antenatal care. 
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 Paper 4: Costs and health consequences of chlamydia management 
strategies among pregnant women in sub-Saharan Africa 
Chlamydia trachomatis infection is the most common bacterial STI worldwide, with 
highest prevalences in sub-Saharan Africa (29). It is a major cause of morbidity, 
particularly among women and neonates (31). The majority of infected women is 
asymptomatic and will not be diagnosed with the current syndromic management – thereby 
risking the development of complications and transmission of the infection. Low specificity 
of the strategy results in high levels of overtreatment, which increases drug costs and the 
risk of drug resistance (45). Simple, affordable and preferably on-site tests are needed to 
improve the management of C trachomatis infections in the developing world (12).  
The aim of this economic evaluation was to compare the costs and health 
consequences in sub-Saharan Africa of screening with a POC test versus syndromic 
management of chlamydia in the antenatal care – from the health care providers’ 
perspective. Two treatment alternatives in pregnancy were evaluated: erythromycin and 
azithromycin; doxycycline was modelled to partners. Three screening options were 
evaluated: screening all women, screening women under 30, and screening women less 
than 20 years.  
A decision analytic model was developed to compare the diagnostic and treatment 
strategies, using Botswana as a case. Model input was based upon 1) our study of 703 
antenatal care attendees in Botswana, 2) literature reviews and 3) experts’ opinions. 
Probabilities and costs were given a base case value and upper and lower values - to capture 
and evaluate the uncertainty, and to ensure relevance to other countries. We expressed the 
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 study outcome in terms of costs (US$), cases cured, magnitude of overtreatment and 
successful partner treatment.  
The results of this study indicate that there may be substantial benefits from 
changing current diagnostic and treatment strategies for chlamydia in the antenatal care in 
sub-Saharan Africa. Azithromycin was less costly and more effective than was 
erythromycin. Compared with syndromic management, testing all attendees at the first visit 
with a 50%-sensitive POC test increased the number of cases cured from 1 500 to 2 400 in 
a population of 100 000 women, at a cost of US$ 87 per additional case cured. With a 75%-
sensitive POC test, the number of cases cured increased to 3 500, at a cost of US$ 38 per 
additional case cured.  This cost was lower in high-prevalence populations or if testing was 
restricted to teenagers. The POC tests provided the advantage of substantial reductions in 
overtreatment with antibiotics and improved partner management. In conclusion, using 
POC tests to diagnose chlamydia during antenatal care in sub-Saharan Africa entails greater 
health benefits than syndromic management does. Changes in diagnostic strategy and 
treatment regimens may improve people’s health and even reduce health care budgets. 
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 Discussion
General comments 
The prevalence of cervical and vaginal infections among pregnant women in Botswana is 
very high. The results in this thesis indicate that there may be substantial benefits in 
improving the management of these conditions in antenatal care in sub-Saharan Africa. In 
the decision analysis of diagnostic and treatment strategies for chlamydia, the prevailing 
syndromic management of all attendees was the least effective, it incurred high costs per 
case cured and entailed considerable overtreatment.  
Methodology of the epidemiological study 
Study design 
We used a cross-sectional study design to determine the prevalence of STIs/RTIs and to 
evaluate the syndromic approach among antenatal care attendees in Botswana. This type of 
observational study is well suited and commonly used to find prevalences and risk factors 
of disease. The method provides a description of the population only at the time when 
information is collected. The use of confidence intervals reduces the uncertainties in 
prevalence related to sample size and enables us to generalize from the study population to 
the antenatal care population in Gaborone. The incidences of the STIs/RTIs, or any increase 
or decrease in the prevalences over time is not studied with this design.  
 Not all aspects of the vaginal discharge syndrome are captured in this thesis. I 
performed the clinical examinations of all the attendees myself, and the evaluation of the 
algorithm is based on my clinical findings in a study setting. Thus, this study can indicate, 
but not provide exact information of sensitivity and specificity of the algorithm performed 
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 by nurses in routine practice. Clinical signs – as the assessment of normal versus abnormal 
vaginal discharge in pregnancy – are to a certain extent subjective, and nurses’ assessment 
may differ from mine. In addition, a study setting is close to ideal, measuring efficacy 
rather than effectiveness. As discussed in the introduction, the syndromic approach is 
vulnerable to performance of the clinicians. An observational study of the STI management 
in Botswana showed that among female STI patients, adequate history was taken in 25% of 
the consultations, adequate examination in 23% (7).  
 
Sample and representativeness 
As described in the methods, we made an effort to ensure a study population representative 
of antenatal care attendees in Gaborone. The age distribution in the sample is comparable 
to the antenatal care attendees in Gaborone and in Botswana in 2000 (Appendix 4). Age is 
the most important predictor of having an STI. There are 10% teenaged participants in our 
study, compared to 14% in the population of antenatal care attendees in Gaborone and 
20% in Botswana in the year 2000. If anything, this may result in an underestimate of the 
STI prevalences. 
The level of health care is comparable throughout Botswana, and HIV prevalence 
among pregnant women is similar in urban and rural areas (76). In a previous national 
study, we found slightly, but significantly higher prevalences of trichomoniasis, gonorrhoea 
and/or syphilis in rural areas. Combined with an antenatal coverage of 95%, this situation 
leads us to believe that we present an adequate picture of the prevalence and management 
challenges of cervical and vaginal infections in pregnant women in the country as a whole 
(104). 
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 Both new and repeat attendees were included in this study. By including repeat 
attendees, we also included attendees who had been diagnosed with and treated for 
STIs/RTIs earlier in pregnancy. This gave us epidemiological data to examine the 
effectiveness of the vaginal discharge syndrome, such as prevalence of infection among 
women who had and women who had not received treatment. To the extent the treatment 
had been effective; this may have resulted in an underestimation of the RTI/STI 
prevalences. To exclude 34 women on STI treatment may also have led to an underestimate 
of these prevalences.  
 
Validity 
When determining RTI/STI prevalence, and in the evaluation of the vaginal discharge 
syndrome algorithm, we immediately encounter “The gold standard problem”. Most 
infectious diseases do not have a perfect reference test which can reveal the true infection 
status in an individual. When evaluating the sensitivity and specificity of a diagnostic tests 
in the absence of a gold standard, discrepant analysis has been widely used to solve this 
methodological challenge (105). In discrepant analysis, the samples which are positive with 
the new diagnostic test and negative with the imperfect reference test are subjected to 
additional testing – usually with a third test. Subsequently, cases which are positive with 
the additional test will be reclassified. The method is criticized as severely biased, but other 
statistical methods do also have to rely on “empirically unverifiable assumptions about the 
unknowns of the situation” (106). 
The exact sensitivity and specificity of the diagnostic tests we have used to identify 
STIs/RTIs in this study, and following, the exact prevalences, can not be determined. The 
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 performance of a diagnostic test in a given setting is dependent on the sampling procedures 
and transport, the qualities of the test, the reference standard used and the experience and 
skills of the laboratory staff. The literature provides approximate estimates for sensitivity 
and specificity – with the limitations described above. The specimens were tested at the 
NHL by either a very experienced laboratory technician or technicians who were trained in 
STI analyses prior to the study. We have not performed reproducibility testing or more than 
standard quality control of the laboratory analyses, mainly due to resource constraints. 
If the sensitivity and specificity of a diagnostic method had been known exactly, the 
true prevalence can be calculated using the equation below: 
 
True prevalence = (Observed prevalence + Specificity – 1) 
         (Sensitivity + Specificity - 1) 
 
Chlamydia and gonorrhoea were identified with LCR amplification technology of cervical 
specimens. Published evaluations of test have found a sensitivity of 85-97% and a 
specificity of 97-100% (ref). Assuming for example a sensitivity of 85% and a specificity 
of 95% in the diagnosis of chlamydia, the true prevalence in our study population would 
have been: 
 
True prevalence = (7.5+ 0.95 – 1)    = 8.75 
              (0.85 + 0.95 - 1) 
 
Trichomoniasis was identified with wet-mounts and culture. With the development 
of molecular techniques to identify T vaginalis, it has become evident that culture and 
microscopy miss a substantial proportion of the infections (68, 70). With the use of 
molecular techniques as a reference standard, the sensitivity of wet-mounts and culture 
combined has been found to be approximately 70%. The techniques identify live, motile 
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 trichomonads, resulting in close to 100% specificity. This implies that the true prevalence 
of trichomoniasis is higher than found in this study. However, it is common practice to 
report unadjusted prevalences. 
Bacterial vaginosis is a clinical syndrome presenting with a malodorous vaginal 
discharge and increased vaginal pH. It is associated with a group of genital microorganisms 
rather than a single agent, and the alteration of the normal vaginal flora is a continuum - 
making the diagnosis challenging. There are two well described diagnostic methods for 
bacterial vaginosis: Amsel’s criteria, a clinical diagnosis including a wet smear, and 
Nugent’s criteria based on a Gram stain of vaginal fluid. As the clinical signs are subtle and 
dependent on the clinician performing the test, bacterial vaginosis was identified using 
Gram stain, acknowledged as a reproducible and reliable test and commonly used as the 
diagnostic standard (72). The slides which were used to identify bacterial vaginosis were 
meant to be re-read in Norway, but they were stolen together with other valuables from my 
suitcase at Johannesburg airport. Thus, we have no quality control of the diagnosis of 
bacterial vaginosis. 
Candida species were identified with wet-mounts, gram stain and culture, and 
patients with positive results were classified having variants of vulvovaginal candidiasis 
according to their presence of symptoms and signs of infection. The identification and 
typing of candida species will presented and discussed in a separate paper.  
In our evaluation of the vaginal discharge algorithm, we have used laboratory 
verified diagnosis as the reference standard, illustrated in Table 6. This is in line with other 
research evaluating the syndromic approach (107-109), but the method is unavoidably 
biased. As the reference standard is imperfect, all cells will have misclassified cases (false 
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 positive or false negative laboratory results), affecting the calculation of sensitivity and 
specificity. In our example below, 93 cases in which the algorithm was positive and the 
laboratory results negative were classified as false positive. The disconcordance might have 
been due to a false negative laboratory result, and if so, the evaluation renders the algorithm 
less sensitive than correct. Among the 11 cases in which the algorithm and the laboratory 
test was positive, there may be false positive test results, rendering the algorithm more 
sensitive than correct – and so on. We acknowledge the described misclassification, but 
have not attempted to adjust for it.  
 
Table 6 Evaluation of the vaginal discharge algorithm diagnosis of cervicitis   
Cervical infection  
Positive Negative N (%) 
  n (%) n (%)   
Positive 11 (16) 93 (15)   104 (15) 
Negative 56 (84) 543 (85) 599 (85) 
Syndromic approach 
Total 67 (100) 636 (100) 703 (100)
 
Methodology of the economic evaluation 
Knowledge gaps in the burden of STIs 
Major challenges in performing economic evaluations of chlamydia management lie in 
estimating the health- and economic benefits of the interventions (Box 5). The main 
objectives, or benefits, of diagnosing and treating chlamydia are to prevent complications 
and reduce onward transmission. However, the natural history of C trachomatis is not fully 
known and the risk of developing complications not firmly determined (110). Some of the 
complications caused by the infection are immediate, whilst the majority occur after a long 
time and are difficult to measure. In addition, pelvic inflammatory disease, extrauterine 
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 pregnancy, premature labour, neonatal infections and HIV transmission occur both because 
of and independent of chlamydia. Next, trial evidence for the long term effectiveness of 
chlamydia screening or case management is very limited, and there are no trials on the use 
of POC tests. 
 
Box 5 Benefits of a health intervention   
1. Health consequences 
a) Reduced morbidity and complications 
b) Reduced mortality 
 
2. Economic consequences 
a) Direct benefits 
           Saved future health care costs  
b) Indirect benefits 
           Improved future working capacity  
           The value of less personal pain and loss 
 
In Botswana, as in most developing countries, estimates of the occurrence of 
chlamydia related complications are largely unavailable. To the extent any information or 
statistics exists, the proportion of these conditions that may be attributed to chlamydia is 
unknown. Similarly, evidence is too weak to estimate the proportion of HIV-infections 
attributable to and preventable by treating chlamydia in this population, or to estimate any 
reduction in the mother-to-child transmission of HIV. Consequently, modelling DALYs or 
QALYs lost due to C trachomatis infections in the population was virtually impossible.  
The costs to the health services in sub-Saharan Africa of a given complication of 
STIs or of a HIV infection are also nearly impossible to estimate – and thereby also the 
economic benefits of diagnosing and treating STIs/RTIs. In Botswana, the public health 
sector operates with overall lump sums, for example salaries or drug use in primary health 
care (111). There are no separate budgets at hospitals and clinics or for specific programs 
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 such as antenatal care, and the cost of for example, a hospital stay or specific diagnostic or 
treatment procedures is unknown.  
Our reluctance to use chlamydia related complications or HIV-infections averted as 
the outcome in our analysis concurs with an ongoing debate on chlamydia screening in high 
income countries (91, 94, 110). Authors of systematic reviews of the evidence point out 
that the excess risk of pelvic inflammatory disease and infertility in women who have had 
chlamydia is not adequately studied (112, 113). As the complication rates are based on data 
from high-risk populations, case-control studies and data not accounting for misdiagnosis, 
it is argued that an overestimation of the current complication rates is likely. This has 
obvious implications for the interpretation of cost-effectiveness studies which have used 
these probabilities, rendering the benefits of chlamydia screening too optimistic. A recent 
editorial in Sexually Transmitted Infections concluded that ‘more work is required before 
we can fully justify and appropriately design chlamydia control programs’ in this setting 
(114). 
Similarly, the effect of STI management on HIV transmission in a specific 
population is very difficult to predict (36, 37). The size and range chosen for the co-factor 
parameter in a cost-effectiveness model will directly influence the results. Several reviews 
of cost-effectiveness analyses as applied to HIV/AIDS prevention strategies have noted the 
paucity of data, and in particular, the dearth of studies from low and middle income 
countries (115, 116).  
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 Validity and generalizability of the model 
There is a particular need to exercise caution when interpreting results of an economic 
evaluation. The uncertainty is pervasive, entering the evaluation process at every stage 
(117). To a large extent, the uncertainty in an analysis reflects a true, real world 
uncertainty. A model is only as good as the input, and the availability, quality and 
generalizability of data will influence the results. In addition, there is uncertainty related to 
the choice of model and the model structure, and to how the analyses are conducted.  
The choice of a static model is discussed below. Obviously, our decision tree is a 
simplification of the reality. We did not attempt to assess the effect of the model 
uncertainties, whereas the parameter uncertainties were explored using sensitivity analysis. 
The one-way sensitivity analysis showed how higher or lower parameter values would 
change the incremental cost per case cured of the POC-tests strategy. In the tornado 
diagram, the results of the one-way sensitivity analysis are brought together in a single 
graph, illustrating to what extent the parameter uncertainty has an effect on the results 
(Figure 8). The bars are arranged in order, with the widest bar at the top (the most critical 
uncertainty).  
Test costs and drugs purchased in international markets are the cost drivers in the 
model, and these prices will be relatively similar across countries. The cost of the POC test 
was the largest source of variation in the results. As prevalences may differ in other settings 
or change over time, we analysed a prevalence range from 3% to 31%, representing the 
range of prevalences reported in other studies among antenatal care attendees in sub-
Saharan Africa (118). This broad range made prevalence the second most important source 
of variation in the results. Authorities who consider implementing a POC test strategy are 
 71
 likely to have more exact estimates for the three most critical parameters in the model: the 
chlamydia prevalence in the population, the POC test sensitivity as well as cost proposals 
for the test. The model is also available to anyone who wants to modify the decision trees 
or run the analysis with other model input parameters. 
 
Figure 8 Tornado diagram  
0 2 0 4 0 6 0 8 0 10 0
Cost  of  P OC  t e st  ( US $ 0 . 5 0 - 4 . 0 0 )
Chl a my di a  pr e v a l e nc e  ( 0 . 0 3 - 0 . 3 1)
S e nsi t i v i t y  of  P OC  t e st  ( 0 . 5 0 - 0 . 8 5 )
P r oba bi l i t y  of  pa r t ne r  not i f i c a t i on ( P OC t e st )  ( 0 . 3 5 - 0 . 6 5 )
Cost  of  a z i t r omy c i n ( U S $ 0 . 4 3 - 1. 6 5 )
Chl a my di a  t r a nsmi ssi on r a t e  ( 0 . 5 0 - 0 . 9 6 )
C ost  of  pe r f or mi ng P OC  t e st  ( US $ 0 . 0 8 - 0 . 2 5 )
S e nsi t i v i t y  of  sy ndr omi c  a ppr oa c h ( 0 . 3 6 - 0 . 6 2 )
P r oba bi l i t y  of  c ur e  wi t h a z i t r omy c i n ( 0 . 8 8 - 1. 0 0 )
Incremental cost per case cured (US$)  
 
Static versus dynamic modelling 
The majority of published cost-effectiveness analyses of chlamydia screening are based on 
static models, commonly a decision tree model (91). Decision trees work well in analysing 
relatively simple events over a limited time horizon (88). In 2000, the first dynamic 
transmission models of chlamydia screening were published (119, 120). These models aim 
to incorporate the complexity of an infectious disease, including the impact of re-infection, 
continued transmission and the change of prevalence over time. Welte et al. have compared 
a static and a dynamic model of opportunistic chlamydia screening of in the Netherlands, 
and showed that the different model approaches produced different results (121). The static 
model estimated a cost-effectiveness of US$ 700 per complication averted, whereas the 
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 dynamic model rendered net savings. The diverging outcomes were explained with the 
transmission chains considered in the dynamic model and the assumptions about the 
screening program’s influence on chlamydia prevalence.  
There is a role for both static and dynamic models in the evaluation of C 
trachomatis screening programs (122). We chose to develop a static model on the basis of 
three arguments: First, the use of dynamic models has been advocated in the evaluation of 
large-scale screening programs. Programs targeting smaller groups such as pregnant 
women have been specifically mentioned as an exception, as they are less likely to lower 
the force of infection (92). Second, due to the use of intermediate outcomes as discussed 
above, the analysis has a limited time horizon. Third, dynamic models require much more 
data, such as the population’s sexual behavior and the natural history of C trachomatis 
infections. How is the formation and termination of steady and casual partnerships or the 
frequency of sexual intercourse in these relations? For our population, such information is 
at best very imprecise, and the additional data needed would be based on unreliable 
estimates or “educated guesses”. For example, in our epidemiological study, almost all 
women stated that they had one partner the last year. Simultaneously, the prevalences of 
STIs were very high. With these premises, it is questionable whether a dynamic model 
would perform better than a static model.  
 
Prevalence of sexually transmitted infections 
Systematic and comprehensive STI surveillance to facilitate disease control efforts is 
almost non-existing in developing countries, and most epidemiological data have been 
obtained from prevalence studies (45). In Botswana, STI surveillance is based on STI 
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 syndromic case reports and periodically performed studies of syndrome etiology to guide 
therapy. These activities are not reliable for assessment of STI incidence or prevalence or to 
measure the impact of STI/HIV prevention program s (123). 
In the prevalence assessment in this study, we find that 54% of antenatal care 
attendees in Gaborone have chlamydia, gonorrhoea, trichomoniasis or bacterial vaginosis. 
Published studies of STIs among pregnant women in other countries in sub-Saharan Africa 
show similar trends in the prevalence of cervical and vaginal infections. In our study, 8% 
have chlamydia, compared to rates between 6% in Tanzania and 13% in Cape Verde (2, 
124). Gonorrhoea is found in 3% of the women, compared to rates that range from 2% in 
Gabon to 8% in South Africa (125, 126).  The prevalence of trichomoniasis in Gaborone 
was 18%, in other studies of low-risk women in sub-Saharan Africa, the prevalence ranges 
from 10–31% (45, 101). The bacterial vaginosis prevalence of 38% also corresponds well 
with other studies. Bacterial vaginosis is shown to be particularly common in the sub-
Saharan region, where prevalences up to 50% are not uncommon (102). 
 There are four other studies on STI epidemiology in Botswana, from 1993-2003, of 
which three are unpublished. There are indications that the etiology of the STI syndromes 
has changed since syndromic management was introduced in Botswana in 1992; with a 
reduction in bacterial STIs and trichomoniasis (127). However, the populations studied are 
small, from different health facilities in different towns, and the studies are conducted by 
different researchers using different laboratory methods. Bearing this in mind, we have 
aggregated the prevalence results for comparison (Table 7).   
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 Table 7 Studies on STI epidemiology in Botswana* 
 Chlamydia Gonorrhoea Trichomoniasis Bacterial 
vaginosis 
Candida 
species 
      
1993 study 
    STI clients (102) 
    FP clients   (102) 
1997 study 
    STI clients (57) 
    FP clients   (131) 
    ANC clients (341) 
2000-2001 study 
    ANC clients 
2002 study 
    STI clients (431) 
    FP clients   (269) 
2001-2003 study 
   ANC clients (HIV+) (717) 
 
16 
20 
 
- 
- 
- 
 
8
 
14 
12 
 
10 
 
16 
7 
 
4 
4 
5 
 
3
 
6 
3 
 
5 
 
13 
17 
 
11 
13 
28 
 
18
 
10 
7 
 
21 
 
53 
47 
 
- 
- 
- 
 
38
 
59 
49 
 
- 
 
49 
49 
 
35 
28 
46 
 
58
 
15 
10 
 
- 
 
*The study presented in this thesis is the 2000-2001-study, with prevalences in bold 
 
The effectiveness of syndromic management 
This study has evaluated the effectiveness of the vaginal discharge syndrome from two 
perspectives. First, we measured the prevalence of infections among new compared to 
repeat attendees who had already been provided with standard care. The high prevalences 
among repeat clients indicate low effectiveness of the syndromic management. Second, the 
sensitivity and specificity of the vaginal discharge algorithm were estimated using 
laboratory verified diagnosis as the reference standard. For cervical infections as well as for 
trichomoniasis and bacterial vaginosis, the algorithm was no better than random treatment. 
We conclude that most of the women with these conditions go untreated through normal 
antenatal care services, and that the currently provided standard management is 
inappropriate. Candida species were identified in 59% of the women, strongly associated 
with symptoms of vaginal discharge, and probably the pathological cause most often 
leading to this complaint in pregnancy. Candida is not associated with any serious 
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 complications, and we observed during the data collection that vulvovaginal candidiasis 
was under-emphasized among the nurses when managing symptomatic women.  
Improving health care seeking, clinical management, the prescription of effective 
drugs, patient compliance and partner notification may all have an effect of the overall 
burden of STIs. Research has tended to focus on the performance of syndromic 
management (43). Not all evaluations are directly comparable to ours, due to differences in 
populations studied, the laboratory methods used or differences in the protocols evaluated. 
However, our results concur with the overall finding that the vaginal discharge algorithm is 
neither sensitive nor specific in the diagnosis of chlamydia and gonorrhoea, or 
trichomoniasis or bacterial vaginosis - particularly not in antenatal care attendees (43, 45, 
57). It can be argued that this part of the study fall into the “me too”-research category. 
However, it is a major concern that this strategy continuously and frequently is in use in the 
antenatal care. I believe that it is essential to continue to express that the current 
management of these potentially serious infections among pregnant women in Sub-Saharan 
Africa is inadequate, and to highlight the need for a replacement.  
There is also a need for attention to what happens to the STI clients after the 
encounter with the health care provider. Most governments are interested in ensuring 
availability and access to drugs, but the issue of adequate drug use should receive 
increased attention (128, 129). We find that antenatal care clients with a recent history of 
STI symptoms who have been prescribed ceftriaxone are successfully treated for 
gonorrhoea. This drug is provided as a single injection in the “dressing room” at the clinic 
immediately after the consultation. Clients who have been prescribed erythromycin have 
identical prevalence of chlamydia as the clients without such history. When erythromycin 
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 is prescribed during a consultation, the patients have to collect the tablets at the clinic’s 
“dispensary” and then take one tablet four times daily the next week. It is known that 
complex treatment regimens as well as side effects of drugs reduce patient compliance 
(50). The efficacy of erythromycin is high (130, 131), and we argued that low compliance 
most probably the main cause of the low treatment effect.  
Seventeen of 703 women had been prescribed metronidazole during their 
pregnancy. None of these had a T vaginalis infection when included in the study, while 3 
(18%) of them had bacterial vaginosis. The reduction in prevalence of T vaginalis and 
bacterial vaginosis among the treated women is not significant, but it is not unlikely that 
the lack of significance is due to low statistical strength. The results are in line with the 
knowledge that metronidazole is known to be effective against T vaginalis (132). The drug 
is slightly less effective against bacterial vaginosis, and more than 50% may have 
recurrence within two months of treatment (133). 
 
Chlamydia management strategies 
We compared the number of cases cured, overtreatment and partner treatment in our 
evaluation of chlamydia management strategies: intermediate, but reliable and meaningful 
outcome measures. Short-term outcomes are not ideal for making policy recommendations, 
but as the existing management requires substantial resources, information about 
possibilities for more advantageous resource use should be highly relevant to health policy 
makers. We found that in Botswana, the current costs for a cured infection, and thereby the 
current willingness to pay, were higher than for any of the evaluated alternatives.  
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 Treatment for chlamydia 
In practice, there are three recommended treatment alternatives to treat chlamydia in 
pregnancy: erythromycin 500 mg orally 4 times a day for 7 days, amoxicillin 500 mg orally 
3 times a day for 7 days and azithromycin 1 g orally in a single dose (6, 134, 135). In the 
national guidelines in Botswana, the erythromycin regimen is the first choice. The 
epidemiological study of the effectiveness of erythromycin (Paper 1) indicated that low 
compliance to the erythromycin regimen reduces cure rates. The cost-effectiveness study 
(Paper 4) showed quite clearly that single-dose azithromycin was more effective and less 
costly than erythromycin. We evaluated azithromycin as an alternative to erythromycin 
because of the advantage that adherence can be guaranteed (131). Amoxicillin has not been 
discussed in this thesis. In general, the week-long regimen with amoxicillin has similar 
costs, cure rates and levels of adverse effects as azithromycin (130, 136). 
Efficacy, tolerance, compliance, and cost are factors to consider when preparing 
guidelines for antibiotic treatment. After losing its patent, the price of azithromycin is lower 
than of erythromycin (136). With regards to compliance, erythromycin regimen is complex 
in itself, and patients who are diagnosed with the vaginal discharge syndrome are 
prescribed multiple drug regimens that require many tablets to be administered correctly. 
Compared to the alternatives, erythromycin has a significantly higher level of 
gastrointestinal side effects, which frequently discourages patients from complying with the 
regimen (134, 137). This may be especially problematic in women who experience 
pregnancy nausea.  
Erythromycin has been on the market in more than 50 years and has been 
considered safe in pregnancy (131). There is less experience with azithromycin, but no 
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 evidence of adverse effects when used in pregnancy (130, 131). In 2005, an 
epidemiological study from Sweden suggested a possible association between maternal 
erythromycin use and infant cardiovascular malformations (138). This resulted in a change 
in Norwegian guidelines, now recommending amoxicillin in the first and azithromycin in 
the second and third trimester (139). In 2008, the same Swedish research group presented 
the results of a new large study not confirming the association suggested earlier (140). The 
most recent STI management guidelines from the WHO are from 2003, and recommends 
erythromycin or amoxicillin to treat chlamydia in pregnancy. The use of azithromycin is 
commented as follows: “Preliminary data suggest that azithromycin is safe to use in 
pregnant women. However, the number of women in the trials so far is too small to assess 
safety for use in pregnancy as rare adverse outcomes are unlikely to be detected” (6).  
An area of concern in Botswana as well as other sub-Saharan countries is that the 
pregnant women may be enrolled in the PMTCT program  or be on treatment with highly 
active anti-retroviral therapy (HAART). Erythromycin is a strong inhibitor of the enzyme 
cytochrome P450 CYP3A4, which metabolize many of the antiretroviral drugs. The 
interactions are most problematic with concomitant use of erythromycin and protease 
inhibitors, used as second line HIV drugs – due to a risk of of QT prolongation. In general, 
azithromycin is a weaker inhibitor of CYP3A4, and will have less interaction with HIV 
drugs (personal communication with the Liverpool HIV Pharmacology Group and RELIS). 
To summarize, countries recommending erythromycin to treat chlamydia in 
pregnancy should consider changing the treatment guidelines. 
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 Point-of-care tests for chlamydia 
In the cost-effectiveness model, even a POC test with 50% sensitivity increased the cases 
cured with 60%, reduced the over-treatment to 6% and reduced the number of partners who 
should not have been notified with 87% compared to the current level. These results concur 
with the body of knowledge that POC tests for chlamydia are necessary to improve 
effectiveness, reduce the excessive overtreatment and improve partner notification with the 
syndromic management (61). 
The health benefits of improved case detection and treatment is not captured in this 
analysis. If successful chlamydia treatment reduces complications such as neonatal and 
post-partum infections, or reduces HIV transmission, the advantage of using POC tests 
increases (92). Further, the benefits of reducing the substantial over-treatment with POC 
tests do not only imply reduced costs of drug wastage. We estimated that 20 persons with 
syndromic approach and less than one with the POC test strategy were treated unnecessary 
with antibiotics per chlamydia infection cured. Although difficult to measure, the value for 
individuals of not being unnecessary diagnosed and treated for an STI, and the value of 
reducing the risk of antibiotic resistance in the population are aspects that need to be taken 
into account. Targeted partner notification is another important argument for introducing 
specific POC tests. Managing sexual partners of STI patients is essential to prevent re-
infection, cure partners, break the chain of transmission and prevent complications (45). In 
studies from Africa, partner notification has been associated with potential harm, including 
domestic violence, and using an unspecific syndrome diagnosis as a basis for notifying 
partners is questionable (45, 49). 
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 With regards to introducing POC tests, any new diagnostic technology should be 
assessed adequately to determine whether their application improves public health (106).  
Before recommending the routine use of POC tests for cervical infections in developing 
countries, carefully designed impact evaluations are needed. 
 
Age-based case finding 
Youth was the single factor most strongly associated with chlamydia among pregnant 
women in Botswana (141), which is consistent with established knowledge on STI 
epidemiology (44, 142). This is already utilized in the syndromic management guidelines:  
WHO recommends adding a risk assessment to the diagnosis of chlamydia and gonorrhoea 
with the vaginal discharge flowchart. The assessment should include population specific 
demographic and behavioral risk factors such as being less than 21 years, being unmarried 
and having more than one partner (6). In Botswana, the risk assessment is considered 
positive if the patient is under 21 years (Figure 2).  
If POC tests are introduced, age can be useful as a screening tool in the traditional 
sense, to minimize the number of standard diagnostic tests by identifying people with a 
higher-than-average prevalence of infection (143). Chlamydia screening programs in high 
income countries commonly select people for testing based on their age (134, 144). The 
cost-effectiveness analysis indicates that adoption of age-restricted chlamydia treatment 
will entail lower program costs and be more cost-effective than would the management of 
all pregnant women. Testing pregnant teenagers may be a feasible and reasonable way of 
introducing POC tests for chlamydia to antenatal care programs in sub-Saharan Africa.  
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 Should POC tests for chlamydia have priority in sub-Saharan Africa?  
Ideally, research should provide policy makers with the answer to the question “Is 
diagnosing and treating STIs worthwhile, compared to health benefits that could be 
achieved from an alternative use of the resources?” Currently, evidence is too scarce to 
ensure that economic evaluations can assist optimally in ensuring allocative efficiency in 
the health sector in sub-Saharan Africa. A complete and credible database might be decades 
away, and priorities and decisions are made continuously. What can be said about 
prioritizing STI management in sub-Saharan Africa with our current knowledge? And what 
about POC tests for chlamydia? 
Improving maternal and perinatal conditions and combating HIV/AIDS received 
substantial attention in the Millennium Declaration (15, 17) In general, diagnosing and 
treating STIs in developing countries have been considered highly cost-effective2 (145, 
146). Treatment of STIs is a strategy area that has already been prioritized in sub-Saharan 
Africa (97). It has been said that if countries are to have any chance of achieving their 
development goals, they need to re-evaluate existing strategies and replace less effective 
strategies with more effective ones (16). Chlamydia management in pregnancy is well 
within the scope of the development goals, and this study points to changes in diagnosis 
and treatment which may contribute to achieving these goals more efficiently. There is a 
critical health worker shortage the Region, but improving the current strategy is not likely 
to require allocation of additional human resources to STI management. 
                                                 
2 The WHO has deemed interventions to be highly cost effective if they cost less than the gross 
domestic product (GDP) per capita to avert each disability adjusted life years (DALY) and cost 
effective if each DALY could be averted at a cost of between one and three times the GDP per 
capita - compared to a do nothing strategy  
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 The Countdown to 2015 for Maternal, Newborn, and Child Survival monitors 
coverage of priority interventions to achieve the MDGs. With the publishing of the 
Countdown 2008 results, the need to better integrate and link program s and initiatives was 
advocated as one of four new directions that should be vigorously pursued (147). 
Introducing the use of POC tests to diagnose chlamydia in pregnancy is a clear example of 
a single, biologically based intervention that calls for cooperation between two existing 
programs and enables mutual benefits. A shift in the diagnostic strategy of chlamydia in 
antenatal care fits well within the ongoing training and supervision activities of the national 
STI management programs. Integrating POC testing with antenatal care can relatively 
easily be incorporated in the routine management of the attendees, and thereby facilitate the 
uptake and coverage of the intervention. The Countdown has shown that improvements in 
services that can be routinely scheduled, such as antenatal care, are easier to achieve than in 
curative services (148).  
With regard to need principles for allocation of health resources, it can not be said 
that chlamydia management is an intervention towards the most severely ill patients. As the 
morbidity related to STIs disproportionately affects women, it could be argued that it 
reduces inequities in health between different groups in the population. Due to the high 
antenatal care coverage in sub-Saharan Africa, improved diagnosis of chlamydia in 
pregnancy is absolutely a health investment which many could benefit from (30, 118). To 
introduce a service that aims to cover all reproductive women and subsequently their 
children and their partners promotes a high degree of fairness in resource distribution. 
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 Concluding remarks 
This thesis demonstrates severe shortcomings of the management of cervical and vaginal 
infections in pregnant women in Botswana, and indicates that changing diagnostic and 
treatment strategies may improve maternal and infant health as well as resource use. The 
economic evaluation provides policy makers with information to decide whether to 
continue the current chlamydia management or to implement new strategies - given that 
chlamydia management should be funded.  
During the work with the economic analysis model, it became evident that using 
DALYs or QALYs as an outcome measure for the chlamydia management was out of 
reach; the knowledge gaps were too large. There is an overall lack of data, from the natural 
history of STIs to the health- and economic benefits of health interventions in sub-Saharan 
Africa. If the international research community was willing to prioritize their resources 
differently, and need principles, maximizing principles or egalitarian principles were 
included in their criteria, this is a possible research area.   
I hope this work can contribute to an increased awareness of the need to improve 
the management of STIs in pregnant women in sub-Saharan Africa. I also hope that it has 
illuminated the potential of cost-effectiveness analysis to aid decision making and priority 
setting in health care in resource constrained settings.  
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 Appendix 3 
Model input parameters: The female decision tree  
The expert panel assumed that the probability of correct prescription by nurses, patients’ 
compliance to prescribed drugs and partner notification will be higher if an antenatal care 
attendee is diagnosed with chlamydia using point-of-care (POC) tests than with the 
syndromic management strategy. This is because when a pregnant woman is diagnosed 
with ‘vaginal discharge syndrome’, she may have candida, bacterial vaginosis, 
trichomoniasis, chlamydia or gonorrhoea, physiologically increased discharge or abdominal 
pain related to pregnancy. The treatment for vaginal discharge syndrome includes a 
multiple and complex drug regimen, and both the nurses’ adherence to the treatment 
guidelines and patients’ compliance to this regimen is known to be low. As the condition 
most likely is not sexually transmitted, it is understandable that neither nurses nor patients 
are dedicated to ensure partner notification, not risking domestic disturbance unnecessarily. 
 All POC tests for chlamydia have high specificities, and thereby the advantages of a 
specific test which the syndromic approach is lacking. A positive test requires the 
prescription of and compliance to one drug; and partner treatment is imperative. For the 
POC test strategy, there are no data on these events. The expert panel inflated the values 
used for the probabilities in the syndromic strategy, assuming that the additional confidence 
in the POC test result would improve management. The possibility that this is not the case 
was covered by using large uncertainty bounds, including in the lower bound a value that 
represents syndromic management. The upper bound represents much better performance, 
as found in developed countries where specific chlamydia tests are in use. 
 
Chlamydia prevalence  
Chlamydia prevalence is based on data from our study among 703 antenatal care attendees 
in Gaborone, Botswana. In this population, young age was the factor most strongly 
associated with cervical infection (Table A1). Based on this knowledge, we modelled 
different management strategies: to include all women, selective management of women 
under 30, and selective management of teenagers. Chlamydia incidence is not included in 
the model. As prevalences may differ in other settings as well as change over time, we used 
broad uncertainty ranges to assess the effect of prevalence on the cost-effectiveness 
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 estimates in one-way sensitivity analysis. The prevalence range from 3% to 31% represents 
the range of prevalences found in other studies among antenatal care attendees in sub-
Saharan Africa (1). 
Table A1 Chlamydia prevalence by age among 703 antenatal care attendees in Gaborone, Botswana 
Age N (%) Prevalence (95% Confidence interval) 
<20 
20-29 
30+ 
  76 (10.8) 
432 (61.5) 
195 (27.7) 
15.8 (9.3-25.6) 
  8.1 (5.9-11.1) 
3.1 (1.4-6.5) 
Total 703 (100) 7.5 (5.8-9.7) 
Sensitivity and specificity of the POC test   
Several POC tests for C trachomatis are commercially available. The evaluated specificity 
of the tests is consistently found to be high and was therefore set at 98.5% (97.0-100%) 
(Table A2). The sensitivity has not yet been firmly determined. It has varied widely across 
tests and the populations being tested, ranging from 25 to 85% (2, 3). The evaluations have 
also differed with respect to reference standard used. Introduction of a test with a sensitivity 
of at least 50% is a current option, and most likely, more sensitive tests will be available 
within the next few years. We therefore modelled a baseline sensitivity of the test of 50%, 
with a range from 50% to 85%. Tests with sensitivities lower than 50% were not 
considered, as they would detect fewer infections than the syndromic approach.  
Table A2: Sensitivity and specificity of Chlamydia trachomatis point-of-care tests 
 
Point-of-care test Patient group Sensitivity Specificity Reference 
Antigen detection assay 
Chlamydia optical immunoassay  
Chlamydia optical immunoassay  
Chlamydia optical immunoassay  
Direct fluorescent antibody test 
IgA Rapid Sero Test (ELISA) 
“High risk women” 
Female STI clients 
“Female clients” 
Female STI clients 
Female STI clients 
Pregnant women 
49.7% 
73.8% 
31.6% 
64.2% 
73.6% 
69.6% 
97.9% 
100% 
98.9% 
99.1% 
99.9% 
97.2% 
Yin et al. 2006 (4) 
Pate et al. 1998 (5) 
Widjaja et al. 1999 (6) 
Swain et al. 2004 (7)  
Swain et al. 2004 (7) 
Witkin et al. 1997 (8)  
Sensitivity and specificity of syndromic management 
The sensitivity and specificity of the syndromic approach were based on data on the 157 
new antenatal care attendees in our epidemiological study. Pregnant women coming for 
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 their first antenatal care visit who complain of vaginal discharge or lower abdominal pain 
will be managed with the vaginal discharge algorithm. In addition, all new attendees are 
clinically screened for STIs. This strategy, in which symptoms and/or signs are used as 
entry points to the vaginal discharge algorithm, has a sensitivity of 49% (95% CI 0.36-0.62) 
and a specificity of 65% (95% CI 0.61-0.69) in the diagnosis of chlamydia. 
Probability of drug being prescribed 
The probability of nurses’ adherence to prescription guidelines for the syndromic diagnosis 
is also based on study data. Among 165 attendees who had been diagnosed with vaginal 
discharge syndrome, 140 (85%, 95% CI 79-90%) had been prescribed erythromycin. This 
is consistent with other studies from sub-Saharan Africa. In an observational study from 
Botswana including 66 female STI clients who were diagnosed with vaginal discharge 
syndrome and 33 who were diagnosed with lower abdominal pain, health workers 
prescribed treatment for chlamydia to 92 (93%) of the clients (9). This prescription rate is 
likely to be higher than in an antenatal care population: The health workers know they are 
observed, the probability of chlamydia is higher among STI clients, and with the lower 
abdominal pain syndrome, only drugs for chlamydia and gonorrhoea is recommended. 
Buve et al estimated in their report from Tanzania that 80% of the STI clients were 
prescribed adequate drugs (10). 
The probability of prescription of the recommended drug is likely to be higher if the 
specific POC test is positive. The nurse can rely on the diagnosis, and if the attendee is 
asymptomatic, only one drug regimen is necessary. Numerous discussions with nurses in 
primary health clinics in Botswana revealed that low rates of prescription in accordance 
with the treatment guidelines in the syndromic management strategy are caused by the 
uncertainty in the diagnosis and the complexity of the treatment regimens. The nurses 
reported using their own judgement and clinical experience to prescribe drugs for what they 
think is causing the patient’s symptoms or signs. Their knowledge of type and dosage of 
drugs to treat chlamydia is high. Cost-effectiveness analyses of chlamydia screening from 
developed countries are all operating with 100% probability of correct prescription (11, 12). 
A Medline search yielded no studies on health workers’ prescription of treatment for 
chlamydia specifically (see the technical report (13)). The expert panel agreed that if a 
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 specific POC test for chlamydia is positive, it is unrealistic to assume full adherence.  The 
nurses may forget the prescription or prescribe ineffective drugs, and it is was concluded 
that this is likely to happen in about one in 15 test positive cases. We therefore used 93% 
(85-100%) probability of correct prescription with the POC test strategy. 
 
Compliance and drug effectiveness 
A correct prescription does not necessarily lead to a successful cure of chlamydia. 
Treatment failures may be due to non-compliance, microbiological cure failure or re-
infection. It is generally accepted that the drugs recommended for chlamydia are nearly 
100% effective when taken as recommended. We have therefore used a combined 
probability for drug efficacy and compliance (Box A1). The risk of reinfection is captured 
in a separate variable.  
Studies, primarily from developing countries, have measured compliance and partner 
notification in randomized, controlled trials (Table A3) (14-16). These methods are 
hampered by methodological challenges such as observational bias (patients are likely to 
perform better in a defined research setting), or there may be a self-selection of patients, in 
that the less conscientious individuals will be lost during the follow-up stage. Additionally, 
most studies have focused on “treatment failures” without being able to tell if it is 
insufficient compliance, incomplete efficacy of the drug or reinfection from an infected 
partner which has caused the failure to obtain cure. 
 
Box A1 Probability of cure with the two alternative drug- and management strategies 
Compliance and drug efficacy with erythromycin  
 Probability of cure with syndromic management = 0.50 (0.30-0.70) 
 Probability of cure with point-of-care tests = 0.86 (0.50-0.95)  
Compliance and drug efficacy with azithromycin  
 Probability of cure with syndromic management = 0.95 (0.88-1.00) 
 Probability of cure with point-of-care tests = 0.95 (0.88-1.00) 
 
There are few papers published in Medline on patient compliance to STI drugs in 
developing countries. With the syndromic management of STIs, information on drug 
efficacy or reinfection rates is unachievable. As it is unknown which infection or condition 
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the patient is suffering from, only clinical cure rates can be measured. Buve et al estimate 
the proportion of symptomatic patients with a bacterial sexually transmitted infection cured 
by primary health care services in Mwanza, Tanzania. Within this project, patients with an 
STI syndrome assessed at outpatient clinics were requested to report back after 1 week. Of 
the female returners, 69% said they took the full treatment. The authors assume that the 
selection of dutiful patients results in an overestimate of the total compliance rate (10).  
It is consistently shown that the compliance and drug effectiveness for single dose 
treatment with azithromycin is very high. For optimal compliance, directly observed 
treatment can be introduced. Cure rates for erythromycin are lower, as the more complex 
treatment regimen and a greater occurrence of adverse effects reduce compliance (17, 18). 
In original studies and reviews from developed countries where the chlamydia diagnosis is 
based on a specific laboratory test, the probabilities of cure with erythromycin were 0.86 
(0.72-0.95). The expert panel believe that the cure rates for attendees diagnosed with a POC 
test are likely to be similar, but assigned large uncertainty bounds (0.50-0.95).  
The estimated 0.50 (0.30-0.70) probability of cure when erythromycin is prescribed 
to attendees diagnosed with syndromic approach is based on expert opinions and indirect 
data from our study among antenatal care attendees. Patients diagnosed with the vaginal 
discharge syndrome must simultaneously administer up to four drug regimens correctly, 
and often don’t know what condition they are suffering from - both aspects obviously 
having a negative impact on compliance. In our study from Botswana, the prevalence of 
chlamydia was identical (7.5%) among women who had been prescribed erythromycin 
earlier in the current pregnancy and among women who had not. Low compliance was a 
core factor in explaining why the prescribing of erythromycin did not necessarily cure the C 
trachomatis infection. The attendees, who in the study setting are diagnosed with a cervical 
infection using the vaginal discharge algorithm, had an insignificantly higher prevalence of 
chlamydia compared to those who have not been diagnosed. I can tell numerous anecdotes 
from my experience during the field work illustrating a high level of non-adherence to 
erythromycin among pregnant women diagnosed with vaginal discharge syndrome. A 
common error was to take one tablet daily in four weeks instead of one tablet four times 
daily for one week.  
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4
 Model input parameters: The partner decision tree  
The risk of reinfection due to failed partner referral was included in the model. In our 
study among antenatal care attendees, 671 (95%) of 703 women reported one partner 
during the last 12 months. We therefore assume that the women have, as a median, one 
partner with whom she will be sexually active during the current pregnancy. We did not 
include further transmission from the male partner. We are aware that multiple 
partnerships are common in Botswana (1). This, combined with the high prevalences of 
STIs among the antenatal care attendees, make us believe that modelling a steady couple 
may not represent the full reality. If the pregnant women or her partner has more than one 
partner, the effect of correctly diagnosing and treating chlamydia will be underestimated.  
Probability of partner being infected and probability of reinfection 
The chlamydia transmission rate between pregnant women and their partners in sub-
Saharan Africa is unexamined. The probability of the partner being infected, and a cured 
female or male being reinfected, is based on co-infection studies from the US, UK or 
Australia on patients in STI clinics and their steady and casual partners (Table A4). These 
studies are hampered by the lack of gold standard laboratory tests, by their inability to have 
included nearly all partners, and by the fact that both steady and casual partners are 
examined. The probability of transmission will vary from individual to individual and 
between subgroups, and the studies may therefore not necessarily be relevant to a 
population of antenatal care attendees with steady partners in a developing country. The 
studies indicate that the transmission of chlamydia is equal and bidirectional between 
sexual partners (27). It is also dependent on the number of sexual contacts in the couple, 
and thus higher among steady partners. The expert panel concluded that the transmission 
probability will be in the higher range (0.80), but we have used wide uncertainty bounds 
(0.50-0.96). The panel’s main arguments were a) The majority of the pregnant Batswana 
women in our study reported that they had one steady partner with whom they had had a 
relationship for one year or more, and b) The prevalences of other STIs/RTIs are very high 
in this area, most likely increasing the susceptibility and infectiousness of genital 
infections.  
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 We have not modelled possible chlamydia infections in partners of uninfected 
women. We assumed that male partners who are effectively treated do not reinfect their 
female partner before their infection is cured. 
 
Table A4: Studies of infection rates in partners of males and females with chlamydia 
Study population Infection in  
partners 
Infection in  
partners 
Reference 
1. STI clinic, USA. 53 couples concordantly infected;  
    in 48 couples one was infected 
2. STI clinic, UK. 97 M and 93 F index cases,  
    half of their partners were tested 
3. STI clinic, UK..404 chlamydia-infected  reported  
    632 sexual contacts and 147 (23%) were tested 
4. Australian study, primary health care and specialist 
    clinics. 87 M/F index cases w/chlamydia 
68% 
 
75% 
 
44% 
 
52% 
70%  
 
75% 
 
- 
 
52% 
(27) 
 
(28) 
 
(29) 
 
(30) 
 
Probability of infected male being symptomatic 
Economic evaluations of chlamydia screening which include partner notification and 
treatment, estimate that 30-50% of men with chlamydia infection are symptomatic. We 
have not found any original studies verifying this estimate, such data are virtually non-
existing (10). Studies among men seeking care overestimate the symptomatic/asymptomatic 
ratio, while population prevalence studies underestimate the ratio –as symptomatic men 
will have sought care and been treated. In a population-based study from Uganda, 92% of 
men with chlamydia reported no symptoms during the last 6 months (31). In a work-site-
based study from Tanzania, 89% of men with chlamydia reported no symptoms (32). In a 
study among young incarcerated minority males in the US, 90% of men with chlamydia 
were asymptomatic (33). Two population based studies on urethritis in men from Tanzania 
showed that 35% of men with chlamydia and/or gonorrhoea were symptomatic (10). As 
gonorrhoea more often is symptomatic, this value is probably too high for chlamydia 
infections. Based on these data, we modelled that 0.15 (0.10-0.20) male partners are 
symptomatic. 
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Probability of partner notification and health care attendance 
Many factors will influence if a partner is notified and subsequently attends a health care 
facility. The health care worker has to counsel the antenatal care attendee on partner 
notification, the woman has to notify her partner, and the partner has to attend a health 
facility. The success of a partner notification attempt is dependent on whether the partners 
are steady or casual, whether the diagnosis is syndromic or specific, on the notification 
strategy applied, as well as the cultural setting. We have used the same value for the 
probability of partner being notified and attend a health facility for all partners of the 
diagnosed females. The probability will vary in the different subgroups of antenatal care 
attendees in the model (A2), but this is difficult to estimate.  
 
Box A2 Factors which may influence partner notification and/or attendance at individual level in our model 
 If the antenatal care is prescribed correct treatment or not 
(The nurse may be less likely to counsel on partner notification, and the antenatal care attendee may be 
less conscious regarding notification. On the other hand, women who are not prescribed correct 
treatment are often prescribed other, but inappropriate drugs, a situation which not necessarily will be 
associated with reduced partner notification). 
 If the male partner is symptomatic or not 
(Symptomatic males may be more likely to attend a clinic when being notified by their partner. Or; 
symptomatic males may be less likely to attend a clinic when notified because he may have sought 
other care (independent care seeking is included in the model). 
 If the male partner seek other care independently (mutual influence) 
 
We used an estimate of 8.5% (5-15%) for partner notification within the syndromic 
approach – based on health statistics data from Botswana. These data are in line with 
studies from other sub-Saharan countries (Table A5). There were 0.085 male STI contacts 
registered per female STI client in Botswana in 2002, demonstrating that partner 
notification is very poor (34).  The 91 738 registered STI syndromes among female clients 
do not include the STI syndromes diagnosed among the approximately 40 000 antenatal 
care attendees registered the same year. We do not know how many of the men who were 
referred by a pregnant partner, and thus lack direct data on the partner referral rate among 
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 pregnant women diagnosed with an STI. Two observational studies on STI management in 
Botswana report that advice on partner notification including the issuing of a contact slip 
was provided to 61% and 66% of the STI clients, respectively (9, 35).  Less than five 
minutes in total was spent per STI client, in a consultation which is meant to contain history 
taking, clinical examination, diagnosis, treatment and counselling. These data underpin that 
the number of partners who will be notified by the women and subsequently attend a health 
facility is low. 
The participants in the expert panel have wide theoretical knowledge and clinical 
experience with partner notification in developing countries. They concluded that with the 
use of specific point-of-care tests, a realistic estimate of the probability of partner 
notification and attendance will be 25% (0.085-0.65%). The lower bound of partner 
notification and attendance with the POC test strategy represents the current partner 
attendance, whereas data from studies in developed countries was used as a basis for the 
upper bound. Medline searches and the studies identified are described in the technical 
report (13). Many studies on partner notification are performed under optimal conditions, 
often with the aim of improving the partner management, and may not represent routine 
care. 
Table A5 Studies used as a basis for the modelled probability of partner notification and attendance  
Partners Description of study  
Notified Attend 
Reference 
Syndromic management/African countries 
  Male partners per female STI client in Botswana 
  Female STI clients in Uganda. A study to improve partner notification 
  Female STI clients in Uganda 
  STI clients in South Africa 
Diagnostic test/western countries 
STI clients in the Netherlands. Optimal conditions. 
  STI clients in the UK. Optimal conditions.
 
 
 
  4%
 
    8.5% 
     22% 
 
   <20% 
 
60-82% 
   <65% 
 
(34) 
(36) 
(31) 
(16) 
 
(37) 
(38) 
Probability of symptomatic males seeking other care and being cured  
Symptomatic males may seek care independently of their pregnant partner, and the care 
providers will range from street vendors and faith healers to pharmacies, private doctors 
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 and public clinics. Data on health care seeking among symptomatic males and the quality 
of care provided is scarce. Buve et al. has reported from Tanzania that 51% of males and 
females with genital discharge or genital ulcer sought care (10). How many of the partners 
who seek care after being notified by a partner and how many who seek care independently 
is not reported –and probably not known. In a population-based study in Botswana, 85% of 
the male respondents who ever had STI symptoms had been to a public health facility 
(which may or may not be because he has been notified by his partner), 26% had sought a 
traditional healer, 16% had been to the pharmacy and 14% to a private doctor (1). The 
number of symptomatic episodes among these males was not reported.  
The probability of cure among symptomatic males seeking other health care is the 
sum of a correct diagnosis, a correct prescription, sufficient compliance and avoidance of 
reinfection. We lack accurate data from public clinics in sub-Saharan Africa on cure rates 
among males with urethral discharge. The described study by Buve et al. estimated cure 
among male STI clients in public health facilities: 63% were diagnosed correctly, 73% 
were prescribed correct treatment and 84% were compliant (10). In an observational study 
from primary health care in Botswana, adequate history taking among male STI clients was 
performed in 54% and clinical examination in 57% of the cases (9). Of the males who were 
diagnosed with urethral discharge syndrome, 91% received an appropriate prescription. 
Compliance was not measured in this study, and the authors noted that nurses may perform 
better when being observed. We have not found any literature estimating cure rates of the 
management of patients with genital symptoms in private clinics, in pharmacies or among 
traditional or faith healers.  
The probability of symptomatic males seeking other care and subsequently being 
cured are expert opinions. The expert panel based their estimates on available studies, their 
common clinical experience (for example that many patients don’t seek health care before 
their symptoms are severe), knowledge of and literature on the wide use of alternative 
medicine in sub-Saharan Africa, and on discussions with nurses in the primary health care. 
The panel agreed that the parameters have a large degree of uncertainty, and estimated that 
50% (30-70%) of the symptomatic males who do not attend a health facility as a result of 
partner notification seek the health services independently. They estimated that 50% (30-
70%) of the symptomatic males who seek care independently are cured for their chlamydia 
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 infection. We have not accounted for the fact that an infected male partner may notify his 
pregnant partner resulting in her treatment and cure.   
 
Probability of correct prescription to male partner 
We have not identified studies on quality of prescription to partners, but we assume that the 
probability of correct prescription will be similar to the probability among index patients. A 
0.85 (0.76-1.00) probability of correct prescription to male partners with the syndromic 
approach strategy is based on the two observational studies on syndromic management of 
STI clients in Botswana. The first study among 33 males with urethral discharge found that 
70% were prescribed ceftriaxone for gonorrhoea and 76% were prescribed doxycycline for 
chlamydia (35). In the second study, all 32 males with urethral discharge syndrome were 
prescribed ceftriaxone and doxycycline (9).  
As discussed under the description of the parameters in the female decision tree, the 
expert panel assumed that the probability of correct prescription to male partners will be 
higher if a specific POC test is positive than with the syndromic approach. The expert panel 
assumed that with the POC test strategy, it is realistic with a 93% (85-100%) probability of 
prescription of treatment. Cost-effectiveness analyses of chlamydia screening from 
developed countries are all operating with 100% correct prescription, but we added a dose 
of realism (the nurses may forget the prescription or prescribe ineffective drugs). 
 
Probability of compliance and drug effectiveness among male partners 
In Botswana, the standard treatment for chlamydia in males and non-pregnant women is 
doxycycline 100 mg tablets twice daily in one week (39, 40). Doxycycline and 
azithromycin are juxtaposed by the WHO, Center for Disease Control and Prevention and 
others, but the former drug is cheaper (40, 41). We modelled doxycycline treatment to 
partners, although single-dose treatment with 1g azithromycin may be considered to 
improve compliance. We mainly found data on compliance to doxycycline from developed 
countries (Table A3), and we did not identify any studies on compliance and cure rates in 
partners as such. The probability used for the syndromic management strategy, 0.80 (0.60-
1.00), was adjusted by the experts based on their knowledge of the local conditions and 
assigned large confidence intervals. Further, the expert panel assumed that partners of 
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 patients with a positive POC chlamydia test will be more compliant than partners of 
patients diagnosed with vaginal discharge syndrome: The male will know that their partner 
had chlamydia, and for partners of asymptomatic attendees only one drug regimen is 
necessary. The lower bound of the 0.90 (0.80-1.00) probability with the POC strategy is 
identical to the estimate of the current level, whereas the upper bound is based on the 
original studies and reviews from developed countries. As data on compliance among 
symptomatic versus asymptomatic partners are lacking, we used the same probability of 
compliance and drug effectiveness for all male partners regardless of symptoms. 
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Appendix 4 
Table A6 Age of ntenatal care attendees in the study compared to new attendees in Botswana
Age groups Study setting New antenatal care attendees in Gaborone 
 Year 2000-2001 Year 2000 Year 2001 Year 2002 
 n (%) n (%) n (%) n (%) 
<20 
20-29 
30+ 
All 
  76 
432 
195 
703 
(10.8) 
(61.5) 
(27.7) 
(100) 
  7 965  
21 314  
10 466  
39 745  
 (20.0) 
 (53.6) 
 (26.3) 
 (100) 
  8 594  
23 257  
11 031  
42 882  
(20.0) 
(54.2) 
(25.7) 
(100) 
  8 264  
23 569  
11 333  
43 166  
(19.1) 
(54.6) 
(26.3) 
(100) 
<20 
<30 
All 
  76 
508 
703 
(10.6) 
(72.3) 
(100) 
  7 965  
29 279  
39 745  
 (20.0) 
 (73.7) 
 (100) 
  8 594  
31 851  
42 882  
(20.0) 
(74.3) 
(100) 
  8 264  
31833  
43 166  
(19.1) 
(73.7) 
(100) 
 
Table A7 Age of antenatal care attendees in the study compared new attendees in Gaborone
Age groups Study setting New antenatal care attendees in Gaborone 
 Year 2000-2001 Year 2000 Year 2002 
 n (%) n (%) n (%) 
<15 
15-19 
20-29 
30-39 
40-44 
45+ 
    0 
  76 
432 
179 
 16 
   0 
- 
(10.8) 
(61.5) 
(25.7) 
(2.3) 
- 
    14 
  860 
4164 
1163 
  117 
     7 
(0.2) 
(13.6) 
(66.1) 
(18.4) 
(1.9) 
(0.1) 
7 
633 
4008 
1529 
134 
4 
(0.1) 
(10.0) 
(63.5) 
(24.2) 
(2.1) 
(0.1) 
Total 703 (100) 6325 (100) 6315 (100) 
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Background: Millions of patients are prescribed drugs for sexually transmitted infections (STIs) in
developing countries each year, yet the treatment effect of these prescriptions is largely unknown.
Objectives: To determine if the prescribing of erythromycin and ceftriaxone to pregnant women with STI
symptoms leads to a reduction in the prevalence among these women of chlamydia and gonorrhoea,
respectively.
Methods: We compared the prevalence of chlamydia among 116 pregnant women who had been
prescribed erythromycin for a history of STI symptoms in their current pregnancy with the prevalence in a
control group of 557 pregnant women who had not been prescribed this drug. Similarly we compared the
prevalence of gonorrhoea among 110 pregnant women who had and 561 women who had not been
prescribed ceftriaxone.
Results: There was no significant difference in the prevalence of chlamydia among the women who had
and the women who had not been prescribed erythromycin four times daily for 10 days (7% v 8%).
Contrarily, none of the women who had been prescribed a single dose of ceftriaxone had gonorrhoea,
whereas 4% of the women who had not had this drug prescribed did have gonorrhoea.
Conclusions: The prescribing of erythromycin seems to have had a limited effect on chlamydia in this
population, whereas the prescribing of ceftriaxone led to the curing of gonorrhoea. Ceftriaxone is
provided as a single dose injection at the point of care, and the differential effectiveness between the two
drugs may reflect low compliance with the complex erythromycin regimen. Interventions to increase
compliance could improve cure rates. The use of a simpler drug regimen should be considered when low
compliance is likely.
S
exually transmitted infections (STIs) are a major health
problem in many parts of the developing world. STIs
cause substantial morbidity and mortality, which
disproportionately affect women. Because many of the
complications are pregnancy related,1 2 adequate diagnosis
and effective treatment of STIs in pregnancy are critical.
Additionally, there is substantial evidence that the presence
of other STIs increases both HIV infectiousness and suscept-
ibility,3 4 and a long term STI control programme is
emphasised as one of the cornerstones of HIV prevention.5
Striving for optimal performance of the STI programme is
essential; in countries where healthcare budgets are limited,
the potential for improvement is often larger and can have a
substantial effect on the overall burden of disease.
Evaluations of STI programmes are usually limited to an
assessment of the proportion of patients with an STI that is
correctly diagnosed and to the prescribing of effective drugs.
Previous studies have tended not to focus on the fact that
patients with an STI must overcome a series of hurdles after
their encounter with the healthcare system before they can
be considered cured. STI clients who are adequately assessed
must obtain prescribed drugs, comply with treatment, and
ensure that their partners are treated to avoid re-infection.6
Patient compliance with medical advice and drug regimens is
an increasingly significant issue in developing countries. The
consumption of drugs is on the rise, and drugs represent a
high proportion of healthcare budgets.7 Although most
governments are interested in ensuring availability and
access to drugs, addressing the issue of adequate drug use
remains a low priority.8
In Botswana, a country of 1.7 million people, the burden of
STIs is high. Extrapolating from the 37% of the pregnant
women who are known to be HIV positive, the Ministry of
Health has calculated that 275 000 of 15–49 year olds are
infected with the virus.9 Because of a lack of laboratory
facilities, STI diagnosis and treatment are usually limited to
case management in which algorithms are used to classify
presenting symptoms and clinical signs into defined syn-
dromes. There were 180 000 registered STI related outpatient
consultations in 2000, 150 000 of which led to a syndrome
diagnosis.10 However, syndromic management leads to
diagnostic uncertainty and limits epidemiological surveil-
lance. Patients are prescribed multiple drug regimens to cover
every possible microbiological agent that is known to cause
each syndrome, and antimicrobials for STIs constitute a
substantial share of the total drug use in the country. Despite
the large number of prescriptions, treatment success among
STI patients in the primary healthcare system remains
unknown.
The aim of this article is to draw attention to the
consequences of prescribing antibiotics to STI patients in
Botswana and to discuss possibilities for improving the cure
rates. In a larger research project on STIs among antenatal
care (ANC) clients in Botswana, we found that many of the
women had a history of STI symptoms in their current
pregnancies and had been prescribed the recommended STI
treatment. Given the epidemiological data, we present the
following research question: Is there a lower prevalence of
Chlamydia trachomatis and Neisseria gonorrhoeae among ANC
clients who have had drugs against these bacteria prescribed
to them in their current pregnancy, compared to ANC clients
who have not had these drugs prescribed?
METHOD
Included in this study were 703 ANC clients who visited the
primary healthcare clinics in Gaborone, the capital of
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Botswana, between October 2000 and February 2001. A
proportionate sample of ANC clients was chosen from each of
the clinics, based on the ANC patient load during the same
period in the previous year. All volunteers gave written,
informed consent, and our only exclusion criterion was the
use of antibiotics in the 2 weeks before their visit. A
structured interview and data from the patient held obstetric
record were used to obtain information on sociodemographic
factors, past and current pregnancies, and STI symptoms.
When a patient is diagnosed with an STI syndrome during
pregnancy, the syndrome and the prescribed drugs are
documented in the obstetric record. In pregnant women,
STIs are often diagnosed during the mandatory speculum
examination at the first ANC visit. Prescribed treatment for
any STI during the current pregnancy was recorded in this
study along with the syndrome diagnosis. In Botswana, the
recommended treatment for C trachomatis is 100 mg of
doxycycline taken orally twice daily for 10 days; in preg-
nancy, the recommended treatment is 500 mg of erythromy-
cin taken orally four times daily for 10 days.11 The treatment
for N gonorrhoeae is 250 mg of ceftriaxone given as a single
intramuscular injection by a healthcare provider at the point
of care.
All patients underwent a genital examination, and clinical
signs from external and internal genitalia were recorded.
Signs of a sexually transmitted infection were classified into
defined syndromes following the national guidelines and
were treated accordingly. Cervical swabs were obtained from
all women for ligase chain reaction (LCR) amplification
technology for the direct, qualitative detection of specific
target nucleic acid sequences of C trachomatis and N
gonorrhoeae. The swabs were placed in LCx transport media,
transported to the laboratory at ambient temperature the
same day, and stored at 220 C˚ before batch processing. The
LCx assays (Abbott Laboratories, IL, USA) were performed
according to the manufacturer’s instructions. A case of C
trachomatis or N gonorrhoeae infection was defined as an
individual with a positive LCR analysis. DNA amplification
testing methods can remain positive up to 3 weeks after
treatment. A positive test performed 3 or more weeks after
completed treatment should thus be interpreted as true
positive, reflecting either treatment failure or re-infection.12
In this study, rather than assume that every patient began
medication the day she received her prescription, we
calculated up to 2 weeks to complete the course of medica-
tion. Patients who had been prescribed treatment for either of
the two infections under study were therefore divided into
two groups: (a) patients for whom treatment was prescribed
up to 5 weeks earlier and who were still within the period in
which a confirmed case of infection could be a false positive,
and (b) patients for whom treatment was prescribed 5 or
more weeks previous, and for whom a confirmed case was
likely to be true positive. Patients who had not been
prescribed treatment were used as controls.
The study was approved by the national ethics committees
of Botswana and Norway.
RESULTS
The median age of the 703 ANC clients was 25 years and the
median gestational age 30 weeks (range 8–42); 53 (8%) of
the women had a laboratory verified C trachomatis infection
and 21 (3%) had laboratory verified N gonorrhoeae infection.
Further background characteristics and genital symptoms
and signs are described in table 1. Both erythromycin and
Figure 1 Prescription of erythromycin and ceftriaxone earlier in current pregnancy among 703 antenatal care clients in Gaborone, Botswana, and
the distribution of Chlamydia trachomatis and Neisseria gonorrhoeae infections in this population.
396 Romoren, Rahman, Sundby, et al
www.stijournal.com
 on 17 April 2008 sti.bmj.comDownloaded from 
ceftriaxone had been prescribed to 132 of the women earlier
in their pregnancies; erythromycin only had been prescribed
to 14 women and ceftriaxone only to 10 women. Figure 1
shows the distribution of confirmed cervical infections
among women who had and had not been prescribed
erythromycin and/or ceftriaxone.
The diagnosis for which the antibiotics were prescribed is
shown in table 2. Vaginal discharge syndrome (VDS) was the
most common diagnosis, leading to 137 (86%) of 159
erythromycin prescriptions and 130 (85%) of 153 ceftriaxone
prescriptions. According to national syndromic management
guidelines,11 a woman who complains of abnormal vaginal
discharge should, if the condition is confirmed at a speculum
examination, be prescribed treatment for vulvovaginal
candidiasis, trichomoniasis, bacterial vaginosis, chlamydia,
and gonorrhoea. How many of these women actually had
chlamydia, gonorrhoea or any of the other infections is not
known.
There was no significant difference in the prevalence of
chlamydia or gonorrhoea among women with and without
clinical signs of vaginal discharge syndrome: 27 (9%) of the
308 women with VDS and 26 (7%) of the 395 women without
VDS had chlamydia (Fisher’s exact test 0.31 (two sided)),
and 13 (4%) of the 308 women with VDS and eight (2%) of
the 395 women without VDS had gonorrhoea (Fisher’s exact
test 0.12 (two sided)). Using only clinical signs of abnormal
vaginal discharge as a diagnostic tool to identify cervical
infections in this study population has a low sensitivity and
specificity: VDS has a sensitivity of 0.51 for chlamydia and
0.62 for gonorrhoea and a specificity of 0.57 for both
chlamydia and gonorrhoea.
Of the 703 ANC women, 146 (21%) had been prescribed
the recommended erythromycin regimen for chlamydia—13
of them twice. The prevalence of chlamydia among women
who had and had not been prescribed erythromycin is
identical at 8%. Confirmed C trachomatis cases in the different
erythromycin prescription groups are shown in table 3; none
of these prevalences are significantly different. Of the 116
women who had been prescribed erythromycin 5 or more
weeks earlier (median 11 weeks), eight (7%) had chlamydia;
and 42 (8%) of the 561 women who had not been prescribed
this drug during pregnancy had chlamydia (Fisher’s exact
test 1.0 (two sided)). There were no significant differences in
age, median gestational week, parity, educational level,
marital status, or length of current relationship among the
women who had and had not been prescribed erythromycin
earlier in pregnancy.
Of the 703 ANC women, 142 (20%) had been prescribed
ceftriaxone in their current pregnancy, 11 of them twice.
Among these 142 women, none had a positive N gonorrhoeae
test result. Among the 110 women who had been prescribed
ceftriaxone 5 or more weeks earlier (median 12 weeks), none
had gonorrhoea, whereas 21 (4%) of the 561 women who had
not been prescribed the drug had gonorrhoea (table 3). The
difference in gonorrhoea prevalence between the two groups
is significant (Fisher’s exact test=0.035 (two sided)).
Table 1 Background characteristics, genital symptoms and signs, and the prevalence of
cervical infections among 703 antenatal care clients in Gaborone, Botswana
No (%)
Age groups (years)
15–19 76 (11)
20–24 249 (35)
25–29 183 (26)
30–34 126 (18)
35–43 69 (10)
Education
Primary school or less 168 (24)
Junior secondary school 310 (44)
Secondary school or higher 225 (32)
Marital status
Married 114 (16)
Living with husband 97 (85)
Non-marital steady partner 572 (81)
Living with partner 256 (45)
Single 17 (2)
Number of pregnancies
1st pregnancy 243 (35)
2nd pregnancy 208 (30)
3rd pregnancy 122 (17)
4th+ pregnancy 130 (18)
Number of antenatal care visits
1st visit 157 (22)
2nd–4th visit 300 (43)
5th–7th visit 182 (26)
8th+ visit 64 (9)
Self reported symptoms of STIs
Increased vaginal discharge 119 (17)
Itching/soreness 58 (8)
Lower abdominal pain 53 (8)
Genital warts 16 (2)
Genital ulcer 8 (1)
Dysuria 8 (1)
Clinical signs of STIs
Vaginal discharge syndrome 308 (44)
Genital warts 29 (4)
Genital ulcer 5 (1)
Cervical infection (chlamydia and/or gonorrhoea) 67 (10)
Chlamydia 53 (8)
Gonorrhoea 21 (3)
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DISCUSSION
This retrospective study reviews treatment success among
ANC clients who were prescribed drugs for C trachomatis and
N gonorrhoeae during pregnancy. We demonstrate that
prescribing erythromycin orally four times daily in 10 days
does not necessarily lead to a cure for C trachomatis in
pregnancy and that ceftriaxone prescribed as a single dose
injection against N gonorrhoeae appears to be effective. The
differences in the effect of prescribing these two drug
regimens are thought provoking.
When the correct drug has been prescribed, patient
compliance and treatment of an infected partner are the
main factors necessary for the successful treatment of STIs.
Research on these issues can be limited by methodological
pitfalls, and different research strategies should complement
each other. Studies, primarily from developing countries,
have measured compliance and partner notification in
randomised, controlled trials.13–15 Yet these methods are
hampered by challenges such as observational bias (patients
are likely to perform better in a defined research setting), or
there may be a self selection of patients, in that the less
conscientious individuals will be lost during the follow up
stage.
Epidemiological data have an advantage in evaluating the
true effect of STI management from a public health
perspective—in this case, illustrating the impact of treating
cervical infections among ANC clients in the primary
healthcare system in Botswana. A methodological weakness
in our study, which is an inherent problem of syndromic
management, is the unknown prevalence of infection before
the prescription of antibiotics. ANC clients who were and
were not prescribed erythromycin earlier in pregnancy
demonstrate a similar prevalence of chlamydia. Is there
reason to believe that the prevalence of chlamydia among
clients who had been prescribed erythromycin was higher
before treatment, and was therefore significantly reduced?
The answer to this question is mainly dependent on the
sensitivity of the clinical signs on which the prescription was
based. The majority (85%) of the patients had had
erythromycin prescribed to them because of clinical signs of
VDS. It is well known that the algorithms currently available
for the management of cervical infections are far from
ideal.16–18 Previous research from Africa reports no or poor
association between vaginal discharge and cervical infec-
tions.2 19 20 In our data we do not find a significant association
between VDS and C trachomatis infection among pregnant
women. It is also relevant to note that the women who had
and the women who had not had erythromycin prescribed to
them earlier in their pregnancies are similar in sociodemo-
graphic risk factors, including age—a consistent risk factor
for cervicitis. Thus, circumstantial evidence indicates that the
prevalence of cervical infection among the patients who had
been prescribed erythromycin and/or ceftriaxone was prob-
ably the same or slightly higher before treatment.
Lack of efficacy in the prescribed antibiotics is not likely in
this study. Erythromycin and ceftriaxone have been shown to
be effective against C trachomatis and N gonorrhoeae respec-
tively, and bacterial resistance to these treatment regimens
has not yet been found to be of clinical importance.21 The
availability of STI drugs is high in Botswana, even in rural
areas, and they are provided to the patients free of charge.22
Of the 122 women who had had erythromycin and/or
Table 2 Diagnosis leading to prescription of erythromycin and ceftriaxone to 156
antenatal care clients in Gaborone, Botswana, of which 132 clients were prescribed both
drugs, 14 clients were prescribed erythromycin only, and 10 ceftriaxone only
No (%)
Reasons for prescribing 500 mg of erythromycin 164 in 10 days to 146 women, 13 of whom were diagnosed
twice (n = 159)
Vaginal discharge syndrome 137 (86)
Cervical erosion 18 (11)
Lower abdominal pain 3 (2)
Genital ulcer 1 (1)
Reasons for prescribing 250 mg of ceftriaxone intramuscularly, single dose to 142 women of whom 11 were
diagnosed twice (n = 153)
Vaginal discharge syndrome 130 (85)
Cervical erosion 17 (11)
Lower abdominal pain 2 (1)
Genital ulcer 3 (2)
Syphilis 1 (1)
Table 3 Prevalence of chlamydia and gonorrhoea among 703 ANC clients in
Gaborone, Botswana, compared to prescription of the drugs recommended for these
infections earlier in current pregnancy
No (%) Total No
500 mg erythromycin 164 in 10 days C trachomatis infection
No erythromycin prescribed 42 (8) 557
Erythromycin prescribed less than 5 weeks earlier 3 (10) 30
Erythromycin prescribed 5 or more weeks earlier 8 (7) 116
Total sample 53 (8) 703
Ceftriaxone 250 mg im in a single dose N gonorrhoeae infection
No ceftriaxone prescribed 21 (4) 561
Ceftriaxone prescribed less than 5 weeks earlier 0 – 32
Ceftriaxone prescribed 5 or more weeks earlier 0 – 110
Total sample 21 (3) 703
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ceftriaxone prescribed to them 5 or more weeks before this
study, 104 (85%) had had both drugs prescribed. No
substantial crossover effect between the two drugs is likely,
however. Neither drug regimen is satisfactory for treatment
of the other microbe,21 and we found no significant reduction
of gonorrhoea among patients who were prescribed erythro-
mycin and no significant reduction in chlamydia among
patients who were prescribed ceftriaxone.
Re-infection
Could the treatment failure of erythromycin be due to re-
infection or to a newly acquired infection? Chlamydia and
gonorrhoea can cause urethral discharge in men, and men
with this symptom and partners to women with VDS are
usually treated with both doxycycline and ceftriaxone.
Among the ANC clients in this study with an N gonorrhoeae
infection who were prescribed ceftriaxone, all were treated
successfully and had not been re-infected by their partners at
the time of our study. Two factors can possibly lead to a lower
impact of re-infection with N gonorrhoeae than with C
trachomatis in this population. We cannot ignore the fact that
the level of healthcare seeking among partners with gonor-
rhoea (which causes symptoms among men more often than
does chlamydia) is likely to be somewhat higher. It is also
possible that treatment success with the single dose therapy
for gonorrhoea is higher among partners than is the
doxycycline regimen for chlamydia.
Theoretically, all women treated for chlamydia could have
been re-infected or acquired a new infection after being
cured. However, it would have required a substantial failure
in the notification and treatment of the partners of ANC
clients with C trachomatis and complete success in notifying
and treating partners of the women with an N gonorrhoeae
infection—a highly unlikely state of affairs. Sexual absti-
nence in the gonorrhoea group could explain their lack of re-
infection and multiple partners in the chlamydia group could
have caused new infections, but there is no reason to believe
that that would have been the case. Women in both groups
reported one sexual partner the last year and it seems safe to
assume that these two groups should not differ system-
atically in their sexual behaviour. These arguments lead to
the conclusion that re-infections or new infections can not be
a major cause of the documented failure to treat C trachomatis.
One is left with the impression that patient compliance is a
more important variable.
Patient compliance
Although evidence from developing countries is limited, a
substantial level of non-adherence to antibiotic prescriptions
in most cultures is well known and reviews of studies from
developed countries suggest that at least 30% of patients fail
to follow medical advice on drug use.23 Of the many variables
involved in non-adherence, non-modifiable factors include
characteristics of the patient, practitioner, or illness; whereas
potentially modifiable factors relate to aspects of the
interaction between patient and healthcare provider and
aspects of the drug regimen. The complexity of the regimen
(frequency of administration, number of tablets required
daily, and length of treatment) is closely related to
adherence.23 The number of patients who do not comply
with prescribed courses of antibiotics may be increased in
asymptomatic STI clients, and the occurrence of adverse
effects is also associated with non-compliance.21
As in most developing countries, ANC clients in Botswana
with STI symptoms are prescribed a multiple drug regimen
that requires many tablets to be administered correctly,
which in itself may reduce compliance. The erythromycin
regimen is complex in itself, the medication is frequently
followed by gastrointestinal side effects, and the patient’s
complaint is not severe. We suspect that low compliance is a
central factor in explaining why the prescribing of erythro-
mycin orally four times daily in 10 days does not necessarily
lead to a cure for C trachomatis in pregnancy.
Improving cure rates
According to national guidelines in Botswana, all STI patients
should be counselled on patient based partner referral and
should receive contact cards with information to give to their
partners. However, referred partners to symptomatic STI
patients comprise less than 10% of all registered STI
outpatients,10 suggesting that there is room for improvement
in the partner notification system. Unfortunately, few studies
on this issue have been undertaken in resource poor
countries where it is essential that resources be used
effectively and efficiently, and the cultural contexts are
different.15 The relatively high levels of overdiagnosis of STIs
in syndromic management, especially in women, may not, in
fact, provide an appropriate basis for recommending the
management of partners, as we may not be sure that the
individual is truly infected.24 Thus, improving partner
notification in women with VDS is a complicated issue. A
more obvious and simple strategy to improve C trachomatis
cure rates within the national control programmes is the use
of a single, supervised dose of antibiotics.
Several drugs, typically used in combination, can satisfac-
torily cure cervical infections. If poor compliance is suspected,
as is the case with the ANC clients in Gaborone who are
treated with erythromycin for C trachomatis infections,
directly observed single dose therapy should be considered.25
Gonorrhoea has been treated in this manner since the
beginning of the antibiotic era; and with the development
and licensing of azithromycin, chlamydia can also be
effectively treated with single dose therapy.26 The oral
administration of 1 g of azithromycin has a similar or higher
efficacy and similar or fewer side effects than all the
alternative week long regimens,12 27 and has become the drug
of choice in most of the developed world. Although
azithromycin is still not officially licensed for the treatment
of chlamydia in pregnancy, clinical experience and research
data suggest that azithromycin is effective and safe for the
fetus,13 28 and the drug is listed as an alternative regimen for
pregnant women in the Centres for Disease Control STD
treatment guidelines.29 Compared to azithromycin, erythro-
mycin has a significantly higher level of gastrointestinal side
effects, which frequently discourage patients from complying
with the regimen and thereby reduces the cure rate.26 29
A comparative study on STI drugs from 15 countries in
Africa and Asia concludes that azithromycin is not routinely
used for chlamydia in developing countries.30 Single dose
therapies were used to treat N gonorrhoeae in 12 out of 15
countries, but week long regimens were used in all 15
countries to treat C trachomatis. Efficacy, tolerance, compli-
ance, and cost are factors to consider when preparing
guidelines for antibiotic treatment of chlamydial infection.
An important obstacle to single dose therapy in countries
where resources are limited is the higher drug acquisition
cost for azithromycin compared to doxycycline. The erythro-
mycin regimen is more expensive than azithromycin, and in
pregnant women, azithromycin could be recommended.31
When it comes to other STI patients, economic analysis
clearly favours single dose therapy when the indirect costs of
treatment failures are included.28
It is also clear that an investment of additional time is
necessary during consultation in order to provide patient
education and counselling on compliance, partner notifica-
tion, and safe sex. Female STI patients in Botswana are
managed in an average of 5.4 minutes.22
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CONCLUSION
When assessing the performance and cure rates achieved by
STI programmes, it is necessary to focus on the consequences
of the STI patient’s diagnosis and treatment prescription. Low
compliance with recommended drug regimens and lack of
partner notification and treatment are the main obstacles
that hinder a cure. In this study, many ANC clients in
Botswana are successfully treated on the spot for N
gonorrhoeae with an intramuscular injection with ceftriaxone,
whereas many clients who are prescribed one tablet of
erythromycin four times daily for 10 days are not cured of C
trachomatis. We argue that the complexity of the erythromycin
regimen most probably is the main cause of the low
treatment effect.
Improving patient compliance, but also facilitating partner
notification, and promoting sexual abstinence until the
patient and partner are treated can be effective and cost
effective ways to improve treatment with STI drugs.
Healthcare professionals prescribing antibiotics must give
their patients clear information that emphasises the impor-
tance of adhering to the treatment and examine the patient’s
health beliefs and understanding of the instructions.
Interventions to improve patient compliance as well as
partner treatment should be based on area specific research.
We also recommend that health authorities in developing
countries consider the use of directly observed single dose
therapy for the treatment of chlamydia if low compliance is
considered to be likely.
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Key messages
N In sub-Saharan Africa, the burden of STIs is high, and
antimicrobials for STIs constitute a substantial share of
the total drug use. Despite the large number of
prescriptions, treatment success among STI patients in
the primary healthcare system remains unknown
N This study draws attention to what happens after STI
patients in Botswana have been diagnosed and
prescribed treatment. We find that antenatal care
clients with a recent history of STI symptoms who have
received prescriptions of ceftriaxone are successfully
treated for Neisseria gonorrhoeae. ANC clients who
have been prescribed erythromycin have identical
prevalence of Chlamydia trachomatis to ANC clients
without such history. We argue that the complexity of
the erythromycin regimen is most probably the main
cause of the low treatment effect
N Improving patient compliance, but also facilitating
partner notification, and promoting sexual abstinence
until the patient and partner are treated can be
effectivel and cost effective ways to improve treatment
with STI drugs. The use of directly observed single dose
therapy for the treatment of chlamydia should be
considered if low compliance to more complex
treatment regimens is likely
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Objective To measure the prevalence of Trichomonas vaginalis (TV) infection and bacterial vaginosis (BV) among pregnant women 
in Botswana, and to evaluate the syndromic approach and alternative management strategies for these conditions in pregnancy.
Methods In a cross-sectional study, 703 antenatal care attendees were interviewed and examined, and specimens were collected 
to identify TV, BV, Candida species, Chlamydia trachomatis and Neisseria gonorrhoeae. Information on reproductive tract infections 
earlier in pregnancy was obtained from a structured interview and the antenatal record.
Findings TV was found in 19% and BV in 38% of the attendees. Three-fourths of women with TV or BV were asymptomatic. 
Syndromic management according to the vaginal discharge algorithm would lead to substantial under-diagnosis and over-treatment 
of TV and BV. Signs of vaginal discharge were more predictive of the presence of these conditions than were symptoms. Among the 
546 attendees on a repeat antenatal visit, 142 (26%) had been diagnosed with vaginal discharge earlier in their pregnancy – 14 of 
them twice. In 143 cases, an attendee was diagnosed with vaginal discharge in the second or third trimester; however, metronidazole 
had been prescribed only 17 times (12%).
Conclusion Diagnosis and treatment of TV and BV among pregnant women in sub-Saharan Africa presents major challenges. 
Half the pregnant women in this study were diagnosed with TV or BV, but these conditions were not detected and treated during 
antenatal care with syndromic management. Also, health workers did not adhere to treatment guidelines. These results indicate that 
management guidelines for TV and BV in antenatal care should be revised.
Bulletin of the World Health Organization 2007;85:297-304.
Une traduction en français de ce résumé ﬁgure à la ﬁn de l’article. Al ﬁnal del artículo se facilita una traducción al español.
Trichomoniasis and bacterial vaginosis in pregnancy: 
inadequately managed with the syndromic approach
M Romoren,a M Velauthapillai,b M Rahman,c J Sundby,d E Klouman e & P Hjortdahl d
Introduction
Trichomonas vaginalis (TV) infection 
is the most common curable sexually 
transmitted infection (STI) worldwide.1 
In studies of low-risk women in sub- 
Saharan Africa, the prevalence ranges 
from 10–31%.2,3 Bacterial vaginosis (BV) 
is a syndrome characterized by a shift 
in vaginal ﬂora; it is particularly com-
mon in the sub-Saharan region, where 
prevalences up to 50% are not uncom-
mon.4 These two vaginal conditions are 
thought to cause substantial morbidity 
among women in developing countries. 
Both infections have been linked to 
preterm delivery and low birth weight 5 
and, as reproductive tract infections 
(RTIs), they are likely to increase both 
infectiousness of HIV and susceptibility 
to the disease.6,7  It appears to be criti-
cal to diagnose and treat TV and BV in 
pregnancy, especially in high-prevalence 
settings.8,9
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There are few studies from devel-
oping countries on eﬀective strategies 
to prevent the adverse outcomes associ-
ated with TV and BV in pregnancy. Sys-
tematic reviews from developed coun-
tries of antibiotic treatment for these 
conditions in asymptomatic pregnant 
women show no signiﬁcant reductions 
in adverse pregnancy outcomes.5,10–12 
However, antibiotic treatment for BV 
may reduce the risk of low birth weight 
and preterm rupture of the membranes 
among pregnant women with previous 
preterm deliveries.13 Provision of treat-
ment for TV or BV in symptomatic 
pregnant women has not been adequate-
ly evaluated.11,12
Diagnosis of TV and BV in women 
in sub-Saharan Africa is based on the 
vaginal discharge syndrome – the most 
common syndrome in the syndromic 
approach (i.e. treating symptoms and 
signs of disease based on the organ-
isms most commonly responsible for 
the particular syndrome). In the early 
1990s, the World Health Organization 
developed syndromic management 
guidelines for symptomatic STI patients 
for countries without laboratory sup-
port. Easily recognized symptoms and 
signs are combined using ﬂowcharts, 
and patients are then treated with two or 
more antibiotic regimens.14 In Botswana, 
women reporting vaginal discharge or 
lower abdominal pain are managed us-
ing the vaginal discharge algorithm.15 
Based on a risk assessment and clinical 
signs, the women are provided with 
treatment for TV and BV and/or chla-
mydia and gonorrhoea and/or candi-
diasis. Where a woman has chlamydia 
and gonorrhoea, partner treatment is 
always recommended; however, where 
a woman has TV, partner treatment 
is only recommended if the woman’s 
symptoms persist.
For pregnant women, the Botswana 
STI manual states that asymptom-
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atic women with a history of previous 
preterm delivery should be examined 
for vaginal discharge to detect and 
treat BV.15 Syndromic management of 
asymptomatic antenatal care attendees 
in general is not recommended in ei-
ther the national or the World Health 
Organization’s STI management guide-
lines. In practice, however, all antenatal 
care attendees in Botswana are clinically 
screened for RTIs because the country’s 
antenatal care guidelines recommend a 
routine speculum examination at the 
ﬁrst antenatal visit to “exclude genital 
infections, abnormalities and pelvic 
tumours”.16 It is not uncommon for 
abnormal vaginal discharge to be found 
in women not displaying symptoms. The 
nurses will act on pathological ﬁndings, 
and asymptomatic women with signs of 
vaginal discharge are thus provided with 
syndromic treatment. This management 
bypasses the original entry point of the 
syndromic algorithms: symptoms that 
lead patients to seek health care.
The aim of this paper is to pres-
ent results on the prevalence of TV and 
BV among antenatal care attendees in 
Botswana, to examine the use of the 
vaginal discharge algorithm earlier in 
the current pregnancy, and to evaluate 
the syndromic approach and clinical 
screening in the diagnosis of these two 
conditions in pregnancy.
Methods
A total of 703 pregnant women par-
ticipated in this study. The women were 
selected from those visiting the 13 main 
facilities providing antenatal care (12 pri-
mary health clinics and one outpatient 
department) in Gaborone, Botswana, 
between October 2000 and February 
2001. A proportionate sample of attend-
ees was recruited from each location, 
based on the percentage of all antenatal 
care attendees who attended that facil-
ity the previous year. In most clinics, 
all attendees were included in the data 
collection; a sample of the attendees was 
included from the busiest clinics. All par-
ticipants gave written, informed consent; 
the study was approved by the national 
committees for research ethics in Bo-
tswana and in Norway. The only exclu-
sion criterion was the use of antibiotics 
during the previous two weeks.
A structured interview and data 
from the patient-held antenatal record 
were used to obtain information on 
sociodemographic factors, current 
RTI symptoms, and diagnosis and 
prescribed treatment for RTIs earlier in 
the pregnancy. All attendees underwent 
a genital examination by a medical 
doctor, and clinical signs from external 
and internal genitalia were recorded. 
Amount, consistency, colour and odour 
of vaginal discharge were described and 
categorized as “normal”, “Candida-like” 
or “non-Candida-like” discharge.
One high vaginal swab was placed 
in Stuart transport medium; another 
was used for a vaginal smear. Specimens 
were transported at ambient temperature 
to the National Health Laboratory for 
further processing. Wet-mounts made 
from the swabs in transport media were 
examined for motile trichomonads by 
light microscopy. The swabs were then 
agitated into bottles of Diamond’s modi-
ﬁed medium, the bottles were incubated 
in Oxoid gaspack jars, and wet-mounts 
were examined for trichomonads once 
daily for up to ﬁve days. The vaginal 
smears were Gram-stained and scored for 
BV according to Nugent’s criteria17 by an 
experienced laboratory technician.
Culture of Candida species was initi-
ated by direct inoculation of Saboraud 
plates at the clinic, incubated at 35 °C 
(5% CO2), and examined after 24 and 
48 hours. Smears of colonies from posi-
tive cultures were Gram-stained and 
examined for budding yeast cells and 
pseudohyphae. The wet-mounts and 
Gram-stained smears were also exam-
ined for Candida. Presence of Candida 
was veriﬁed by positive growth and/or 
microscopy. Cervical swabs were ob-
tained for ligase chain reaction (LCR) 
ampliﬁcation, for direct, qualitative 
detection of speciﬁc target nucleic acid 
sequences of Chlamydia trachomatis and 
Neisseria gonorrhoeae.18
Data were analysed using the sta-
tistical package SPSS, Version 11. To 
evaluate the clinical diagnosis of TV and 
BV, univariate logistic regression analy-
ses were used to assess the association 
between laboratory-veriﬁed diagnoses 
and genital symptoms and signs. So-
ciodemographic risk factors and genital 
symptoms and signs that, in univariate 
analysis, were associated at a 0.2 level 
(P-value of odds ratios [OR]), were in-
cluded in multivariate logistic regression 
analysis. Validity of the vaginal discharge 
algorithm and of the clinical screening 
were assessed by measuring sensitivity, 
speciﬁcity, positive and negative likeli-
hood ratios (LR+ and LR–), and positive 
and negative predictive values, using the 
laboratory diagnosis of TV and BV as 
the reference standard.
Results
General characteristics
The median age of the 703 antenatal care 
attendees was 25 years (range of 15–43) 
and median gestational age 30 weeks 
(range of 8–42). Selected background 
characteristics, genital symptoms and 
signs, and the prevalence of RTIs are 
shown in Table 1. TV and/or BV was 
present in 359 (51%) of the women, 
Chlamydia and/or gonorrhoea in 67 
(10%), and Candida species in 416 
(59%). Among the 132 women with 
TV, 100 (76%) reported no symptoms 
of vaginal discharge or lower abdominal 
pain. Among the 268 women with BV, 
205 (76%) were asymptomatic.
Vaginal discharge and its 
association with TV and BV
Table 2 (available at http://www.who.
int/bulletin) shows selected genital 
symptoms and signs, and their univari-
ate association with TV and BV. Of the 
symptoms, only vaginal discharge was 
associated with TV, albeit weakly (OR 
1.6; 95% conﬁdence interval (95%CI), 
1.0 to 2.5), and only in the univariate 
analysis. None of the genital symptoms 
evaluated were signiﬁcantly associated 
with BV. Vaginal discharge and genital 
itching were, however, signiﬁcantly as-
sociated with Candida species. Candida 
was identiﬁed in 84 (71%) of the 119 
women with symptoms of vaginal dis-
charge, compared with 332 (57%) of 
the 585 women without this symptom 
(P < 0.01).
In the clinical evaluation of the 
discharge, non-Candida-like vaginal 
discharge was associated with increased 
prevalence of TV and BV, whereas 
Candida-like discharge was not (Table 
2, available at http://www.who.int/bul-
letin). Runny, frothy and malodorous 
discharges were strongly associated with 
both TV and BV; results from women 
with one or more of these discharge char-
acteristics were OR 7.1 (95%CI, 4.7 to 
10.8) for TV, and OR 3.3 (95%CI, 2.3 
to 4.8) for BV. Adjusted odds ratios are 
shown in Table 3.
Table 4 compares the diagnostic 
accuracy of the vaginal discharge al-
gorithm, screening for signs of vaginal 
discharge and for speciﬁc discharge 
characteristics. The vaginal discharge 
algorithm failed to detect most cases 
of TV and BV. Also, women diagnosed 
by the algorithm as diseased were not 
signiﬁcantly more likely to have TV 
and BV than women not diagnosed 
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Table 1. Background characteristics, genital symptoms and signs and prevalence of 
reproductive tract infections (RTIs) among 703 antenatal care attendees 
in Gaborone, Botswana
Characteristics n (%)
Age groups
15–19 76 (11)
20–24 249 (35)
25–29 183 (26)
30–34 126 (18)
35–43 69 (10)
Education
Primary school or less 168 (24)
Junior secondary school 310 (44)
Secondary school or higher 225 (32)
Marital status
Married 114 (16)
Non-marital steady partner 572 (81)
Single 17 (2)
Living with husband/partner 353 (50)
Not living with husband/partner 350 (50)
Pregnancy number
1st pregnancy 243 (35)
2nd pregnancy 208 (30)
3rd pregnancy 122 (17)
4th+ pregnancy 130 (18)
Antenatal care visit number
1st visit 157 (22)
2–4th visit 300 (43)
5th + visit 246 (35)
Self-reported symptoms of RTIs
Vaginal discharge 119 (17)
Itching/soreness 58 (8)
Lower abdominal pain 53 (8)
Genital warts 16 (2)
Genital ulcer 8 (1)
Dysuria 8 (1)
Clinical signs of RTIs
Vaginal discharge (not Candida-like) 227 (32)
Candida-like vaginal discharge 81 (12)
Genital warts 29 (4)
Genital ulcer 5 (1)
Presence of pathogens
Chlamydia trachomatis 53 (8)
Neisseria gonorrhoeae 21 (3)
Trichomonias vaginalis 132 (19)
Bacterial vaginosis 268 (38)
Candida species 416 (59)
as diseased (LR+ 1.35; 95%CI, 0.97 
to 1.89).
Signs of non-Candida-like vaginal 
discharge gave an LR+ of 3.00 (95%CI, 
2.31 to 3.92) in the diagnosis of the 
two conditions combined. Screen-
ing the women for speciﬁc discharge 
characteristics increased the LR+ to 
6.66 (95%CI, 4.25 to 10.5), but also 
increased the proportion of undetected 
infections.
Diagnosis and treatment of 
vaginal discharge earlier in 
current pregnancy
An indicator of eﬀectiveness of the cur-
rent RTI management in antenatal care 
is the prevalence of infections among 
the repeat attendees because, unlike new 
attendees, they have already been pro-
vided with standard care. TV prevalence 
was 15% for new and 20% for repeat 
attendees (P = 0.22) and BV prevalence 
was 41% for new and 37% for repeat 
attendees (P = 0.44).
Among the 546 repeat attendees, 
142 (26%) had been diagnosed with 
vaginal discharge earlier in their cur-
rent pregnancy – 14 of them twice. 
Prevalence of TV and BV was similar, 
whether or not the women had a history 
of vaginal discharge.
Treatment guidelines for vaginal 
discharge were usually not followed 
appropriately. At the time of the study, 
the recommended regimen to cover 
TV and BV was 400 mg metronidazole 
twice daily for 7 days; treatment for 
these conditions in the ﬁrst trimester 
of pregnancy was not recommended. 
Consistent with the guidelines, met-
ronidazole had not been prescribed to 
any of the 13 women diagnosed with 
vaginal discharge in the ﬁrst trimester. 
In 143 cases, however, attendees were 
diagnosed with vaginal discharge in the 
second or third trimester, but metro-
nidazole had been prescribed only 17 
times (12%).
Of the 17 attendees for whom met-
ronidazole was prescribed, none had 
TV, compared to 132 (19%) of the 686 
women who had not been prescribed 
the drug (P < 0.05). Three (18%) of the 
17 attendees had BV, compared to 265 
(39%) of the women who had not been 
prescribed metronidazole (P > 0.1).
Discussion
In our study of RTIs in pregnant 
Batswana women, we found high preva-
lence of TV and BV, and no indication 
that syndromic management reduces the 
prevalence of these conditions. The vagi-
nal discharge algorithm was extensively 
used by the health workers, but had low 
accuracy in diagnosing TV and BV. In 
addition, staﬀ often did not adhere to 
treatment guidelines. TV and BV may 
contribute substantially to the risk of 
preterm delivery, low birth weight and 
increased HIV transmission in sub-
Saharan Africa. Apparently, diagnosis 
and treatment strategies for TV and BV 
among pregnant women in this setting 
require reconsideration.
The study population is represen-
tative of antenatal care attendees in 
Gaborone. The level of health care is 
comparable throughout Botswana, and 
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HIV prevalence among pregnant women 
is similar in urban and rural areas.19 
Combined with an antenatal coverage 
of 95%, this situation leads us to believe 
that we present an accurate picture of 
management challenges of TV and BV 
in pregnant women in the country as a 
whole.20
Table 3. Univariate and multivariate logistic regression analysesa of determinants of trichomoniasis and bacterial vaginosis 
among 703 antenatal care attendees in Gaborone, Botswana
Trichomoniasis N Crude odds ratio
(95% conﬁdence 
interval)
Adjusted odds ratio
(95% conﬁdence interval)
% Positive 
(n = 132)
% Negative 
(n = 571)
Sociodemographic factors
Age groups
< 20 20 9 76 4.55 (2.35–8.82) 7.05 (3.23–15.37)
20–29 65 61 432 2.18 (1.29–3.66) 3.00 (1.66–5.43)
30+ 15 31 195 1 1
Education
Primary school or less 30 23 168 2. 65 (1.52–4.65) 5.25 (2.75–10.02)
Junior secondary school 54 42 310 2.56 (1.54–4.25) 2.68 (1.56–4.60)
Senior secondary or higher 17 35 225 1 1
Antenatal care visit
New client 17 24 157 1 1
Repeat client 83 77 546 1.45 (0.89–2.37) 1.67 (0.98–2.85)
Symptoms
More discharge than usual
No 77 84 584 1 1
Yes 23 16 119 1.59 (1.00–2.54) 1.09 (0.63–1.87)
Clinical signs
Vaginal discharge
Negative 36 61 395 1 1
Candida-like discharge 3 14 81 0.38 (0.13–1.07) 0.32 (0.11–0.96)
Other vaginal discharge 61 26 227 3.93 (2.62–5.91) 3.61 (2.31–5.65)
Bacterial vaginosis
% Positive 
(n = 268)
% Negative 
(n = 435)
Sociodemographic factors
Age groups
< 20 14 9 76 2.10 (1.22–3.60) 1.73 (0.75–1.62)
20–29 62 61 432 1.32 (0.92–1.89) 1.10 (0.75–1.62)
30+ 24 30 195 1 1
Marital status
Unmarried 88 81 589 1.63 (1.05–2.52) 1.37 (0.85–2.19)
Married 12 19 114 1 1
Symptoms
Malodorous discharge
No 94 96 671 1 1
Yes 6 4 32 1.66 (0.82–3.38) 1.34 (0.62–2.88)
Clinical signs
Vaginal discharge
Negative 50 59 395 1 1
Candida-like discharge 4 16 81 0.27 (0.14–0.54) 0.26 (0.13–0.52)
Other vaginal discharge 46 24 227 2.28 (1.63–3.18) 2.13 (1.51–2.99)
a  Only factors that were associated with the respective conditions at a 0.2 level (P-value of odds ratio) in the univariate analysis are presented in the table.
Clinical management of TV and 
BV in pregnancy
In antenatal care, health-care workers 
manage women who report vaginal 
discharge and women in whom vaginal 
discharge is found at the routine exami-
nation. The vaginal discharge algorithm 
recognizes that women reporting vaginal 
discharge commonly suﬀer from TV, BV 
or vulvovaginal candidiasis and, in rarer 
cases, a cervical infection.21–23 Symptoms 
of vaginal discharge or lower abdominal 
pain are unspeciﬁc, especially in preg-
nancy, where physiological discharge 
and the presence of candidiasis increase. 
We found that TV and BV were equally 
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prescriptions to women with runny, mal-
odorous or foamy discharge. Diﬀerent 
speciﬁc discharge characteristics have 
been associated with both TV and BV,24 
and it could be useful to employ these 
characteristics in settings where diag-
nostic tests are unavailable. However, 
discharge associated with the two con-
ditions in this study population may 
not be applicable to other populations 
of pregnant women. Speciﬁc clinical 
criteria are diagnostically demanding 
for health-care workers, and if speciﬁc-
ity increases, so does the proportion of 
undetected cases.
Studies among pregnant women in 
other developing countries have shown 
low correlations between symptoms 
and signs of vaginal discharge and the 
presence of TV or BV.25–28 With the 
development of molecular techniques 
to identify Trichomonas vaginalis, it has 
become evident that culture and micros-
copy miss a substantial proportion of 
the infections.29,30 This implies that the 
sensitivity of syndromic management for 
identifying TV is likely to be lower than 
estimated in this and other studies using 
traditional diagnostic techniques.
Adherence to the syndromic 
management treatment 
guidelines
As many as one of four pregnant women 
who had at least one encounter with the 
antenatal services had been diagnosed 
with vaginal discharge syndrome. In 
most cases, the health workers had 
not prescribed metronidazole, although 
the availability of drugs is excellent in 
Botswana. This ﬁnding is consistent 
with another study on quality of STI 
management from primary health care in 
Botswana that showed substantial ﬂaws 
in history-taking, clinical examination 
and prescriptions.31 A tendency to devi-
ate from recommended RTI guidelines 
is common throughout the world.32–34 
Adherence to clinical guidelines is noto-
riously diﬃcult to achieve, even when in-
tensively promoted.35 The uncertainties 
of the vaginal discharge algorithm may 
discourage health workers from optimal 
performance, increasing the number of 
inadequate prescriptions and untreated 
infections.
Management of TV and BV in the 
antenatal care is further complicated by 
the situation regarding the advisability 
of using metronidazole in pregnancy.36 
Multiple studies and meta-analyses have 
concluded that metronidazole does not 
appear to be associated with an increased 
teratogenic risk.37–39 However, two stud-
ies have suggested that treatment with 
metronidazole in women with TV can 
increase preterm birth.40,41 This adverse 
eﬀect has been diﬃcult to explain, but 
raises a caution about the unnecessary 
use of metronidazole in pregnancy.
Table 4.  Accuracy of the vaginal discharge algorithm, and of screening for signs of vaginal discharge or speciﬁc discharge 
characteristics, in the diagnosis of trichomoniasis and bacterial vaginosis among 703 antenatal care attendees in 
Gaborone, Botswana
Conﬁrmed 
infection (n)
Sensitivity Speciﬁcity LR+a LR– PPV NPV
Trichomoniasis (n = 132)
VDS algorithm 28 0.21 0.84 1.35 (0.91–1.94) 0.93 0.24 0.82
Signs of vaginal discharge (other than 
Candida-like)
80 0.61 0.74 2.35 (1.92–2.85) 0.53 0.35 0.89
Signs of speciﬁc discharge characteristics 
(runny and/or frothy and/or malodorous)
71 0.54 0.86 3.84 (2.96–4.95) 0.54 0.47 0.89
Bacterial vaginosis (n = 268)
VDS algorithm 50 0.19 0.84 1.19 (0.86–1.66) 0.96 0.42 0.63
Signs of vaginal discharge (other than 
Candida-like)
123 0.46 0.76 1.92 (1.55–2.37) 0.71 0.54 0.70
Signs of speciﬁc discharge characteristics 92 0.34 0.86 2.53 (1.90–3.38) 0.72 0.61 0.68
BV and/or TV (n = 359)
VDS algorithm 69 0.19 0.86 1.35 (0.97–1.89) 0.94 0.59 0.50
Signs of vaginal discharge (other than 
Candida-like) 172 0.48 0.84 3.00 (2.31–3.92) 0.62 0.76 0.61
Signs of speciﬁc discharge characteristics 132 0.37 0.95 6.66 (4.25–10.5) 0.67 0.87 0.58
LR+, positive likelihood ratio; LR–, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; VDS, vaginal discharge syndrome.
a  The positive likelihood ratios are calculated with 95% conﬁdence interval (score method).
common in both symptomatic and 
asymptomatic pregnant women, and 
that the algorithm was neither sensitive 
nor speciﬁc in the management of these 
conditions in pregnancy.
Candida species were common 
among the antenatal care attendees, 
strongly associated with symptoms of 
vaginal discharge, and probably the 
pathological cause most often leading 
to this complaint. Candida is not asso-
ciated with any serious complications, 
and should therefore be treated only in 
symptomatic women. Conversely, iden-
tiﬁcation and treatment of chlamydia 
and gonorrhoeae in pregnancy is critical. 
We have previously shown that the 
vaginal discharge syndrome is an inad-
equate management strategy for cervi-
cal infections in pregnant Botswana 
women.18
In this study population, clinical 
screening for signs of vaginal discharge 
at the ﬁrst antenatal care visit appears to 
be more eﬀective than the use of symp-
toms as an entry point for metronidazole 
treatment. The magnitude of undetected 
cases is the main challenge to clinical 
screening: six of ten attendees with 
TV and one of two with BV remained 
unidentiﬁed. However, using this ap-
proach, one of four women receiving 
metronidazole does so unnecessarily. 
Over-treatment could be substantially 
reduced by limiting metronidazole 
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Revised guidelines in Botswana rec-
ommend metronidazole 2 g in a single 
dose to cover TV in pregnancy, and 
250 mg three times daily for 7 days to 
cover BV.15 This management is based 
on evidence of optimal treatment eﬀect 
for each condition, and would minimize 
metronidazole use in pregnancy if the 
women were treated for only one of 
the conditions.13,37,42 However, as an 
etiological diagnosis cannot be made 
in primary health care, this strategy re-
quires the prescription of two regimens 
to pregnant women with vaginal dis-
charge – a situation that is both confusing 
and unnecessary. According to recently 
updated guidelines from the Centers for 
Disease Control and Prevention, metro-
nidazole 500 mg twice daily for 7 days is 
the only regimen which eﬀectively treats 
both conditions.37
Simple diagnostic tests to 
identify TV and BV
Accurate diagnosis and prompt treat-
ment of STIs is important from a public 
health perspective, and this includes 
detection of asymptomatic cases. With 
the demonstrated shortcomings of the 
management of TV in Botswana, and 
the lack of treatment for partners of 
women whose symptoms do not persist, 
the high prevalence of TV is likely to 
continue.
A focus on the implementation 
of the syndromic approach may have 
superseded an exploration of the use of 
point-of-care tests for TV and BV in 
developing countries. Contrary to many 
other RTIs, simple and cheap tests for 
TV and BV are available. TV can be 
identiﬁed immediately with a simple 
latex agglutination test 43 or by saline 
wet preparation. BV can be diagnosed 
on-site, with or without the aid of a 
microscope.44
Introduction of point-of-care tests 
for TV and BV in the antenatal care 
in countries where prevalences of RTIs 
and HIV are high requires further ex-
ploration. Antenatal screening would 
identify asymptomatic cases, and testing 
attendees with vaginal discharge would 
reduce over-treatment with metroni-
dazole in pregnancy. Health workers’ 
prescriptions and patients’ compliance 
would probably improve with a speciﬁc 
diagnosis, and treatment regimens could 
be optimized. Treating sexual partners of 
women with vaginal discharge has been 
debated because the majority of the 
identiﬁed women do not have an STI.45 
An important beneﬁt of testing for TV is 
the relative ease of notifying and treating 
partners of patients with a positive test.
Botswana has a relatively well-
functioning health system and could 
serve as an exploratory site for the use 
of point-of-care tests for TV and BV. 
Through the programme to prevent 
mother-to-child transmission of HIV, all 
health posts and clinics have lay workers 
who perform rapid tests for HIV. Simple 
tests for TV and BV performed by clini-
cians or lay workers could contribute to 
improving diagnosis and reducing the 
disease burden of these conditions in 
sub-Saharan Africa.
Conclusion
The inaccuracy of vaginal discharge in 
predicting pathological conditions in 
pregnancy and the magnitude of asymp-
tomatic TV and BV is a challenge in 
developing countries, as is the quality 
of care provided. Guidelines are inad-
equate and there is a lack of adherence 
to guidelines by health workers. Our 
results from Botswana indicate that 
national health authorities should revise 
the diagnosis and treatment guidelines 
for TV and BV in antenatal care. Also, 
the results of this study may be useful 
in the process of continuous revision of 
World Health Organization guidelines 
for the management of these conditions 
in developing countries.  O
Competing interests: None declared.
Résumé
Insufﬁsances de l’approche syndromique pour la prise en charge de la trichomonase et de la vaginite 
bactérienne chez la femme enceinte
Objectif Déterminer la prévalence des infections à Trichomonas 
vaginalis (TV) et des vaginites bactériennes (VB) chez les femmes 
enceintes du Botswana et mener une évaluation comparée de 
l’approche syndromique et d’autres stratégies pour la prise en 
charge de ces pathologies pendant la grossesse.
Méthodes Dans le cadre d’une étude transversale, on a interrogé 
et examiné 703 femmes se présentant aux visites prénatales et 
on a prélevé chez elles des échantillons pour recherche de TV, 
d’une éventuelle VB, de Candida, de Chlamydia trachomatis et de 
Neisseria gonorrhoeae. Des entretiens structurés et l’exploitation 
des dossiers prénatals ont permis de recueillir des éléments sur 
les infections de l’appareil reproducteur survenues à un stade 
antérieur de la grossesse. 
Résultats On a diagnostiqué une infection à TV chez 19% 
des femmes examinées et une VB chez 38% d’entre elles. Trois 
quarts des femmes atteintes d’infection à TV ou VB étaient 
asymptomatiques. Une prise en charge syndromique selon 
l’Algorithme pour les pertes vaginales de l’OMS aurait conduit 
à un sous-diagnostic notable de certaines pathologies et à un 
surtraitement des infections à TV et des VB. Les pertes vaginales 
se sont révélées plus fortement prédictives de la présence de 
ces affections que les symptômes. Parmi les 546 femmes reçues 
dans le cadre des visites prénatales, 142 (26 %) avaient déjà été 
diagnostiquées comme présentant des pertes vaginales à un stade 
antérieur de la grossesse (à deux reprises pour 14 d’entre elles). On 
a relevé 143 cas de pertes vaginales au deuxième ou au troisième 
trimestres de grossesse parmi les femmes examinées lors de ces 
visites prénatales. Néanmoins, ces pertes n’ont donné lieu que 17 
fois à la prescription de métronidazole (12 % des cas).
Conclusion Le diagnostic et le traitement des infections à TV 
et des VB chez les femmes enceintes d’Afrique subsaharienne 
présentent des difﬁcultés majeures. Cette étude a conduit à 
diagnostiquer une infection à TV ou une VB chez la moitié des 
femmes enceintes, mais ces affections n’ont été ni détectées, ni 
traitées, par la prise en charge syndromique appliquée lors des 
visites prénatales. De même, le personnel soignant ne suivait par 
les recommandations thérapeutiques. Ces résultats témoignent 
de la nécessité d’une révision du Guide pour la prise en charge 
des IST à TV et des VB dans le cadre des soins prénatals.
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Resumen
Tricomoniasis y vaginosis bacteriana en el embarazo: insuﬁciencias del manejo sindrómico
Objetivo Medir la prevalencia de la infección por Trichomonas 
vaginalis (TV) y la vaginosis bacteriana (VB) entre las embarazadas 
en Botswana, y evaluar el manejo sindrómico y otras estrategias 
de tratamiento para esas enfermedades en el embarazo.
Métodos Se realizó un estudio transversal en el que se entrevistó 
y examinó a 703 mujeres que recibieron atención prenatal. Se 
obtuvieron muestras para detectar los casos de infección por TV, 
VB, Candida, Chlamydia trachomatis y Neisseria gonorrhoeae. 
La realización de una entrevista estructurada y el examen de 
los registros prenatales permitieron reunir información sobre las 
infecciones del aparato reproductor sufridas en fases anteriores 
del embarazo.
Resultados Se detectó TV en el 19% de las mujeres examinadas, 
y VB en el 38%. Tres cuartas partes de las mujeres con TV o VB 
no presentaban síntomas. El manejo sindrómico basado en el 
algoritmo del ﬂujo vaginal llevaría a subdiagnosticar y sobretratar 
considerablemente la infección por TV y la VB. A la hora de 
determinar la presencia de esas enfermedades, los signos de ﬂujo 
vaginal tenían un mayor valor predictivo que los síntomas. Entre 
las 546 mujeres que ya habían realizado antes una visita prenatal, 
a 142 (26%) se les había diagnosticado ﬂujo vaginal en fases 
anteriores del embarazo (a 14 de ellas dos veces). En 143 casos 
se diagnosticó ﬂujo vaginal en el segundo o tercer trimestre, pero 
sólo se había prescrito metronidazol en 17 ocasiones (12%).
Conclusión El diagnóstico y tratamiento de la infección por TV 
y la VB entre las embarazadas en el África subsahariana tropieza 
con importantes diﬁcultades. A la mitad de las embarazadas 
participantes en este estudio se les diagnosticó TV o VB, pero 
esas afecciones no fueron detectadas y tratadas en visitas de 
atención prenatal en que se aplicaba el manejo sindrómico. 
Además, los trabajadores sanitarios no seguían las directrices 
terapéuticas. Estos resultados indican que es necesario revisar 
las directrices de tratamiento de la infección por TV y la VB en la 
atención prenatal.
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Table 2. Association between symptoms and signs and laboratory-veriﬁed trichomoniasis or bacterial vaginosis among 703 
antenatal care attendees in Gaborone, Botswana
Trichomoniasis N Odds ratio
(95% conﬁdence interval)
P-value
% Positive
(n = 132)
% Negative 
(n = 571)
Symptoms
More discharge than usual
No 77 84 584 1
Yes 23 16 119 1.59 (1.00–2.54) 0.049
Itching or soreness
No 91 92 645 1
Yes 9 8 58 1.14 (0.59–2.22) 0.70
Lower abdominal pain
No 96 92 650 1
Yes 5 8 53 0.53 (0.22–1.27) 0.15
Clinical signs
Moderate/profuse discharge
No 46 68 447 1
Yes 55 32 256 2.52 (1.72–3.71) 0.000
Runny discharge
No 62 93 615 1
Yes 38 7 88 8.55 (5.23–13.84) 0.000
Malodorous discharge
No 84 96 659 1
Yes 16 4 44 4.51 (2.41–8.43) 0.000
Frothy discharge
No 56 90 590 1
Yes 44 10 113 7.35 (4.73–11.44) 0.000
Speciﬁc discharge characteristics
Negative 46 86 552 1
Runny/malodorous/frothy 54 14 151 7.14 (4.71–10.83) 0.000
Vaginal discharge
Negative 36 61 395 1
Candida-like discharge 3 14 81 0.38 (0.13–1.07) 0.068
Other vaginal discharge 61 26 227 3.93 (2.62–5.91) 0.000
Bacterial vaginosis
% Positive 
(n = 268)
% Negative 
(n = 435)
Symptoms
More discharge than usual
No 82 84 584 1
Yes 18 16 119 1.12 (.075–1.67) 0.585
Itching or soreness
No 91 92 645 1
Yes 9 8 58 1.25 (0.73–2.16) 0.415
Lower abdominal pain
No 92 93 650 1
Yes 8 7 53 1.17 (0.66–2.06) 0.598
Clinical signs
Moderate/profuse discharge
No 62 65 447 1
Yes 38 35 256 1.15 (0.84–1.58) 0.383
Runny discharge
No 82 91 615 1
Yes 18 9 88 2.16 (1.37–3.38) 0.001
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Bacterial vaginosis N Odds ratio
(95 % conﬁdence interval)
P-value
% Positive 
(n = 268)
% Negative 
(n = 435)
Malodorous discharge
No 88 97 659 1
Yes 12 3 44 4.25 (2.18–8.27) 0.000
Frothy discharge
No 74 90 590 1
Yes 26 10 113 3.08 (2.04–4.67) 0.000
Speciﬁc discharge characteristics
Negative 66 86 552 1
Runny/malodorous/frothy 34 14 151 3.33 (2.30–4.84) 0.000
Vaginal discharge
Negative 50 59 395 1
Candida-like discharge   4 16 81 0.27 (0.14–0.54) 0.000
Other vaginal discharge 46 24 227 2.28 (1.63–3.18) 0.000
(Table 2, cont.)
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Abstract
Background: Chlamydia and gonorrhoea are major causes of morbidity among women in developing countries.
Both infections have been associated with pregnancy-related complications, and case detection and treatment in
pregnancy is essential. In countries without laboratory support, the diagnosis and treatment of cervical infections
is based on the syndromic approach. In this study we measured the prevalence of chlamydia and gonorrhoea
among antenatal care attendees in Botswana. We evaluated the syndromic approach for the detection of cervical
infections in pregnancy, and determined if risk scores could improve the diagnostic accuracy.
Methods: In a cross-sectional study, 703 antenatal care attendees in Botswana were interviewed and examined,
and specimens were collected for the identification of C trachomatis, N gonorrhoeae and other reproductive tract
infections. Risk scores to identify attendees with cervical infections were computed based on identified risk
factors, and their sensitivities, specificities, likelihood ratios and predictive values were calculated.
Results: The prevalence of chlamydia was 8%, and gonorrhoea was found in 3% of the attendees. Symptoms and
signs of vaginal discharge did not predict cervical infection, and a syndromic approach failed to identify infected
women. Age (youth) risk factor most strongly associated with cervical infection. A risk score with only
sociodemographic factors had likelihood ratios equivalent to risk scores which incorporated clinical signs and
microscopy results. However, all the evaluated risk scores were of limited value in the diagnosis of chlamydia and
gonorrhoea. A cut-off set at an acceptable sensitivity to avoid infected antenatal care attendees who remained
untreated would inevitably lead to considerable over-treatment.
Conclusion: Although in extensive use, the syndromic approach is unsuitable for diagnosing cervical infections
in antenatal care attendees in Botswana. None of the evaluated risk scores can replace this management. Without
diagnostic tests, there are no adequate management strategies for C trachomatis and N gonorrhoeae in pregnant
women in Botswana, a situation which is likely to apply to other countries in sub-Saharan Africa. Screening for
cervical infections in pregnant women is an essential public health measure, and rapid tests will hopefully be
available in developing countries within a few years.
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Background
Sub-Saharan Africa has the highest prevalence of gonor-
rhoea and chlamydia worldwide. These two sexually
transmitted infections (STIs) have a major impact on
health, particularly in women and neonates [1]. A cervical
infection with Neisseria gonorrhoeae or Chlamydia trachom-
atis can cause serious complications, such as ascending
infections, infertility, cervical cancer, spontaneous abor-
tion, premature delivery and low birth weight [2]. Epide-
miological and biological studies have shown that
ulcerative and non-ulcerative STIs can enhance HIV trans-
mission [3,4].
It should be part of the mandate of the antenatal care pro-
grammes to diagnose and treat C trachomatis and N gonor-
rhoeae, due to their association with maternal, foetal and
infant morbidity. In developing countries, diagnosis of
cervical infections is limited to the syndromic approach,
using the 'vaginal discharge syndrome' (VDS) algorithm.
In the early 1990s, the World Health Organization devel-
oped syndromic management guidelines as a case man-
agement of symptomatic STI patients in countries without
laboratory support [5]. Easily recognized symptoms and
signs are combined using flowcharts, and patients are
treated with two or more antibiotic regimens to cover the
majority of, or the most serious, organisms responsible
for producing a syndrome. The VDS algorithm for the
management of vaginal and cervical infections is far from
ideal, and for chlamydia or gonorrhea, this simplified
approach is neither sensitive nor specific [2,5-8]. Simple,
rapid tests for these infections have been requested for
more than a decade [9,10], and the continued use of the
syndromic approach in the management of cervicitis has
been viewed as a temporary solution while awaiting the
development of such tests [11].
The majority of women with a cervical infection are
asymptomatic [12] and their infection will not be
detected by the syndromic approach. As screening with
specific diagnostic tests have been out of reach, risk scores
based on sociodemographic risk factors, symptoms or
signs of infection, urine sticks and microscopy have been
explored as screening tools to identify asymptomatic
infections among pregnant women. Studies from sub-
Saharan countries have shown variable and unconvincing
results [9,10,13-16].
It has become clear that vaginal discharge is poorly predic-
tive of cervicitis, and in order to reduce over-treatment,
the WHO recommends the incorporation of risk assess-
ments in the syndromic management of cervical infec-
tions [5]. In Botswana, the syndromic approach has
recently been revised, and lower abdominal pain was
included as a second entry symptom in the VDS algorithm
[17]. Treatment for C trachomatis and N gonorrhoeae is
reserved for women who present with vaginal discharge or
lower abdominal pain and have either a positive risk
assessment (age less than 21 years or complaints of yellow
discharge) or yellow discharge or cervical mucopus on
examination. These new recommendations are based on a
non-validated study of female STI patients [18]. Risk fac-
tors' association with infection is specific to the popula-
tion group from which they are extracted [5,13], and a
validation of the algorithm in the antenatal care is lacking.
There are two parallel strategies to manage reproductive
tract infections (RTIs) in pregnancy in Botswana. In addi-
tion to the syndromic management of women with symp-
toms, all antenatal care attendees are clinically screened
for RTIs. The antenatal care guidelines recommend a rou-
tine speculum examination at the first antenatal visit, to
"exclude genital infections, abnormalities and pelvic
tumours" [19]. It is not uncommon for abnormal vaginal
discharge to be found in women who are not eliciting
symptoms. Asymptomatic pregnant women with signs of
vaginal discharge will also be provided with syndromic
treatment. Clinical screening bypasses the original entry
point of the syndromic algorithms: symptoms which lead
to health-care seeking, and it is not within the WHO rec-
ommendations.
The aim of this study was to determine the prevalence of
C trachomatis and N gonorrhoeae among antenatal care
attendees in Botswana, and to assess the validity of the
'vaginal discharge syndrome and lower abdominal pain'
algorithm in the diagnosis of cervicitis in pregnancy. We
also evaluated the diagnostic accuracy of risk scores based
on sociodemographic factors, specific symptoms or signs,
or microscopy. The results from Botswana are used to dis-
cuss the management of cervicitis in pregnancy in sub-
Saharan Africa.
Methods
Participating in this study were 703 pregnant women who
visited the 13 main facilities providing antenatal care in
Gaborone, Botswana: 12 primary health clinics and one
outpatient department. A proportionate sample of attend-
ees was recruited from each location. This proportion cor-
responded to the percentage of all antenatal care attendees
in Gaborone who visited that facility during the previous
year. Facilities were visited one-by-one by a medical doc-
tor between October 2000 and February 2001. In the
majority of clinics, all attendees were included in the
study. In the busiest clinics, only a sample of the attendees
was included; the selection of attendees in these clinics
was incidental. Approximately one out of every four ante-
natal care attendees in Gaborone was included in the
study during the period of data collection. All participants
gave written, informed consent. The only exclusion crite-
BMC Infectious Diseases 2007, 7:27 http://www.biomedcentral.com/1471-2334/7/27
Page 3 of 11
(page number not for citation purposes)
rion was the use of antibiotics during the previous two
weeks.
A structured interview and information from the patient-
held antenatal record were used to obtain data on socio-
demographic and behavioural factors, current RTI symp-
toms, and diagnosis and prescribed treatment for such
conditions earlier in the pregnancy. All patients under-
went a genital examination; appropriate specimens were
collected; and abnormal signs from external and internal
genitalia were recorded in detail.
Laboratory analyses
Urine was checked on site with a dipstick; all other speci-
mens were analysed at the National Health Laboratory in
Gaborone. Cervical swabs were obtained for ligase chain
reaction (LCR) amplification technology for detection of
C trachomatis and N gonorrhoeae. The swabs were placed in
LCx® transport media, transported to the laboratory the
same day, and stored at -20°C prior to batch processing.
The LCx® Assays (Abbott Laboratories, IL) were performed
according to the manufacturer's instructions. A case of C
trachomatis or N gonorrhoeae infection was defined as an
individual with a positive LCR analysis.
A high vaginal swab for identification of Trichomonas vag-
inalis was placed in Stuart transport media. Before cultur-
ing, a wet-mount was made and examined for the
presence of motile trichomonads by light microscopy,
100 × magnification. The swab was then agitated into a
bottle of Diamond's modified medium. The bottles were
incubated with indicators in Oxoid gaspack jars (3.4 litres,
with anaerobic system BR 038B). Wet-mounts from the
cultures were examined once a day for five days by light
microscopy.
Gram-stained vaginal smears were scored for bacterial
vaginosis according to Nugent's criteria [20]. Culture of
Candida species was initiated by direct inoculation of a
high vaginal swab on Saboraud plates on site, and Gram-
stained smears and wet-mounts from high vaginal swabs
were examined for budding yeast cells and pseudohyphae.
A cervical smear was gram-stained to count polymorpho-
nuclear leukocytes per high power field (PMN/HPF).
Statistical analyses and risk scores
Data were analysed with the statistical package SPSS Ver-
sion 11. We performed univariate analyses on all inde-
pendent variables in our dataset which could be
associated with cervical infection. The factors were within
four categories: sociodemographic and behavioural fac-
tors, symptoms, clinical signs, and microscopy results.
The dependent variable "cervicitis" was defined as infec-
tion with C trachomatis or N gonorrhoeae, or both. Factors
which in the univariate analysis were associated with
infection at a 0.2 level (p-value of odds ratio (OR)) were
included in multiple logistic regression analyses. We per-
formed multiple logistic regression analyses on sociode-
mographic factors, symptoms, clinical signs and
laboratory results, separately and combined. Due to the
high number of variables, the full analysis of different fac-
tors' independent association with cervicitis had to be per-
formed in two steps. First, multiple logistic regression
analyses for the four variable categories were performed
separately. The analysis was then extended to combining
the factors from the different categories which were signif-
icantly independently associated with cervical infection in
the first step.
Three levels of risk scores were computed and retrospec-
tively applied, and each of them were assessed for their
usefulness as a diagnostic tool to manage N gonorrhoeae
and C trachomatis infections in the antenatal care. The first
risk score level consists of only sociodemographic factors.
At the second risk score level we added findings from the
gynaecological examination. At the third level, we also
allowed the results from microscopy of vaginal and cervi-
cal smears. Microscopy can be done on site, and thus all
three risk score levels – the sociodemographic, the clinical
and the microscopy score – can theoretically be per-
formed during an antenatal care visit. The weights for each
factor used in the risk scores were based on correspondent
multiple logistic regression analysis models. The log of the
OR for the variables in the model multiplied by 10 and
rounded to the nearest whole number were used as
weights for the respective factors in the risk scores [9]. The
factors included and their respective weights are shown
for each risk score in Table 1.
Receiver Operating Characteristic (ROC) curves were used
to compare the different risk scores. The ROC curve shows
the sensitivity and specificity that correspond to each pos-
sible cut-off for the risk score. The validity of different
diagnostic strategies (the existing STI management guide-
lines, diagnosis based on symptoms or signs alone, and
diagnosis based on a risk score) was assessed by measur-
ing sensitivity, specificity, positive and negative likelihood
ratios (LR+ and LR-) and positive and negative predictive
values (PPV and NPV). The LCR-based laboratory diagno-
sis of cervical infection was used as the reference standard.
In the evaluation and comparison of diagnostic strategies,
we present two cut-offs for the risk scores, taken at a sen-
sitivity of minimum 0.40 and 0.70.
The study was approved by ethical committees in Bot-
swana and in Norway.
Results
Of the 703 women, 67 (10%) had laboratory-confirmed
cervical infection: 51 (8%) were infected with C trachoma-
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tis, and 21 (3%) with N gonorrhoea. T vaginalis was identi-
fied in 131 (19%) women and bacterial vaginosis in 268
(38%) women. Candida species were identified by micro-
scopy and/or culture in 416 (59%) of the women. A total
of 561 (80%) of the antenatal care attendees had one or
more of these five reproductive tract infections.
Subjective symptoms and clinical signs
In spite of the high prevalence of cervical and vaginal
infections in this study, few women confirmed symptoms
when probed. Complaints of vaginal discharge were elic-
ited from 119 (17%) of the women and lower abdominal
pain from 58 (8%). Vaginal discharge was the most com-
mon clinical sign; candidalike discharge was found in 81
(12%) and other abnormal discharge was found in 227
(32%) of the women.
Factors associated with C trachomatis and/or N 
gonorrhoeae
Demographic, behavioural, and obstetric factors; symp-
toms, signs, and simple laboratory tests; and their associ-
ation with C trachomatis and/or N gonorrhoeae infection
are shown in Table 2. Age was the strongest predictor of
cervical infection. The prevalence of infection was highest
among teenagers (22%, 95% confidence interval (CI): 13
to 32), whereas two-thirds of the infections were within
the largest age group: women 20–29 years. None of the
evaluated symptoms predicted cervical infection. Symp-
toms of vaginal discharge or lower abdominal pain were
therefore not included in any of the risk scores. There were
65 (9%) women who reported believing that they had a
genital illness, but the prevalence of cervicitis was not sig-
nificantly higher in this group (OR = 1.6, 95% CI: 0.8 to
3.4). Of clinical findings, vaginal (excluding candida-like)
discharge was significantly associated with increased prev-
alence of cervicitis (OR = 1.8, 95% CI: 1.1 to 3.0). Several
discharge characteristics (thin, smelly, foamy and
increased amounts) were also significantly associated
with cervical infection. Two laboratory results were associ-
ated with cervicitis; white blood cells in the cervical smear,
and infection with T vaginalis.
The factors which were independently associated with cer-
vical infection are shown in Table 3.
Table 1: Three levels of risk scores: Variables included and their respective weights
Variables included Sociodemographic score Clinical score Microscopy score
Weight* Weight Weight
Sociodemographic factors
Age <20 21 24 24
20–29 13 14 14
30+ 0 0 0
Education Primary school 10 12 11
Junior secondary school 6 7 6
Senior secondary or higher 0 0 0
Length of relationship 1 year or less 5 - -
Between 1 and 2 years 2 - -
2 years and more 0 - -
Marital status Unmarried 12 - -
Married 0 - -
Clinical factors
Amount of discharge Moderate/profuse - 2 2
Scarce - 0 0
Thin/runny discharge Yes - 8 8
No - 0 0
Smelly discharge Yes - 5 4
No - 0 0
Cervix abnormal Yes - 3 2
No - 0 0
Microscopy results
White blood cell count in cervical smear 3–4+ - - 14
2+ - - 10
1+ - - 7
No/few - - 0
Cut-off at 40% sensitivity Score >32 Score >28 Score >36
Cut-off at 70% sensitivity Score >30 Score >21 Score >29
*The log of the OR from the correspondent multiple logistic regression analysis for each of the variables, multiplied by 10 and rounded to the 
nearest whole number
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Table 2: Univariate analyses on risk factors for cervicitis (C trachomatis and/or N gonorrhoeae) among 703 antenatal care attendees in 
Gaborone, Botswana
No. Women with cervicitis Odds ratio Confidence interval p-value
No. (%) (95%)
Sociodemographic factors
Age groups
< 20 76 17 (22) 9.1 3.4–24.1 0.000
20–29 432 44 (10) 3.6 1.5–8.5 0.004
30+ 195 6 (3) 1
Education
Primary school or less 168 17 (10) 1
Junior secondary school 310 36 (12) 1.2 0.6–2.2 0.620
Senior secondary or higher 225 14 (6) 0.6 0.3–1.2 0.160
Marital status
Married 114 2 (2) 1
Unmarried 589 65 (11) 6.9 1.7–28.7 0.008
Partners last 12 months
One partner 671 64 (10) 1
Two or more 32 3 (9) 1.0 0.3–3.3 0.976
Time in relationship
One year or less 118 19 (16) 2.5 1.4–4.6 0.003
1 to 2 years 137 16 (12) 1.7 0.9–3.2 0.094
>2 years 448 32 (7) 1
Subjective symptoms
Vaginal discharge
No 584 55 (9) 1
Yes 119 12 (10) 1.1 0.6–2.1 0.822
Lower abdominal pain
No 650 63 (10) 1
Yes 53 4 (8) 0.8 0.3–2.2 0.610
Thinks she has an infection
No 638 58 (9) 1
Yes 65 9 (14) 1.6 0.8–3.4 0.217
Clinical signs
Vaginal discharge
Negative 476 37 (8) 1
Positive 227 30 (11) 1.8 1.1–3.0 0.023
Candida-like discharge
Negative 622 61 (10) 1
BMC Infectious Diseases 2007, 7:27 http://www.biomedcentral.com/1471-2334/7/27
Page 6 of 11
(page number not for citation purposes)
Positive 81 5 (6) 0.6 0.2–1.5 0.279
Moderate or profuse discharge
Negative 447 34 (8) 1
Positive 256 33 (13) 1.8 1.1–3.0 0.023
Yellow discharge
Negative 438 38 (9) 1
Positive 265 29 (11) 1.3 0.8–2.2 0.322
Thin/runny discharge
Negative 615 48 (8) 1
Positive 88 19 (22) 3.3 1.8–5.9 0.000
Foamy discharge
Negative 590 1
Positive 113 19 (17) 2.3 1.3–4.1 0.005
Smelly discharge
Negative 659 58 (9) 1
Positive 44 9 (21) 2.7 1.2–5.8 0.014
Cervical bleeding/erythroplaquia
Negative 520 45 (9) 1
Positive 183 22 (12) 1.4 0.8–2.5 0.184
Laboratory analyses
Urine stix (nitritis/leucocytes)
Negative 609 59 (10) 1
Positive 94 8 (9) 0.9 0.4–1.9 0.718
WBC in cervical smear
None/few 124 5 (4) 1
1+ 267 22 (8) 2.1 0.8–5.8 0.135
2+ 171 18 (11) 2.8 1.0–7.8 0.048
3–4+ 140 22 (16) 4.4 1.6–12.1 0.004
Candida (microscopy or culture)
Negative 287 26 (9) 1
Positive 416 41 (10) 1.1 0.7–1.8 0.724
Trichomoniasis
Negative 571 41 (7) 1
Positive 132 26 (20) 3.2 1.9–5.4 0.000
Bacterial vaginosis (BV)
Negative 435 40 (9) 1
Positive 268 27 (10) 1.1 0.7–1.9 0.700
Table 2: Univariate analyses on risk factors for cervicitis (C trachomatis and/or N gonorrhoeae) among 703 antenatal care attendees in 
Gaborone, Botswana (Continued)
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Syndromic management and screening for cervical 
infections
The sociodemographic, clinical, and microscopy-based
risk scores performed similar in the management of N
gonorrhoeae and C trachomatis infection, as illustrated with
their ROC-curves (Figure 1). The diagnostic accuracy of
the risk scores did not increase significantly when detailed
information from the clinical examination and subse-
quently the microscopy results were added to the sociode-
mographic risk factors.
Table 4 presents the evaluated options for the diagnosis of
C trachomatis and N gonorrhoeae in antenatal care in the
absence of specific diagnostic tests: the syndromic algo-
rithm, symptoms, signs, and the three risk scores. The VDS
algorithm did not identify women with C trachomatis and
N gonorrhoeae in our study population (positive likeli-
hood ratio (LR+) 1.1, 95% CI: 0.6 to 1.9). Symptoms of
vaginal discharge or lower abdominal pain in pregnancy
proved inappropriate as an entry point to the VDS algo-
rithm, with a LR+ of 0.94 (95% CI: 0.6–1.5). The current
practice of clinical screening for signs of vaginal discharge
(excluding candida-like discharge) also had low discrimi-
native ability (LR+ 1.5, 95 % CI 1.1–1.9).
All risk scores suffered from the choice between low sen-
sitivity and low specificity. With a cut-off taken at an
acceptable sensitivity of minimum 0.7, the risk score
based on sociodemographic factors identifies 50 (75%)
and misses 17 (25%) of the 67 cervical infections. Per true
case treated, six pregnant women would be prescribed
multiple antibiotic regimens unnecessarily. With a cut-off
at a sensitivity of 0.4, the sociodemographic risk score
identifies only 29 (43%) of the cervical infections. The
majority of the cervical infections would remain
untreated, and although over-treatment is reduced, four
pregnant women would still be unnecessary treated with
multiple antibiotics per infected women. The more com-
prehensive clinical and microscopy risk scores show simi-
lar results.
Discussion
Pregnant women are usually considered to be a low-risk
population, but among antenatal care attendees in Bot-
swana, the burden of reproductive tract infections is very
high. The prevalence of cervical infections is 10%, and
most of the infected women go undetected through nor-
mal antenatal care services. Published studies of STIs
among pregnant women in other countries in sub-Saha-
ran Africa show similar trends in the prevalence of cervical
infections. In our study, 8% have a C trachomatis infection,
compared to rates between 6% in Tanzania and 13% in
Cape Verde [13,22]. Gonorrhea is found in 3% of the
women, compared to rates that range from 2% in Gabon
to 8% in South Africa [16,21]. Although difficult to meas-
ure, it is likely that complications and sequelae due to
these infections among pregnant women and their infants
in sub-Saharan Africa are substantial.
Syndromic approach
Elicited symptoms of increased discharge or lower
abdominal pain are not predictive of cervical infection in
antenatal attendees in Botswana. These symptoms are
non-specific; they are common in pregnancy, and their
association with cervical infections is even lower among
pregnant than among non-pregnant women [23]. The
Table 3: Univariate and multiple logistic regression analysis of risk factors for cervicitis (C trachomatis and/or N gonorrhoeae) among 
703 antenatal care clients in Gaborone, Botswana
Total women Women with cervicitis Multiple logistic regression
No. (%) No. (%) Odds ratio p-value
Age groups
<20 76 (11) 17 (22) 10.5 (3.59–30.72) 0.000
20–29 432 (62) 44 (10) 4.0 (1.60–10.10) 0.003
30+ 195 (28) 6 (3) 1
Education
Primary school or less 168 (24) 17 (10) 1
Junior secondary school 310 (44) 36 (12) 0.6 (0.31–1.23) 0.168
Senior secondary or higher 225 (32) 14 (6) 0.4 (0.16–0.80) 0.013
Thin/runny discharge
No 615 (87) 48 (8) 1
Yes 88 (13) 19 (22) 2.1 (1.06–4.24) 0.035
WBC in cervical smear
None/few 124 (18) 5 (4) 1
1+ 267 (38) 22 (8) 2.0 (0.72–5.52) 0.188
2+ 171 (24) 18 (11) 2.7 (0.92–7.61) 0.070
3–4+ 140 (20) 22 (16) 3.7 (1.31–10.66) 0.014
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Receiver Operating Characteristics (ROC) curves for three levels of risk scores (sociodemographic, clinical and microscopy risk sco es)Figure 1
Receiver Operating Characteristics (ROC) curves for three levels of risk scores (sociodemographic, clinical and microscopy 
risk scores). The risk scores are based on multiple logistic regression analyses and used as a screening tool to identify N gonor-
rhoeae and C trachomatis. The risk scores are applied retrospectively on 703 antenatal care attendees in Gaborone, Botswana.
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VDS algorithm is used extensively to diagnose cervical
infections in antenatal care in Botswana [24], but our
results show that this management is no better than ran-
dom treatment.
To use the genital examination at the first antenatal care
visit as a clinical screening tool for cervical infections is
also unadvisable. According to the newly revised VDS
algorithm in Botswana, symptoms or signs of yellow dis-
charge are risk factors which should lead to treatment for
cervical infections. In our study among antenatal care
attendees, neither symptoms nor signs of yellow discharge
are associated with cervical infection. In pregnancy, symp-
toms or signs of vaginal discharge in general, yellow dis-
charge, or other specific discharge characteristics should
not be used as criteria for treating C trachomatis and N gon-
orrhoeae.
Other studies from sub-Saharan Africa conclude that case
management with the vaginal discharge syndrome has
poor discriminatory ability in the diagnosis of cervicitis
[25-27]. Several reviewers [28-30] emphasise that the syn-
dromic approach should not be used as a screening tool
for N gonorrhoeae and C trachomatis. Our study concurs
with a substantial body of knowledge indicating that the
syndromic approach should be used neither as a case
management of symptomatic women nor as a clinical
screening tool to identify C trachomatis and N gonorrhoeae
in antenatal care attendees in sub-Saharan Africa.
Screening strategies
Despite extensive analyses, all computed risk scores were
of limited value as screening tools in antenatal care
attendees. They had poor discriminative ability, even in
the study population in which they were computed and
adapted to under optimal conditions. As the syndromic
approach, the risk scores also resulted in a large number
of undetected cervical infections and substantial over-
treatment. Additionally, notification and treatment of sex-
ual partners, an essential element of STI management, is
difficult to justify when the majority of the identified
women do not have an STI [8]. A substantial improve-
ment of the management of cervical infections in antena-
tal care in developing countries seems impossible without
specific diagnostic tests.
The development of simple, rapid tests for C trachomatis
and N gonorrhoeae has been a high priority since the 1990s
[9-11]. Major progress has recently been made, and sev-
eral tests for C trachomatis and N gonorrhoeae are now on
the market [7,32]. The Sexually Transmitted Diseases
Diagnostics Initiative at the WHO has begun a pro-
gramme to field test and systematically evaluate these sim-
ple, affordable rapid tests [32,33]. So far, available tests
are found to be specific (>90%), but with a variable sensi-
tivity (25–85%) [34-36]. In Botswana, the health system
is relatively well functioning, and this country could well
serve as an exploratory site for the use of rapid tests for C
trachomatis and N gonorrhoeae. Through the prevention of
mother-to-child transmission of HIV programme, all
health posts and clinics have lay workers who perform
rapid tests for HIV. Simple tests for cervical infections per-
formed by clinicians or lay workers may prove a feasible
contribution to the improvement of diagnosis and the
reduction of the disease burden of these conditions in this
and similar settings.
Consistent with established knowledge on STI epidemiol-
ogy [6,31], youth is the single factor most strongly associ-
ated with C trachomatis and/or N gonorrhoeae in our study
Table 4: Diagnostic strategies to identify infection with Chlamydia trachomatis and/or Neisseria gonorrhoeae in 703 antenatal care 
attendees in Botswana.
Positive on assessment Cervical infection Sensitivity Specificity LR+* LR- PPV NPV
n (%) N (%)
Symptoms and signs
VDS algorithm 104 (15) 11 (11) 0.16 0.85 1.12 (0.63–1.92) 0.98 0.11 0.91
Symptoms alone: VD and/or LAP 155 (22) 14 (9) 0.21 0.78 0.94 (0.57–1.49) 1.02 0.09 0.90
Signs alone: VD (excl. candidiasis) 227 (32) 30 (13) 0.45 0.69 1.45 (1.06–1.89) 0.78 0.13 0.92
Risk scores†, sensitivity minimum 0.7
Sociodemographic risk score 327 (47) 50 (15) 0.75 0.56 1.71 (1.42–1.99) 0.45 0.15 0.96
Clinical risk score 372 (53) 54 (15) 0.81 0.50 1.61 (1.37–1.83) 0.39 0.15 0.96
Microscopy risk score 273 (39) 51 (19) 0.76 0.65 2.18 (1.80–2.55) 0.37 0.19 0.96
Risk scores, sensitivity minimum 0.4
Sociodemographic risk score 156 (22) 29 (19) 0.43 0.80 2.17 (1.55–2.91) 0.71 0.19 0.93
Clinical risk score 117 (17) 29 (25) 0.43 0.86 3.13 (2.20–4.30) 0.66 0.25 0.94
Microscopy risk score 116 (17) 29 (25) 0.43 0.86 3.16 (2.22–4.34) 0.66 0.25 0.94
LR+ = positive likelihood ratio; LR- = negative likelihood ratio; PPV = positive predictive value; NPV = negative predictive value; VDS = vaginal discharge syndrome;
LAP = lower abdominal pain; VD = vaginal discharge
* The positive likelihood ratios are calculated with 95% confidence interval.
†Risk factors included in each risk score are described in Table 1
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population. Thus age can be useful as a screening tool in
the traditional sense, to minimise the number of standard
diagnostic tests by identifying people with a higher-than-
average prevalence of infection [29]. If it were decided in
Botswana to introduce screening for cervical infections
with rapid tests in the antenatal care, selective screening of
younger women should be considered.
Conclusion
Although the vaginal discharge syndrome does not dis-
criminate between infected and uninfected women, the
algorithm is in extensive use to diagnose and treat C tra-
chomatis and N gonorrhoeae among antenatal care attend-
ees in Botswana. Unfortunately, risk scores do not appear
to improve the management of cervical infections in preg-
nancy substantially. To diagnose and treat asymptomatic
cervical infections, and to reduce the massive overtreat-
ment in the syndromic management, specific diagnostic
tests are necessary. Screening for cervical infections in
pregnant women is an essential public health measure,
and rapid tests will hopefully be available in developing
countries within a few years. In the temporary absence of
such tests, health authorities in sub-Saharan Africa should
consider reallocating their resources to other STI measures
rather than diagnosing and treating gonorrhoea and
chlamydia inadequately in antenatal care.
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